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BRAF     B-Raf protooncogene, serine/threonine kinase 
CC10   club cell-specific 10 kD protein 
CCSP        club cell secretory protein 
CDKIs   cyclin-dependent kinase inhibitors 
Cdkn2ab   cyclin-dependent kinase Inhibitor 2A 
CgA   chromogranin A  
CGRP   calcitonin gene-related peptide 
CK14   cytokeratin 14 
CK5   cytokeratin 5 
COPD   chronic obstructive pulmonary disease 
CYP2F2   cytochrome P450 2F2 
DNA   deoxyribonucleic acid 
EGF   epidermal growth factor 
EGFR   epidermal growth factor receptor 
ERBB2   Erb-B2 Erythroblastic Leukemia Viral Oncogene Homolog 
ERK   extracellular signal-regulated kinase 
FAK   focal adhesion kinase 
FGFR1   fibroblast Growth Factor Receptor 1 
FOXJ1   forkhead box J1 
GAP   GTPase-activating protein 
GEF      guanine nucleotide exchange factors 
GEMM    genetically engineered mouse model 
Gr-1   myeloid differentiation antigen Gr-1 
GTPase   small guanosine triphosphatase 
H2-D1    histocompatibility 2, D region locus 1 
H2-M2               histocompatibility 2, M region locus 2 
HRAS   harvey Rat Sarcoma Viral Oncogene Homolog  
IAC   invasive adenocarcinoma 
IHC   immunohistochemistry 
Il1b   interleukin 1 beta  
ITH   intratumoral heterogeneity 
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KL   KrasLSL-G12D/+; Lkb1fl/fl 
KP   KrasLSL-G12D/+;Trp53 fl/fl 
KRAS   Kirsten Rat Sarcoma Viral Oncogene Homolog 
LCC   large cell carcinoma 
LKB1/STK11  liver kinase B1 / serine/threonine-protein kinase 11 
LY6C   lymphocyte antigen 6 complex locus C 
LY6G   lymphocyte antigen 6 complex locus G 
MAC   mucinous adenocarcinoma 
MAPK   mitogen-activated protein kinase 
MDM2    mouse double minute 2 homolog  
MDSC   myeloid-derived suppressor cells 
MHC   major histocompatibility complex 
mTOR   mammalian target of rapamycin  
NGR1   Neuregulin 1 
NKX2-1   NK2 Homeobox 1 
NRAS   neuroblastoma RAS Viral Oncogene Homolog  
NSCLC    non-small cell lung cancer 
p63   tumor protein 63 
PAC   papillary adenocarcinoma 
PAS   periodic acid–Schiff  
PD-1    programmed cell death protein 1 
PD-L1   programmed death-ligand 1  
PI3K   phosphoinositide 3-kinase 
PJS   peutz–Jeghers syndrome 
ProGRP   serum pro-gastrin releasing peptide 
PTEN   phosphatase and tensin homolog 
Q-PCR   quantitative polymerase chain reaction 
RB1   retinoblastoma 1 
RTK   receptor tyrosine kinase 
SCC   squamous cell carcinoma 
SCGB1A1   secretoglobin family 1A member 1 
SCLC   small-cell lung cancer  
SO2   sulphur dioxide 
SOX2   SRY (sex determining region Y)-box 2 
SPC   surfactant protein C 
SRC   proto-oncogene tyrosine-protein kinase Src 
TAN   Tumor-associated neutrophil 
TNM   Tumor-Node-Metastasis system 
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Lung cancer is the leading cause of cancer-related mortality worldwide. Non-small cell lung cancer 
(NSCLC) is the most common type of lung cancer (85%), and is histologically subdivided into 
adenocarcinoma (AC; 40%), squamous cell carcinoma (SCC; 30%) and adenosquamous cell carcinoma 
(ASC; 0,4-4%). Histologically, ASCs harbor both AC and SCC components. Although ASCs are rare, 
they constitute the most aggressive form of lung cancer with poor patient prognosis. While molecularly 
targeted therapies for EGFR/ALK/ROS are typically directed towards ACs, in which these mutations 
are predominantly detected, the majority of NSCLC patients carry mutations in KRAS and LKB1, for 
which no approved therapies exist thus far. Furthermore, while heterogeneity in tumor 
microenvironments and oncogenic signaling are major factors contributing to disease relapse, the 
histotype-specific etiology of tumor heterogeneity remains elusive. Using genetically engineered 
mouse models (GEMMs) of lung cancer it has been shown that the identity of niche-specific 
progenitors defines the phenotype of the tumors that arise. Therefore, an understanding of lung 
histopathology subtype-specific cell(s) of origins will help to dissect the evolution of tumor 
heterogeneity, and ultimately the development of histotype-specific therapies. 
 
This thesis work investigated the role of the cell of origin in defining histotype diversity in a GEMM 
that harbors concurrent activation of KrasG12D with loss of Lkb1 (hereafter called ‘KL’). To do this, 
lung progenitor cells were targeted using cell-type directed Adenoviral Cre viruses (AdCre) to initiate 
tumorigenesis in bronchiolar Club cells (Club cell secretory protein; CC10+) or alveolar type II cells 
(surfactant protein C; SPC+). This approach led to the identification of CC10+ cells as predominant 
progenitors of ASC tumors. In addition, transcriptome analysis together with intratumoral immune cell 
analysis revealed an ASC-specific immunosuppressive phenotype, marked by downregulation of 
antigen-presenting genes, infiltration of tumor-associated neutrophils (TANs), and reduced numbers of  
intratumoral T cells. This part of the thesis work thus demonstrated that progenitor cell-specific 
etiology links to the histopathology spectrum and histotype-specific immune microenvironments of 
KL-driven tumors. 
 
The second part of this thesis work provides a visual demonstration of a methodology for the 
generation, cultivation, and analysis of precision-cut murine NSCLC tissue slices. This work showed 
that optimization for slice thickness was important to retain maximum viability of cultured slices. 
Additionally, this protocol describes how to identify optimal drug concentrations for treatment of tumor 
slices, and highlights that comparison of heterogeneous marker expression in cultivated and 
10 
 
neighboring uncultured slices is important to assess the preservation of tumor-specific biological 
functions in cultured slices.   
 
The thesis next focused on understanding the role of both tumor histotypes in defining oncogenic 
signaling downstream of  KRAS and LKB1, and how such insights can be used for drug testing and 
selection of optimal drug combinations. By utilizing Kras-driven NSCLC GEMMs we demonstrate 
that certain oncogenic signaling pathways are spatially active in a histotype-specific manner, namely: 
predominance of PI3K/AKT and SRC pathways in SCC subregion of ASCs, and enrichment of MAPK 
pathway in ACs. Short-term treatment of tumor tissue slice cultures with combinatorial PI3K/mTOR 
and MAPK inhibitors showed that cytotoxic responses correlated with spatially distributed co-
occurrence of both pathways. This work highlighted that tumor histotype, rather than genotype, is the 
major determinant of oncogenic signaling heterogeneity, and that concomitant spatial activation of 
targeted signaling pathways is essential to achieve optimal cytotoxic response to combination therapy. 
In addition, it demonstrated the utility of tumor tissue slices in modeling spatial response to drug 
treatment. 
  
Finally, this thesis investigated histotype- or genotype-specific drug vulnerabilities using epithelial 
cultures of murine NSCLC. We showed that KL tumor cells are unable to grow under standard 
conditions and require a use of a cell culture protocol called conditional reprogramming (CR). Drug 
sensitivity and resistance testing (DSRT) on murine NSCLC conditionally reprogrammed cells (CRCs), 
followed by in vivo validation of treatment responses, led to the identification of NSCLC subtype-
specific acute responses to single or combinatorial inhibition of the MAPK pathway. We showed that 
NSCLC subtype-specific resistance to MEK inhibition in CRC cultures is mediated by intrinsic or 
adaptive activation of receptor tyrosine kinases (RTKs), specifically activation of ERBBs (in KL;ASC 
and KL;ACs) or FGFR (in ACs). Importantly, we assessed the ability of CRCs to model in vivo drug 
response by performing short-term (3 days) combined MEK/ERBB inhibition in Kras mutant lung 
cancer GEMMs. This in vivo combinatorial inhibition resulted in acute cytotoxic response selectively 
in ASCs (with strongest responses in the SCC subregions of ASC tumors) compared to ACs. This result 
was further supported by the predominance of ERBB activation specifically in SCC regions of in situ 
ASCs. Consistent with murine findings, we showed ASC and SCC histotype-specific predominance of 
selected ERBB family receptors in clinical NSCLC samples.  Collectively, this work suggests that 
NSCLC-derived primary cultures could be used for the identification of subtype-specific acute 
therapeutic responses, and that the coupling of in vivo spatial signaling activities with in vitro drug 




In summary, this thesis demonstrates that the tumor cell of origin defines histotype fate and a 
histopathology-specific immune microenvironment upon expression of oncogenic KrasG12D and loss of 
the tumor suppressor Lkb1, and that activation of oncogenic signaling pathways are also stratified by 
tumor histotype. Therefore, in addition to genotype-based stratification, deeper understanding of tumor 
histotype-specific features will be of importance in clinical settings. This work also validates the utility 
of ex vivo models, namely tumor tissue slices and tumor-derived primary cell cultures, for functional 
diagnostics, permitting assessment of spatial drug response and identification of pathology-specific 




Cancer is a disease characterized by abnormal growth of cells in an uncontrolled manner. Certain cancer 
cells have the potential to invade or spread into surrounding tissues, by a process called metastasis. 
Cancer can arise from any part of the body. Carcinomas are the most common cancer type, and arise 
from epithelial cells that cover the skin and the body’s internal organs. Globally, cancer is the leading 
cause of mortality. During 2012, 8.2 million cancer-related deaths were reported worldwide (Ferlay et 
al., 2015). Cancer develops following somatic genetic abnormalities in normal cells, or inherited 
cancer-causing genetic variations (Hanahan and Weinberg, 2000, 2011; Loeb and Loeb, 2000). 
Exposure to physical (e.g. ultraviolet and ionizing radiation), chemical (e.g. tobacco, asbestos, arsenic), 
or biological carcinogens (e.g. viral and bacterial infections) results in alteration of genes that regulate 
cell growth and differentiation, increasing the risk of cancer development (Anand et al., 2008). 
Furthermore, chronic inflammation, or carcinogen-induced disruption of the host microenvironment 
also facilitates cancer development (Casey et al., 2015; Multhoff et al., 2011). Genes contributing to 
cancer initiation and progression are categorized as oncogenes, which promote cell growth, and tumor 
suppressors, which promote cell death or inhibit cell division under cellular stress conditions. Cancer-
causing genetic alterations can lead to inappropriate activation or overexpression of oncogenes, or 
inactivation or loss of tumor suppressor genes (Balmain, 2001; Knudson, 2001). Transformation of a 
normal cell into a malignant tumor is considered to occur via a multistep process during which cancer 
cells acquire abnormal biological capabilities, termed as ‘hallmarks of cancer’. These include 
sustaining proliferative signaling, evading growth suppressors, activating invasion and metastasis, 
enabling replicative immortality, inducing angiogenesis, resisting cell death, reprogramming of energy 
metabolism, and evading immune destruction (Hanahan and Weinberg, 2000, 2011). 
Lung cancer is the major cause of cancer-related deaths worldwide (Ferlay et al., 2015; Siegel et al., 
2018). Tobacco smoking is the primary risk factor, contributing to nearly 85% of the lung cancer deaths 
(Furrukh, 2013). Lung cancer is histologically and genetically a heterogeneous disease (Gridelli et al., 
2015). Comprehensive genomic profiling has led to the classification of lung cancer into distinct 
molecular subtypes, and the development of targeted therapies against specific genetic alterations 
(Bronte et al., 2010). However, as of yet, no clinically approved therapies available for the treatment 
of lung cancer patients carrying common driver genes, namely mutations in oncogenic KRAS (Kirsten 
Rat Sarcoma Viral Oncogene Homolog), and the tumor suppressor STK11 (Serine/Threonine Kinase 
11, also known as LKB1).  
The average five-year survival of lung cancer patients is only 15%, and the majority of patients are 
diagnosed at late stages, when tumors contain pronounced genetic and histological heterogeneities. 
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This limits the effectiveness of treatment, leading to poor patient survival (Chen et al., 2014; Wang et 
al., 2010). Pharmacological management of advanced NSCLC patients is primarily based on molecular 
and histological subtyping, and most patients develop resistance to targeted therapies within one year 
of treatment (Facchinetti et al., 2017b). Moreover, driver gene alterations do not always predict clinical 
response, highlighting a need for the development of diagnostic methods linked to predictive 
biomarkers (Shepherd et al., 2005; Tsao et al., 2005). Multiple factors contribute to therapy resistance, 
including roles for the tumor microenvironment and infiltrating immune cells, and activation of 
compensatory pathways through rapid rewiring of cancer cell signaling (Rosell et al., 2013; Wang et 
al., 2017). Furthermore, pronounced functional heterogeneity caused by the landscape of genetic 
mutations induced in different tumor cells of origin, as well as branched molecular evolution during 
tumor progression, poses challenges on the success of cancer therapies (Blanpain, 2013; de Bruin et 
al., 2015). A deeper understanding of disease etiology leading to end-stage tumor heterogeneity, using 
physiologically relevant models with intact immune systems, may help to eventually tackle this 
complexity in clinical samples.  
This thesis investigates the role of niche-specific lung progenitor cells in defining NSCLC histotype 
spectra and immune microenvironment heterogeneity, using a murine model driven by oncogenic Kras 
and loss of the tumor suppressor Lkb1. In addition, using Kras-driven NSCLC GEM models, this thesis 
also demonstrates histotype-associated spatial oncogenic signaling heterogeneity and its importance in 
defining therapeutic responses. Furthermore, it establishes Kras-driven NSCLC tumor tissue slice 
cultures and shows their utility as ex vivo models in predicting spatial responses to drug combinations. 
Finally, by performing drug screening on murine NSCLC primary cell cultures coupled with in vivo 
acute drug response analysis, this thesis identifies tumor subtype-selective therapeutic sensitivity and 




1. REVIEW OF LITERATURE 
 
1.1. Structure and function of the lung 
The lung is the principal respiratory organ and plays a vital role in the survival of mammals and some 
vertebrates. The primary function of the lung is gas exchange. It provides oxygen from the air into the 
venous blood and removes carbon dioxide from the blood. The lung is also involved in the metabolism 
of compounds, filtering of unwanted substances from the blood, and also acts as a reservoir of blood 
(Joseph et al., 2013). In addition, recent studies have identified the lung to be a primary site for platelet 
production, and a reservoir of hematopoietic progenitors (Lefrancais et al., 2017). Structurally, the 
human lung consists of five lobes: two on the left and three on the right side of the chest. The trachea 
or windpipe splits into the right and left lungs to form primary bronchi, which in turn divide to form 
bronchioles, terminal bronchioles, and finally respiratory bronchioles that terminate in gas exchange 
units called alveoli. The region between the primary bronchi and the terminal bronchioles constitutes 
the proximal conducting airways, which function to lead the air to and from the distal gas exchange 
regions of the lung. 
 
1.1.1. Cell types in the adult lung 
The adult lung consists of over 40 different cell types, each with specific functions. Proximal airways 
(trachea and bronchi) are lined by a pseudostratified columnar epithelium, consisting of basal cells 
(cytokeratin 5/14; CK5+, CK14+, tumor protein 63; p63+), ciliated cells (forkhead box j 1; Foxj1+), club 
cells (secretoglobin 1 a1; Scgb1a1+, or club cell secretory protein; CCSP+/CC10+), neuroendocrine cells 
(calcitonin gene-related peptide; CGRP+) and mucus-producing goblet cells. The distal airway consists 
of club cells, basal cells, ciliated cells, and neuroendocrine cells. The alveolar epithelium is composed 
of cuboidal surfactant-producing (surfactant protein C; SPC+) alveolar type II cells (AT2) and gas-
exchanging squamous type I cells (AT1) (podoplanin; PDPN+, also known as T1α) (Leeman et al., 
2014; Li et al., 2015b). 
Studies involving lineage tracing of murine lung epithelial cells have been instrumental in 
understanding the role these different cell types in the regeneration and homeostasis of the adult lung. 
However, there are some key differences between the mouse and human lungs, both in terms of 
structure and cellular composition. Unlike humans, mice contain four lobes on the right and one on the 
left side of the thoracic cavity. In mice, mucin-producing submucosal glands are present only in the 
proximal trachea but in humans they penetrate deep into the bronchi. Furthermore, there are striking 
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differences with respect to cellular composition through the airways’ proximal-distal axis. In humans, 
basal cells are present throughout the airways until the terminal bronchioles, whereas in mice these are 
largely restricted to the trachea. Similarly, mucin-producing goblet cells are rare in laboratory mice, 
but are abundant in the human lungs (Figure 1) (Rock et al., 2010). These findings suggest that inter-
species differences in structure and cellular composition of the lung should be taken into consideration 
while performing mechanistic studies using murine models. 
Figure 1. Structure and epithelial cell types in different compartments of the adult mouse lung. Modified 
from (Barkauskas et al., 2017). 
 
 
1.1.2. Stem or progenitor cells of the adult lung 
Stem cells are undifferentiated cells capable of self-renewal and differentiation into specialized cell 
types. Their progeny constitutes progenitor cells that commit to the formation of differentiated cell 
types. Unlike stem cells, which can undergo indefinite cell divisions, progenitor cells have limited 
replicative potential. In adult tissues, stem cells are involved in tissue repair upon injury, and hence 
regulate tissue homeostasis. Deeper understanding of the tissue-specific stem or progenitor cell biology 
majorly impacts on regenerative medicine and disease modelling such as cancer (Singh, 2012). Based 
on their ability to expand and differentiate into mature lung cells, different cell types residing in the 
distinct compartments have been proposed to be the progenitors of the adult mouse lungs. In the upper 
murine airways, tracheal basal cells have been shown to differentiate into ciliated and secretory club 
cells, both under steady state and upon sulphur dioxide (SO2)-induced injury (Rock et al., 2009), while 
club cells can differentiate in to ciliated cells upon SO2 injury (Rawlins et al., 2009). In the conducting 
airways, (bronchi and terminal bronchioles) naphthalene-resistant variant club cells that lack the 
cytochrome p450 enzyme (CYP2F2) that metabolizes naphthalene into a toxic derivative have been 
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shown to replenish ciliated and club cells upon naphthalene injury (Buckpitt et al., 1995; Li et al., 2011; 
Rawlins et al., 2009). Towards the distal part of the lung, SPC+ AT2 cells have been shown to 
regenerate the damaged lung parenchyma following bleomycin injury (Rock et al., 2011). 
Subsequently, Chapman et al showed that integrin α6+β4+ but SPC negative cells from distal lungs also 
have a capacity to expand after bleomycin injury, suggesting the additional existence of SPC- 
progenitors in the distal lung (Chapman et al., 2011). Furthermore, also distal airway stem cells (DASC) 
marked by p63+ Krt5+ have been shown to regenerate both the bronchiolar and alveolar epithelium in 
response to H1N1 influenza virus infection (Zuo et al., 2015). Together, this indicates the existence of 
multiple tissue-regenerating stem cells, and shows that different injury types activate distinct 
progenitors.   
In the bronchioalveolar duct junction (BADJ), CC10 and SPC co-expressing cells, also known as 
bronchioalveolar stem cells (BASCs), have been considered as stem cells with regenerative capacity 
following naphthalene (bronchiolar) or bleomycin (alveolar) injury (Giangreco et al., 2002). These 
BASCs have been shown to possess self-renewal capacity, and could differentiate into CC10+ and SPC+ 
cells when cultured on matrigel (Kim et al., 2005). Contrary to these findings, Rawlins et al did not 
find evidence supporting the role of BASCs in repair following hyperoxia-induced injury (Rawlins et 
al., 2009). Adenoviruses or lentiviruses expressing Cre recombinase-under the control of lung 
progenitor cell-specific promoters such as CC10- or SPC- have been used to investigate the cell of 
origin of lung cancer, and this will be discussed in section 1.8. 
Figure 2. Epithelial stem or progenitor cells in different regions of the adult mouse lung.  Solid arrows point 
at cells that are generated from indicated lineage, either in response to lung injury or during steady state. Dotted 
arrows indicate cells that are derived from a lineage still under debate. Cells with self-renewing capacity are 




1.2. Lung cancer 
Lung cancer is one of the most common cancer types both in terms of incidence and mortality, and 
accounts for nearly 1.6 million deaths per year worldwide (Ferlay et al., 2015; Siegel et al., 2018; Wong 
et al., 2017). Initial lung cancer diagnosis is based on clinical symptoms, which include cough, dyspnea, 
and chest pain. Diagnostic tests to confirm lung cancer include imaging based positron emission 
tomography (PET)/computed tomography (CT) scans, or transesophageal and bronchoscopic 
ultrasound. In addition, a small tissue biopsy is routinely examined by microscopic means to establish 
disease diagnosis (Gridelli et al., 2015). Cancer stage is determined based on TNM classification: size 
of the primary tumor (T), regional lymph node involvement (N), and metastasis to distant organs (M) 
(Goldstraw et al., 2016). The overall survival of the patients diagnosed with lung cancer is strongly 
linked to clinical stage at the time of diagnosis. Patients who are presented at stage I have a five-year 
survival of appr. 73%, while patients with advanced stage IV disease have a poor survival of appr. 13% 
(Woodard et al., 2016). Treatment options depend on the clinical stage: surgery is the most effective 
treatment for stage I, II, and IIIA patients, while patients with stage IIIB or IV disease are mostly treated 
with chemotherapy or radiation therapy (Rocco et al., 2016). Diagnostic molecular profiling 
increasingly guides the prescription of targeted therapies as well as immunotherapies, particularly for 
treatment of metastatic lung cancer, and this will be discussed in detail in the following sections 
(Shojaee and Nana-Sinkam, 2017). 
 
1.2.1. Lung cancer epidemiology 
Lung cancer accounts for nearly 25% of all cancer-related deaths in men and women (Siegel et al., 
2018). Nearly 25% of the lung cancers are detected in non-smoking people (Sun et al., 2007). In 
addition, lung cancer in never- smokers also varies in terms of geographic locations, non-smoking 
people developing lung cancer is higher in South and East Asia compared to Europe or United states 
(Pirie et al., 2016; Subramanian and Govindan, 2007; Thun et al., 2008). A never-smoker is defined as 
an individual who has had exposure to less than 100 cigarettes in a life-time (Sun et al., 2007). While 
smoking is associated with all histological lung cancer subtypes, stronger association has been shown 
for small-cell lung cancer (SCLC) and SCC (Khuder, 2001). Although the AC subtype is the most 
common in never smokers, a major global shift towards increased AC and decreased SCC has been 
observed in smokers (Gabrielson, 2006; Yang et al., 2002). This shift has been attributed to altered 
nicotine and carcinogen contents in cigarettes leading to changes in smoking behavior (Gray, 2006; 




1.2.2. Histological subtypes of lung cancer 
Lung cancer is broadly classified into two main subtypes; 1) NSCLC accounts for 85% of the diagnosed 
cases, 2) SCLC constitutes remaining 15% of the lung cancer (Gridelli et al., 2015). SCLC, previously 
known as oats cell carcinoma, is the most aggressive subset, and shows early and frequent metastasis 
(Bernhardt and Jalal, 2016). SCLC is a neuroendocrine carcinoma originating from neuroendocrine 
cells in the airways. Commonly used diagnostic markers, which distinguish SCLC from NSCLC, 
include serum pro-gastrin releasing peptide (ProGRP), chromogranin A (CgA) and synaptophysin 
(Taneja and Sharma, 2004).  
NSCLC is further classified into sub-histotypes, according to commonly used pathology guidelines 
(Travis et al., 2013; Travis et al., 2011), and based on morphological characteristics as well as 
immunohistochemical markers. Specifically, NSCLC is classified into AC (~40%), SCC (~30%), and 
non-small cell carcinoma (NSCC) not otherwise specified (NOS) (NSCC-NOS: ~10%) (Gridelli wt al., 
2015). A tumor is classified as adenosquamous carcinoma (ASC) if the resected specimens contain 
both AC and SCC biomarker expression; ASCs constitute appr. 4% of the NSCLC histotypes 
(Nakagawa et al., 2003; Travis et al., 2011). 
An update to the AC classification was made in 2011 by the International Association for the Study of 
Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS). 
According to this classification, surgically resected specimens are classified as pre-invasive, minimally 
invasive or invasive adenocarcinomas. Pre-invasive AC include, adenocarcinoma in situ (AIS), in 
which neoplastic cells grow along the pre-existing alveoli (lepidic growth), without stromal or 
endothelial cell infiltrations. Invasive ACs are characterized by disruption of normal alveolar structure 
and are further subtyped based on their lepidic, papillary, acinar, solid, or mucinous growth patterns 
(Travis et al., 2011). 
NSCLC sub-histotypes are distinguished based on immunohistochemistry (IHC) markers. While 
thyroid transcription factor-1 (TTF-1), also known as NKX2-1, and napsin-A are the most widely used 
markers of ACs, SCCs are identified based on positivity for transcription factor p63, specifically 
DNp63 (also known as p40), a dominant negative isoform of p63 (Bishop et al., 2012; Terry et al., 
2010). The cytoskeletal marker CK5/6 is also used as squamous histotype marker. If a tumor cannot be 
differentiated into AC or SCC it is classified as NSCLC-NOS.  For ASCs, which are tumors that contain 
at least 10% of each SCC and AC components, p63 or CK5/6 positivity (SCC component) and NKX2-




1.2.3. Genetic landscape of lung cancer 
Comprehensive genomic analyses over the past decade have identified distinct molecular subtypes of 
lung cancer, characterized by DNA copy number alterations (CNAs), chromosomal rearrangements, 
and mutations in oncogenes or tumor suppressors. In addition to distinct morphological characteristics, 
NSCLCs and SCLCs harbor different sets of genetic alterations. Furthermore, NSCLC subtypes are 
also characterized by distinct genetic alterations (Campbell et al., 2016). 
 
1.2.3.1. Genetic alterations in SCLC 
SCLC is one of the deadliest lung cancer type, with a 5 year overall survival rate of 5-10% (Lassen et 
al., 1995). Almost all SCLC patients are smokers. These tumors show a high burden of carcinogen-
induced mutations, amounting to around 8.62 non-synonymous mutations per million base pairs 
(George et al., 2015; Varghese et al., 2014). Bi-allelic inactivation of tumor suppressors TP53 (Tumor 
Protein 53) and RB1 (Retinoblastoma 1) are the most common genetic alterations in SCLC (George et 
al., 2015). In addition, inactivating mutations in NOTCH1 (Notch homolog 1, translocation-associated), 
PTEN (Phosphatase and Tensin Homolog), copy number gain of MYC (MYC Proto-Oncogene, BHLH 
Transcription Factor), or amplification of FGFR1 (Fibroblast Growth Factor Receptor 1) or SOX2 (Sex 
Determining Region Y-Box 2) genes are reported in SCLC (Peifer et al., 2012; Rudin et al., 2012). 
 
1.2.3.2. Genetic alterations in AC 
Activating mutations in KRAS (32%) and EGFR (Epidermal Growth Factor Receptor: 15%) oncogenes 
are common in lung ACs (TCGA, 2014). The majority of KRAS mutations are detected in smokers (30-
43%), as opposed to never smokers (0-7%). In contrast, EGFR mutations are more common in never 
smokers (45%) compared with smokers (0-7%) (Subramanian and Govindan, 2013). Moreover, the 
frequency of EGFR mutation in ACs vary depending on the geographic location, with the highest 
prevalence in Asia (47%) compared to Europe (15%) or the United States (23%) (Midha et al., 2015). 
This difference has been partially explained by differences in the prevalence of polymorphisms in the 
EGFR promoter region between Asian and Western populations (Nomura et al., 2007). EGFR 
alterations commonly are exon 19 deletions (60%) or missense mutations at exon 858 (L58R), resulting 
in constitutive EGFR activation (Jackman et al., 2006; Rosell et al., 2009). Due to redundancy in 
downstream signaling pathways, KRAS and EGFR mutations are mutually exclusive in ACs (Yang et 
al., 2009). Genetic alteration in STK11/LKB1 is detected in 13-33% of ACs, and these often co-occur 
with KRAS mutations (10-67%) (Koivunen et al., 2008; Matsumoto et al., 2007; Sanchez-Cespedes et 
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al., 2002). Chromosomal translocations between the receptor tyrosine kinase gene ALK (Anaplastic 
Lymphoma Kinase) and EML4 (Echinoderm Microtubule-associated Protein 4) are also common in 
AC patients (4-7%) with a history of never smoking (TCGA, 2014; Wong et al., 2009). In addition, 
nearly 4% of ACs harbor alterations in the receptor tyrosine kinase ERBB2 (V-Erb-B2 Erythroblastic 
Leukemia Viral Oncogene Homolog (TCGA, 2014). Furthermore loss-of function mutations in KEAP1 
(Kelch-like ECH-associated protein 1) are also detected in approximately 20% of ACs (2012; Berger 
et al., 2017; Singh et al., 2006). Nearly 3-10% of lung ACs harbor activating mutations in BRAF (B-
Raf Serine/Threonine-Protein), most commonly a glutamatic acid substitution for valine at codon 600 
(TCGA, 2014; Litvak et al., 2014). 
 
1.2.3.3. Genetic alterations in SCC 
In SCC, alterations are detected in genes involved in growth factor signaling, namely, amplification of 
FGFR1 (22%) (Weiss et al., 2010), loss of function mutation in PTEN (10%) (Jin et al., 2010), or copy 
number gains in PIK3CA (Phosphoinositide-3-Kinase, Catalytic, Alpha Polypeptide: 33-43%) 
(Okudela et al., 2007; Yamamoto et al., 2008). Furthermore, somatic mutations in TP53 (81%) (2012), 
and amplification of SOX2 (20-45%) (Bass et al., 2009; Sasaki et al., 2012) are also predominant in 
SCC. TP53 mutations are associated with cigarette smoking, and carcinogen-associated G-T 
transversions in TP53 have been detected (Halvorsen et al., 2016; Pfeifer et al., 2002). 
 
1.2.3.4. Genetic alterations in ASC 
High prevalence of EGFR mutation has been reported in ASCs, with frequencies ranging from 13%-
55% (Midha et al., 2015; Tochigi et al., 2011; Vassella et al., 2015), particularly in female never 
smokers (Song et al., 2013). Mutational analyses of micro-dissected AC and SCC components have 
revealed EGFR mutations in both the AC and SCC components (Midha et al., 2015; Powrozek et al., 
2014; Tochigi et al., 2011), or shown divergence with glandular AC regions showing predominant 
EGFR mutation (Shi et al., 2016). In addition, mutations in PI3KCA have been detected in ASCs, 
particularly in the SCC component (Shi et al., 2016; Vassella et al., 2015). Compared to frequent overall 
KRAS mutation in ACs (32%), ASCs show lower incidence of KRAS mutation (7-13%) (TCGA, 2014; 
Shi et al., 2016; Tochigi et al., 2011; Vassella et al., 2015). Vassella et al also reported mutations in 
LKB1, APC, KIT, TP53, or RB1, in both the SCC and AC components of ASC (Vassella et al., 2015), 
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with 22% of all ASCs harboring LKB1 mutation (Koivunen et al., 2008). These findings suggest that, 
as a hybrid of two histotypes, ASCs harbor select mutations specific to both the AC and SCC histotypes. 







M: mutation, C: copy number alterations, NA: not available  
Table 2. Selected co-occurring gene mutations in histological subtypes of NSCLC. Information has 
been derived from the following references: (Ji et al., 2007; Matsumoto et al., 2007; Schmid et al., 














EGFR M, C 11-40 4-7 13-55 
KRAS M 30-32 1-2 7-13 
STK11 M 13-33 2-5 6-22 
TP53 M 46 81 38 
PIK3CA M, C 3-6 4-43 13 








 ASC % 
KRAS and EGFR 1-2 NA NA 
KRAS and TP53 12 7 NA 
KRAS and LKB1 10-67 2 NA 
Table 1. Selected genetic alterations in histological subtypes of NSCLC. Information in the table 
has been derived from the following references: (TCGA, 2012; TCGA, 2014; Boch et al., 2013; Joshi 
et al., 2017; Koivunen et al., 2008; Li et al., 2012; Midha et al., 2015; Okudela et al., 2007; Sanchez-




1.2.4. KRAS and its downstream signaling 
 Ras  (Rat sarcoma) family proteins are small guanosine triphosphatases (GTPases) that mediate 
intracellular signal transduction to regulate diverse cellular functions, including proliferation, survival, 
cytoskeletal integrity, migration, adhesion, and apoptosis (Wennerberg et al., 2005). Oncogenic 
functions of the RAS were first identified by the ability of retroviruses from leukemic rats to induce 
sarcomas in new-born rodents (Harvey, 1964; Kirsten and Mayer, 1967). Later, three independent 
studies discovered that human homologues of Kirsten and Harvey sarcoma viruses are found in cancer 
cell lines, and are capable of inducing transformation in mouse embryonic fibroblast NIH/3T3 cells 
(Der et al., 1982; Parada et al., 1982; Santos et al., 1982; Wennerberg et al., 2005). 
RAS genes are highly conserved across different species. The RAS family consists of three members, 
or isoforms, namely HRAS, KRAS, and NRAS, and these are frequently mutated in various human 
cancers (Hobbs et al., 2016). Interestingly, RAS isoforms show tissue-specific differences in mutations 
and context-dependent transformation potential (Castellano and Santos, 2011). Furthermore, of the 
three isoforms, only Kras is essential for the development of mouse embryos; Kras null embryos die 
due to defects in the development of heart and neurons (Koera et al., 1997).  
Among the three RAS isoforms, only KRAS forms two alternate splice variants, giving rise to two 
protein products, KRAS4A and KRAS4B, which differ in their 25 carboxyl terminal residues (Hobbs 
et al., 2016; Tsai et al., 2015). All RAS proteins are membrane localized, and a series of biochemical 
reactions involving C-terminal prenylation, farnesylation, and geranylation mediate the anchoring of 
RAS proteins to the plasma membrane (Casey et al., 1989; Prior and Hancock, 2012; Schaber et al., 
1990). The GTPase activity, or activated form of KRAS, is regulated by two regulatory proteins: i) 
guanine nucleotide exchange factors (GEFs) that mediate the exchange of GDP to GTP, and ii) GTPase 
activating proteins (GAPs), which mediate GTP hydrolysis and conversion to GDP. In the GTP-bound 
active state, KRAS shows high affinity for downstream effector molecules and mediates a cascade of 
signaling events (Wennerberg et al., 2005). Activation of growth factor receptors or receptor tyrosine 
kinases (RTKs) via extracellular cues drives activation of KRAS via KRAS-GEF, which leads to the 
activation of a spectrum of downstream effectors. One of the canonical pathways downstream of KRAS 
is initiated by translocation of the Raf proto-oncogene, a serine/threonine-protein kinase to the plasma 
membrane, followed by its phosphorylation. Activated Raf phosphorylates a dual specificity kinase 
MEK1/2 (mitogen-activated protein kinase), which in turn phosphorylates and activates ERK1/2 
(extracellular signal-regulated kinase). Activated ERK1/2 translocate to the nucleus, where it 
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phosphorylates Ets family transcription factors which regulate cell proliferation, differentiation, tissue 






1.2.4.1. KRAS in lung cancer 
As mentioned, KRAS is among the most frequently mutated genes in lung cancer, particularly in ACs 
of patients with a history of tobacco smoking. KRAS mutations are also observed in SCC (~2%) and 
ASC (7-13%) with less frequency, and very rarely in SCLC (TCGA, 2012; Boch et al., 2013; 
Mitsudomi et al., 1991; Tochigi et al., 2011; Vassella et al., 2015). In lung cancer, KRAS mutations are 
more frequent than HRAS or NRAS mutations (Suzuki et al., 1990). The KRAS gene is located on 
chromosome 12p.12.1. Mutations leading to single amino acid substitutions are commonly found at 
codon 12, and also at codon 13 or 61, though at a lower frequency (Ahrendt et al., 2001). It is thought 
that metabolically active carcinogens in tobacco smoke, such as polycyclic aromatic hydrocarbons 
(PAH) or nicotine-derived nitrosamine ketone (NNK), forms reactive intermediates that bind to the 
DNA and cause point mutations in KRAS leading to  G-C and G-T nucleotide transversions (Hecht, 
2012). In line with this, the G12C (~40%) and G12V (~22%) KRAS point mutations in lung cancers 
constitute G/T transversions (Forbes et al., 2011; Gautschi et al., 2007). Some reports suggest poorer 
prognosis of patients with G12C and G12V mutations compared to other KRAS mutations (Ihle et al., 
2012). Furthermore, the nature of the amino acid substitution has an effect on downstream signaling: 
mutant KRAS with a G12D substitution preferentially activates the PI3K/AKT pathway, while KRAS 
G12C, or G12V signals through the Raf-MEK pathway (Ihle et al., 2012). In addition, due to 
redundancy in downstream signaling, KRAS mutations confer resistance to anti-EGFR therapies 
(Eberhard et al., 2005; Pao et al., 2005).  
Figure 3. RAS-associated signaling pathways. 
RTKs are activated through phosphorylation 
upon ligand binding, which creates binding sites 
for adaptor proteins, including GRB2 and SHP2. 
These in turn recruit SOS, a RAS GEF, to the 
membrane to activate RAS via exchange of GDP 
for GTP. Activated RAS propagates various 
downstream effector pathways to regulate 
diverse cellular processes such as proliferation, 
survival, vesicle trafficking, and cytoskeletal 






LKB1 is located on chromosome 19p13.3, and encodes for a serine threonine kinase (Manning et al., 
2002). It was first identified as a gene whose germline mutation is responsible for Peutz-Jeghers 
syndrome (PJS) (Hemminki et al., 1998; Hemminki et al., 1997; Jenne et al., 1998). PJS is an 
autosomal-dominant disorder distinguished by gastrointestinal hamartomatous polyps and melanocytic 
macules of the lips (Hemminki, 1999). Patients with PJS are at increased risk for cancer, including 
gastrointestinal cancers (Giardiello et al., 1987; Hearle et al., 2006). The tumor suppressor function of 
LKB1 was first identified by overexpression of wild type LKB1 in HeLa and G361 cells, which leads 
to growth suppression via a G1 cell cycle arrest (Tiainen et al., 1999). The same study also showed that 
catalytically inactive LKB1 mutants, including those found in PJS patients, were unable to cause growth 
arrest, confirming the role of kinase activity in blocking cell growth. Mice heterozygous for Lkb1 do 
not display defects in embryonic or postnatal development. However, homozygous deletion of Lkb1 is 
embryonic lethal, and Lkb1 null embryos die in utero between E8.5-E9.5 due to neural tube and heart 
development defects, as well as vascular abnormalities, suggesting that LKB1 plays an important role 
in embryonic development (Jishage et al., 2002; Ylikorkala et al., 2001). LKB1 is mutated in many 
human cancers, with the highest incidence in lung AC (~30%), followed by cervical cancers (Sanchez-
Cespedes, 2007; Sanchez-Cespedes et al., 2002; Wingo et al., 2009). 
 
1.2.5.1. LKB1 signaling 
LKB1 exerts its function by forming a complex with two other proteins, the pseudo kinase STRAD 
(STE20-related adaptor) and scaffold protein MO25 (mouse protein 25) (Baas et al., 2003; Boudeau et 
al., 2003). LKB1 acts as a master kinase to regulate cell metabolism, differentiation, proliferation and 
polarity via a set of 14 downstream kinases (Vaahtomeri and Makela, 2011). AMP-activated protein 
kinase (AMPK), the best characterized LKB1 substrate, is a heterotrimeric kinase composed of a 
catalytic (α) subunit and two regulatory (β and γ) subunits (Novikova et al., 2015). AMPK is an energy-
sensing kinase that is activated upon low cellular energy conditions, when cellular ATP levels are 
decreased and AMP levels are increased, mediated by LKB1-dependent phosphorylation of AMPK 
(Hardie, 2007). Activated AMPK activates catabolic pathways, including glucose uptake, glycolysis, 
and fatty acid oxidation. At the same time, AMPK inhibits anabolic processes such as protein synthesis, 
to restore cellular energy levels (Alexander and Walker, 2011). While the mTOR (mammalian target 
of rapamycin) pathway stimulates cell growth-associated processes in response to growth factor 
signaling, activated AMPK executes growth inhibitory effects, inhibiting mTOR activity through 
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phosphorylation of the tuberculosis sclerosis (TSC1/TSC2) complex, and phosphorylation of raptor, a 
component of mTORC1 (Figure 4) (Gwinn et al., 2008; Inoki et al., 2003). 
LKB1 was first shown to regulate cell polarity in studies performed in C. elegans and Drosophila. The 
C. elegans LKB1 homologue Par-4 was shown to maintain the anterior-posterior polarity of the embryo 
(Kemphues et al., 1988). In Drosophila, Lkb1 mutation affects the anterior-posterior axis as well as 
epithelial polarity (Martin and St Johnston, 2003). Using mammalian intestinal epithelial cells, it was 
later shown that activated LKB1 mediates actin cytoskeleton remodeling and formation of apical brush 
borders (Baas et al., 2004). Other AMPK-related kinases, namely MARK1-MARK4 (microtubule 
affinity-regulating kinases) and SAD-A and SAD-B (synapses of amphid-defective kinases), are known 
to control cell polarity by regulating microtubule assembly (Hezel and Bardeesy, 2008). Another 
AMPK-related kinase downstream of LKB1, NUAK (AMPK-Related Protein Kinase 5), has anti-
apoptotic functions, and is activated upon oxidative stress. Upregulation of NUAK1 has been 
associated with aggressiveness in colorectal cancers (Port et al., 2018; Suzuki et al., 2003). 
 
1.2.5.2. LKB1 in lung cancer 
Loss of heterozygosity (Khosravi et al.) of chromosome 19 were initially observed in 80% of the 
analyzed NSCLC cell lines, compared to less than 30% of the analyzed SCLC cell lines (Virmani et 
al., 1998). Subsequent studies showed that biallelic loss of LKB1 at chromosome 19.13, and loss of 
function mutation in LKB1 (10-50%), are common events in lung cancer (Sanchez-Cespedes et al., 
Figure 4. AMPK-mediated effector functions 
of LKB1. When cellular energy levels are low 
and AMP levels are high, LKB1 phosphorylates 
and activates AMPK. Activated AMPK inhibits 
protein synthesis and cell growth by inhibiting 
mTORC1 function. On the other hand, growth 
factor-mediated activation of the PI3K/AKT 
pathway leads to activation of mTORC1 by 
relieving negative regulation by TSC1/TSC2, 
and this results in cellular growth and protein 






2002). The LKB1 gene is more frequently altered in lung ACs (30%) or ASCs (22%) compared with 
SCCs (1.4-5%); it is never altered in SCLC (TCGA, 2012; TCGA, 2014; Koivunen et al., 2008; 
Sanchez-Cespedes et al., 2002; Vassella et al., 2015). Most of the LKB1 mutations are nonsense, 
frameshift or large intragenic deletions that result in the generation of a truncated protein. Missense 
mutations in the kinase domain have also been reported (Sanchez-Cespedes, 2007). Concurrent LKB1 
loss-of-function mutation and KRAS activating mutations are reported in 67% of analyzed lung cancer 
cell lines, while no significant association exists between LKB1 mutation and EGFR or TP53 mutations 
(Matsumoto et al., 2007). Clinical lung cancers with concomitant KRAS mutation and LKB1 alterations 
(52%) constitute an aggressive subset of NSCLCs, more often found in smokers, and associated with 
poor patient survival (Calles et al., 2015; Facchinetti et al., 2017a; Matsumoto et al., 2007). 
 
1.2.6. TP53 
Tumor protein 53 (TP53) belong to the p53 superfamily of transcription factors. It was discovered 
nearly 40 years ago as the cellular partner of the viral oncoprotein simian virus 40 large T-antigen 
(Kress et al., 1979; Lane and Crawford, 1979). Other members of the p53 family transcription factors 
include p63 and p73 (Levrero et al., 2000). p53 functions as a tumor suppressor in response to various 
cellular stress conditions, including DNA damage, hypoxia, nutrient starvation, oncogene expression 
and ribosome dysfunction, by mediating cell cycle arrest and apoptosis. Murine embryos lacking p53 
(p53-/-) are developmentally normal, but adult mice develop tumors, predominantly lymphomas 
(Donehower et al., 1992). On the contrary, p63 and p73 are involved in development and 
differentiation, and homozygous deletion of p63 (p63-/-) or p73 (p73-/-) leads to embryonic defects 
(Bieging et al., 2014; Levrero et al., 2000; Mills et al., 1999; Yang et al., 2000). TP53 was originally 
thought to function as an oncogene, as it accumulated in the nuclei of the cancer cells. Later discoveries 
showed that it is only the mutated form of p53 cooperated with RAS in inducing cellular transformation, 
assigning it as a tumor suppressor (Finlay et al., 1989; Hinds et al., 1989). TP53 mutations are found 
in the vast majority of human cancers, whereas TP63 or TP73 mutations are uncommon (Hagiwara et 
al., 1999; Hollstein et al., 1991; Melino et al., 2002). 
 
1.2.6.1. p53 regulations and its biological functions 
The transcription factor p53 regulates various biological processes, including DNA repair, cell cycle 
arrest, autophagy, senescence, apoptosis, cellular stem-ness, and metabolic reprogramming (Bieging et 
al., 2014). p53 mediates its function through transcriptional activation, or repression, as well as 
regulation of homologous DNA recombination and protein translation (Zilfou and Lowe, 2009). p53 
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functions as a tetrameric complex, and its function is regulated by affecting protein stability, activity, 
and subcellular localization. Post-translational modifications, which include phosphorylation, 
acetylation, sumoylation, and ubiquitination, play an important role in stabilization of p53. For 
example, p53 activation via protein stabilization is achieved by disruption of its interaction with Mdm2 
(Mouse double minute 2 homolog), a ubiquitin ligase that mediates p53 protein destruction (Hu et al., 
2012). Upon DNA damage, post-translational modification and phosphorylation of p53 by upstream 
kinases such as ATM and ATR disrupt the Mdm2 interaction, leading to protein stabilization (Appella 
and Anderson, 2001). In addition, upon exposure to γ radiation, ATM mediates phosphorylation of 
MDM2, resulting in impaired p53-MDM2 interaction (Khosravi et al., 1999). Following stabilization, 
p53 regulates gene expression by binding to DNA sites that contain two decameric palindromic 
sequences (half-sites) 5′-RRRCWWGYYY-3′, where R is purine, Y is pyrimidine, and W is either A 
or T (el-Deiry et al., 1992; McLure and Lee, 1998). Effector functions regulated by p53 include cell 
cycle checkpoint activation, cellular senescence, and apoptosis (Zilfou and Lowe, 2009). The cell cycle 
effects of p53 are executed via regulation of cyclins and cyclin-dependent kinase inhibitors (CKIs) 
(Brugarolas et al., 1995; St Clair and Manfredi, 2006). One of the p53 target genes, the p21 (waf-1/cip-
1) CKI, negatively regulates the cell cycle by mediating G1 arrest via inhibiting cyclin/cyclin dependent 
kinases. In normal cells, wild type p53 can mediate cellular senescence in response to overexpression 
of oncogenic KRAS (Yang et al., 2006), as a form of cell-intrinsic tumor suppression. This 
phenomenon was later confirmed to occur also in vivo, in a lung cancer model driven by oncogenic 
BRAF, where loss of p53 bypassed senescence in the context of oncogenic BRAFV600E expression, 
resulting in adenoma to AC progression (Dankort et al., 2007). Recently, it was shown that p53 loss 
before the induction of BRAFV600E oncogene-induced senescence (OIS) permits adenocarcinoma 
progression, but p53 loss after the establishment of OIS fails to rescue senescence, and hence does not 
permit tumor progression (Garnett et al., 2017). These results suggest that in the BRAFV600E lung cancer 
model, the timing of p53 loss is crucial for prevention of OIS and hence progression from adenoma to 
adenocarcinoma.  
 
1.2.6.2. TP53 in lung cancer 
Genetic analysis of the bronchial epithelium from chronic smokers revealed frequent LOH on 
chromosome 17p3, which contains the TP53 gene, suggesting a possible link between cigarette 
smoking and TP53 alterations in the lung (Mao et al., 1997). In line with this, the frequency of TP53 
mutations is higher in lung tumors of bronchial origin such as SCLC (100%) and SCC (87%) compared 
to distally arising AC (50%) (TCGA, 2012; TCGA, 2014; D'Amico et al., 1992; George et al., 2015; 
Kishimoto et al., 1992; Takahashi et al., 1991). The high frequency of TP53 mutations in smokers (67% 
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vs 19-26% in never smokers) has been attributed to carcinogen-induced DNA adducts within TP53 
exons (Denissenko et al., 1996; Takagi et al., 1998; Vahakangas et al., 2001). The majority of the 
mutations reside in the DNA binding region of TP53 (Olivier et al., 2002). Clinically, TP53 mutations 
are significant predictor of poor outcome in stage I NSCLC patients (Ahrendt et al., 2003).  
 
1.2.7. ERBB family receptors, ligands and their roles in cancer  
Epidermal growth factor receptor (EGFR) or ERBB family receptors are a group of transmembrane 
tyrosine kinase receptors, consisting of four members: EGFR (ERBB1), HER2 (ERBB2), HER3 
(ERBB3) and HER4 (ERBB4), and regulate cell growth, survival, differentiation, adhesion, and 
migration (Yarden and Sliwkowski, 2001). While inactive ERBB receptors constitute monomeric 
forms, ligand binding to the extracellular domain (ECD) results in homo- or heterodimerization of the 
receptors. In their monomeric state, an intracellular protein kinase (PTK) domain exist in an inactive 
conformation, which is activated in response to receptor dimerization (Fuller et al., 2008). Auto or 
trans-phosphorylation of multiple tyrosine residues within the intracellular domains of dimerized 
partners propagates intracellular signaling, through RAS/RAF/MEK/ERK and PI3K/AKT/mTOR 
signaling, and activation of SRC kinases and STAT transcription factors (Fuller et al., 2008; Yarden 
and Sliwkowski, 2001; Zhang et al., 2006). Although ERBB receptors are structurally similar to each 
other, they show differences in ligand binding and tyrosine kinase activity (Figure 5). ERBB2 is an 
‘orphan’ receptor which lacks a specific ligand, while ERBB3 lacks an intracellular kinase domain. 
However, both can function as heterodimers with other ERBB receptors. Despite lacking functional 
kinase domain ERBB3 can undergo transphosphorylation and transduce intracellular signaling events 
(Citri et al., 2003; Garrett et al., 2003; Guy et al., 1994; Klapper et al., 1999). Ligands of ERBB family 
receptors possess a high affinity EGF-like domain required for receptor binding and activation. EGFR 
has been shown to bind with multiple ligands, which include EGF, transforming growth factor alpha 
(TGF-α), heparin-binding epidermal growth factor like factor (HB-EGF), amphiregulin, epiregulin or 
betacellulin. Of these, EGF, TGF-α and amphiregulin bind exclusively to EGFR, whereas HB-EGF, 
epiregulin and betacellulin also bind to ERBB4. One of the most recently described ERBB ligands, 
epigen, also binds to EGFR, but with lower affinity. Another family of ERBB receptor ligands, called 
neuregulins (NRGs, NRG1-NRG4) can bind to ERBB3 and ERBB4 (Figure 5) (Falls, 2003; Fuller et 
al., 2008). 
Signaling events downstream of ERBB receptor activation involve docking of the adaptor proteins such 
as Grb2 or Shc via SH2/PTB domains to specific receptor phosphotyrosine residues on the cytoplasmic 
domain, followed by activation of RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways, as well as 
activation of Src kinases and STAT transcription factors (Figure 5) (Yarden and Sliwkowski, 2001). 
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Interestingly, ERBB3 is a potent activator of the PI3K/AKT pathway, via its six docking sites for the 
PI3K regulatory subunit p85 (Hellyer et al., 1998). Studies using mouse models have shown that 
targeted deletion of each of the four ERBB receptors leads to embryonic or early postnatal lethality, 
implying that ERBB receptors have non-redundant functions during embryonic development (Lee et 
al., 1995; Miettinen et al., 1995; Threadgill et al., 1995; Tidcombe et al., 2003).  
Emerging evidence suggests that ERBB receptors and their ligands play an important role in cancer 
initiation, progression as well as therapy resistance (Arteaga and Engelman, 2014). Oncogenic 
functions of ERBB receptors were first assigned to EGFR, as it is homologous to the retroviral protein 
v-ERBB that causes the avian erythroblastosis virus to transform chicken cells (Downward et al., 1984). 
Subsequent studies with laboratory models indicated the transforming ability of EGFR and its 
alterations in multiple malignancies (Arteaga and Engelman, 2014). Genetic alterations of ERBB 
receptors, as well as overexpression of certain ERBB ligands, have been detected in multiple cancer 
types (Arteaga and Engelman, 2014). Feedback activation of ERBB receptors, including activation of 
EGFR and ERBB3 following inhibition of MEK/ERK or PI3K/AKT pathways, confer resistance 
mechanisms. In such cases, the combined inhibition of ERBB/MEK or ERBB/AKT signaling provided 
greater anti-tumor effects (Chakrabarty et al., 2012; Chandarlapaty et al., 2011; Corcoran et al., 2012; 
Katayama et al., 2012; Kitai et al., 2016; Prahallad et al., 2012; Turke et al., 2012). 
 
1.2.7.1. ERBB receptors and their ligands in lung cancer 
Genetic alterations in all four ERBB receptors have been detected in human lung cancer. As mentioned, 
EGFR alterations are more common in AC (11-40%) than in SCC (4-7%) (Table 1). Similarly, genetic 
alteration in HER2/ERBB2 (amplifications and mutations) are more prevalent in ACs (3-20%) 
compared to SCC (4%) (TCGA, 2012; TCGA, 2014; Kim et al., 2017; Li et al., 2012). In addition, 
intragenic kinase domain mutations in ERBB2 are exclusively found in ACs and are not accompanied 
with protein overexpression (Stephens et al., 2004). Similar to EGFR mutations, ERBB2 mutations are 
commonly found in female never smokers, accompanied with copy number gains of either ERBB2 or 
EGFR (Li et al., 2012). ERBB2 protein overexpression in NSCLC has been controversial, and a poor 
association between gene copy number alteration and protein overexpression has been observed 
(Hirsch et al., 2002). Furthermore, some studies report that ERBB2 protein overexpression is more 
common in ACs (1.9-38%) (Hirsch et al., 2002a; Hirsch et al., 2002b; Nakamura et al., 2005), while 
others reported that ERBB2 overexpressing tumors are predominantly SCC (Ugocsai et al., 2005). 
Activating mutations in ERBB3 and ERBB4 have also been reported in NSCLC (TCGA, 2012; Kurppa 
et al., 2016). In addition, chromosomal rearrangements in NRG1, one of the ligands of ERBB3, is 
detected in NSCLC. Recurrent rearrangements in the NRG1 gene that result in different fusion gene 
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products, such as CD74-NRG1, RBPMS-NRG1, WRN-NRG1, and SDC4-NRG1, have been identified 
in both AC and SCC, and a pro-tumorigenic effect of NRG1 gene fusions has been attributed to 
overexpression of full-length NRG1 protein driven by WRN promoter (WRN-NGR1), or CD74-NRG1 
fusion protein inducing ERBB2/ERBB3 heterodimers  (Dhanasekaran et al., 2014; Fernandez-Cuesta 




Figure 5. ERBB family receptors, ligands and signaling pathways. ERBB3 lacks a functional 
tyrosine kinase (TK) activity, and there are no specific ligands for ERBB2. Ligand binding to the 
extracellular domain of the ERBB receptors results in homo- or heterodimerization, 
transphosphorylation and receptor dimer activation. This in turn results in activation of downstream 
signaling pathways, namely RAS/RAF/MEK/ERK and the PI3K/AKT/mTOR, and activation of SRC 
family kinases and STAT transcription factors. Together, these pathways regulate cell proliferation, 
survival, invasion, and angiogenesis. Modified from (Modjtahedi et al., 2014). 
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1.3. Targeted therapies for NSCLC 
The discovery of lung cancer driver genes has laid the foundation for implementation of targeted 
therapies against select gene alterations, such as EGFR mutations and ALK rearrangements. Mutations 
in EGFR lead to ligand-independent constitutive activation of the receptor and downstream effectors 
pathways, including activation of MAPK, and PI3K/AKT pathways (Sordella et al., 2004). Small 
molecule TKIs such as gefitinib and erlotinib, or monoclonal antibodies (mAbs) such as cetuximab 
have been developed against mutant EGFR (Pao et al., 2004). Gefitinib and erlotinib are reversible 
competitive inhibitors of ATP, inhibiting the tyrosine kinase activity, and hence downstream pathways. 
Clinical studies have shown improved response with EGFR TKIs in AC histotype tumors, and the 
response correlated with activating somatic mutations in EGFR (Lynch et al., 2004; Miller et al., 2004; 
Pao et al., 2004). Following a phase III clinical trial, both gefitinib and erlotinib were approved as first-
line monotherapy for the treatment of EGFR mutation-positive NSCLC (Pao et al., 2004; Rosell et al., 
2012). However, although EGFR inhibitors prolong patient survival, most patients developed 
resistance following 7-12 months of treatment. In the majority of the cases, acquired resistance was 
due to secondary gatekeeper mutations in exon 20 of EGFR, specifically T790M conversion (Yun et 
al., 2008). Other anti-EGFR resistance mechanisms include MET amplification, or mutations in HER2, 
PIK3CA, BRAF, STAT3, or AXL kinases (Serizawa et al., 2013; Sordella et al., 2004; Wu et al., 2013; 
Zhang et al., 2012). Efforts have focused on targeting EGFR T790M to treat EGFR TKI-resistant 
tumors. Towards this, several third-generation EGFR inhibitors are effective alone or in combination 
with anti-EGFR mAbs in EGFR T790M-positive and EGFR T790M-negative TKI-resistant tumors 
(Politi et al., 2015).  
Clinically, TKIs are not the therapeutic choice after the failure of first-line platinum-based therapy in 
SCC patients (Figure 6). Also, since EGFR alterations are sporadic in the SCC histotype, molecular 
testing for EGFR mutation is not routinely done in patients with SCC. Interestingly, a recent phase III 
trial comprising of molecularly unselected lung SCC patients pretreated with chemotherapy reported 
improved progression-free survival and overall survival of the patients treated with afatinib, an 
irreversible EGFR/ERBB2 inhibitor, compared to erlotinib (Soria et al., 2015). Furthermore, Song et 
al reported that ASC patients treated with erlotinib or gefitinib showed improved progression-free 
survival (ASC: 4.4 months vs SCC: 1.9 months) and overall survival (ASC: 17.6 months vs SCC: 12.2 
months) compared to SCC patients (Song et al., 2013).  
Anaplastic lymphoma kinase (ALK) belongs to the insulin receptor tyrosine kinase family. In lung 
cancer, ALK/EML4 gene fusion is commonly detected in AC (7%) from younger and non-smoking 
patients (Soda et al., 2007; Takahashi et al., 2010; Wong et al., 2009). ALK rearrangements are mutually 
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exclusive with EGFR or KRAS mutation, and at least 27 ALK fusion variants have been reported (Sasaki 
et al., 2010). According to the International Association for the Study of Lung Cancer (IASLC) and the 
European Society for Medical Oncology (ESMO) guidelines, all patients diagnosed with lung AC 
should be tested for ALK rearrangements. The small molecule TKI crizotinib has been approved as a 
first-generation ALK inhibitor, and its mechanism of action is similar to EGFR TKIs. Clinically, 
crizotinib has shown better efficacy compared to standard chemotherapy in ALK positive NSCLC 
patients (Shaw et al., 2013). Crizotinib is also effective against ROS1 and MET tyrosine kinases (Ou 
et al., 2011), (Bergethon et al., 2012). However, similar to first-generation EGFR inhibitors, resistance 
to crizotinib is typically developed within one year of treatment, and 20% of the patients treated with 
crizotinib were diagnosed with brain metastasis following treatment, while no prior metastases were 
present at first diagnosis (Costa et al., 2015). Acquired resistance mechanisms to crizotinib include 
secondary mutations in the ALK kinase domain, copy number gain of the ALK fusion gene, and bypass 
mechanisms consisting of activation of EGFR, KRAS, and c-kit (Choi et al., 2010; Doebele et al., 2012; 
Katayama et al., 2012; Sasaki et al., 2011). Second-generation ALK inhibitors such as ceritinib and 
alectinib have been approved for the treatment of crizotinib-resistant ALK positive tumors (Friboulet 
et al., 2014; Sullivan and Planchard, 2016). 
 
1.4. Immunotherapy for NSCLC 
Cancer immunotherapy involves activation of the patient’s immune system to inhibit tumor 
progression. Immunotherapies can function by breaking so-called immune checkpoints, which are 
generally defined as the set of immune signals required to establish self-tolerance and to prevent the 
immune system from randomly killing cells. Most checkpoint signals are mediated by ligand receptor 
interactions, and they can be grouped as stimulatory or inhibitory. Immune checkpoint molecules can 
be expressed on tumor cells, antigen presenting cells, or T cells. While interactions between stimulatory 
molecules expressed on T cells and antigen presenting cells promote the expansion and effector 
functions of the T cells, interactions between inhibitory checkpoint molecules suppress the activity of 
T cells. For example, interaction between inhibitory checkpoint molecules expressed on the cancer cell 
or tumor-infiltrating immune cells (e.g. Programmed death-ligand 1; PD-L1), and on the T cell (e.g. 
Programmed cell death protein 1; PD-1, or cytotoxic T-lymphocyte-associated protein 4; CTLA-4) are 
known to inhibit T cell proliferation and activation, resulting in escape from anti-tumor immune 
response (Li et al., 2016).  
Immune checkpoint blockade has revolutionized lung cancer therapy. Recently, clinical trials showed 
improved efficacy of mAb PD-1 inhibitors, nivolumab and pembrolizumab, compared to standard-of-
care docetaxel chemotherapy. The CheckMate 017 phase III clinical trial reported an extended median 
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overall survival (OS) of SCC patients treated with nivolumab (9.2 months) compared to docetaxel alone 
(6.0 months). Interestingly, in this study PD-L1 expression was not predictive of response to nivolumab 
therapy, as patients with PD-L1 negative tumors also showed improved response (Brahmer et al., 
2015). A different phase III study on non-squamous lung tumors showed similar responses to 
nivolumab, although in this case response correlated with tumor PD-L1 expression status (Borghaei et 
al., 2015). Similarly, a clinical study evaluated the efficacy of anti-PD-1 pembrolizumab compared to 
docetaxel in pre-treated advanced NSCLC patients. A significantly improved OS was observed in the 
pembrolizumab vs the chemotherapy group (median OS 14.9 vs 8.2 months), with a positive correlation 
between OS and tumor PD-L1 expression status (Herbst et al., 2016). A phase II clinical (POPLAR) 
trial using the anti-PD-L1 mAb atezolizumab has also shown a longer median OS compared to 
docetaxel alone (12.6 vs 9.7 months), and response was associated with increased expression of PD-
L1 (Fehrenbacher et al., 2016). Contrary to this finding, a more recent phase III trial showed that anti-
PD-L1 therapy improved the OS of NSCLC patients regardless of histotype or PD-L1 status (Rittmeyer 
et al., 2017). Based on these clinical trial results, PD-1 and PD-L1 inhibitors have been approved for 
immunotherapy of advanced NSCLC patients. 
Despite the emergence of immune checkpoint inhibitors as powerful approach for treatment of 
advanced NSCLC, response remains limited to a small proportion of the patients (Gettinger et al., 
2015).  Moreover, evidence from murine and human tumors show that the subset of NSCLC that 
harbors KRAS and LKB1 mutations lack PD-L1 expression, and hence are not suitable for immune 
checkpoint inhibition (Calles et al., 2015; Koyama et al., 2016; Skoulidis et al., 2015). This suggest the 
need for alternate effective therapies to treat NSCLC patients who are non-responsive to 
immunotherapy. 
 
1.5. Combination therapies for NSCLC 
Combination therapy combines two or more therapeutic agents. As opposed to a monotherapy 
approach, drug combinations can show improved efficacy by simultaneously inhibiting pathways that 
are synergistic or additive in promoting tumor growth and metastasis. In addition, it was shown more 
recently that inter-patient variability in response to a single drug and independent drug actions can also 
explain combination therapy benefit, without involving synergistic drug effects (Palmer and Sorger, 
2017).  
For lung cancer, FDA approved combination therapies currently include chemotherapy combined with 
targeted therapy or immunotherapy (Ruiz-Ceja and Chirino, 2017). The TRIBUTE randomized phase 
III clinical study  showed that the combination of the EGFR TKI erlotinib with carboplatin and 
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paclitaxel showed improved response compared to chemotherapy alone, and EGFR mutation carriers 
showed improved response to the combination (53%) than wild type EGFR (18%) (Eberhard et al., 
2005). As expected, KRAS mutation in this study was negatively associated with response to 
combination therapy. Recently, the combination of the MEK inhibitor trametinib and the B-Raf 
inhibitor dabrafenib was FDA-approved for the treatment of BRAF mutant metastatic NSCLC. Owing 
to the high incidence ERBB family receptor alterations in NSCLC, (Hendler and Ozanne, 1984; Hirsch 
et al., 2003; Ugocsai et al., 2005), combinations with the pan-ERBB inhibitor afatinib are currently 
being evaluated (Bennouna and Moreno Vera, 2016). Preclinical evidence using NSCLC cell lines has 
shown ERBB3 activation following MEK inhibition (Kitai et al., 2016), and the combination afatinib 
and MEK inhibitor selumetinib treatment for KRAS mutant advanced NSCLC is under clinical 
investigation (Bennouna and Moreno Vera, 2016). The combination of afatinib with the PI3K/mTOR 
inhibitor sirolimus did not provide any therapeutic benefit in a recent phase Ib clinical trial (Moran et 
al., 2017), and the combination of afatinib with the SRC inhibitor dasatinib and the  pan-JAK inhibitor 
ruxolitinib are still under clinical investigation (Bennouna and Moreno Vera, 2016).  
Direct targeting of KRAS has been challenging, due to a number of reasons, including absence of 
known allosteric binding sites, the high affinity of KRAS for GTP over GDP, as well as parallel 
compensatory pathways that provide alternate signaling (Gysin et al., 2011). Attempts to inhibit KRAS 
using farnesyl transferase inhibitors (FTI), which interfere with the post-translational addition of a 
farnesyl group, lead to escape mechanisms via post-transcriptional activation of geranyl-geranylation 
(Adjei et al., 2003; Sousa et al., 2008). Similarly, salirasib, which dislodges farnesylated RAS from the 
cell membrane, was also ineffective in NSCLC patients (Tsimberidou et al., 2010). A recent study 
reported on a new KRAS G12C inhibitor, ARS-1620, and showed it caused tumor regression in patient 
derived xenograft models, but its effect on clinical samples has yet to be investigated (Janes et al., 
2018). The MEK protein downstream of KRAS has also been considered as a potential target to inhibit 
MAPK signaling. However, combinations of docetaxel and the MEK inhibitor selumetinib or 
trametinib in KRAS mutant NSCLC patients did not show favorable outcomes compared to docetaxel 
alone (Blumenschein et al., 2015; Janne et al., 2013). Furthermore, the combination of selumetinib plus 
erlotinib in advanced KRAS mutant or wild type NSCLC patients was not beneficial over monotherapy 
(Carter et al., 2016). Clinical trials evaluating the efficacy of immunotherapy in combination with 
EGFR or ALK TKI in advanced NSLC are ongoing (Moya-Horno et al., 2018), and may give 
encouraging results. Overall, these results highlight an unmet need for effective combinations to treat 
molecularly-defined advanced NSCLC, and particularly its link to companion diagnostics that may 
better stratify the patients.  
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Despite significant advances in the discovery of targeted therapies for the treatment of advanced 
NSCLC, patients eventually develop resistance, culminating in poor clinical outcomes. Despite the 
discovery of select targetable drivers, traditional chemotherapy is the only first-line treatment of choice 
for treating locally advanced or metastatic SCC (Figure 6). In addition to genotype-based patient 
subtyping, efforts must be focused on the identification of histotype-specific predictive biomarkers to 
achieve NSCLC subtype-specific effective therapies.  
 
 
Figure 6.  Pharmacological management of advanced NSCLC. Treatments are based on 
histological and molecular features. Platinum-based chemotherapy is recommended as first-line 
treatment for non-squamous and squamous lung cancer, and second-line treatments are either 
docetaxel alone, or in combination with the anti-VEGFR2 antibody ramucirumab, or anti-PD1 
antibodies nivolumab and pembrolizumab. Anti-EGFR TKIs erlotinib, gefitinib, and afatinib are 
approved as first-line therapy in patients carrying EGFR mutations. Osimertinib, a third-
generation EGFR TKI, is applied as second-line therapy for T790M carriers following first-line 
anti-EGFR therapies. Patients with ALK rearrangements are treated with crizotinib as first-line 
therapy. Progressive disease after second-line therapy is treated with chemotherapy. Adapted from 




1.6. Tumor heterogeneity 
Tumor heterogeneity refers to differences in the genetic, phenotypic and functional profiles of distinct 
cell populations found in a single tumor (intratumor heterogeneity: ITH), or between different tumors 
(intertumor heterogeneity). Tumor heterogeneity is detected at various levels: i) genetic heterogeneity, 
in which each tumor has its own genetic or epigenetic profile, or genetic differences exist between 
subpopulations of the same tumor, ii) microenvironmental heterogeneity, where tumors exhibit distinct 
stromal features composed of, for example, varying immune cell infiltrates, fibroblasts, or vasculature, 
iii) differences in biomarker expression, such as oncogenic signaling activities (de Bruin et al., 2015; 
Hanahan and Coussens, 2012; Liu et al., 2016; Spagnolo et al., 2016). The second and third 
heterogeneity types are considered to represent phenotypic heterogeneity, and all three heterogeneity 
types can be distributed in a spatial manner within the same tumor, referred to as spatial ITH (Hao et 
al., 2016; Spagnolo et al., 2016; Yuan, 2016). Both genetic and phenotypic heterogeneity have been 
implicated in sensitivity to therapies or drug resistance (Junttila and de Sauvage, 2013; Turner and 
Reis-Filho, 2012). 
Two different models have been proposed to explain tumor heterogeneity: i) the cancer stem cell model, 
suggesting that only a subpopulation of tumor cells, called stem cells, possess an ability to self-renew 
and differentiate into non-tumorigenic cells, with heterogeneity arising from differences in genetic and 
epigenetic changes among different stem cells, and ii) the clonal evolution model, suggesting that 
tumors originate as a result of mutation in a single cell of origin, and by temporally accumulating 
mutations, this gives rise to heterogeneous populations which can divide and mutate further (Nowell, 
1976; Reya et al., 2001). The mechanisms by which tumor heterogeneity arises during the patient’s life 
time is currently an intensely investigated subject. Multiregion sequencing analysis pioneered by 
Swanton and Gerlinger suggests that tumor evolution is accompanied with spatially and temporally 
distinct genetic alterations, with subclonal mutations leading to intratumor genetic and phenotypic 
heterogeneity (de Bruin et al., 2015; Gerlinger et al., 2012) 
 
1.6.1. NSCLC heterogeneity and therapeutic implications  
Multiregional analysis of human lung AC for spatial distribution of KRAS and EGFR mutation has 
identified high level of intratumor and intertumor heterogeneity in gene mutations. In addition, analysis 
of tumor subregions has identified correlations between higher variant allele frequencies (VAF) of 
KRAS and EGFR with solid AC growth pattern compared to other histological AC subtypes (Dietz et 
al., 2017). Recent multiregional gene expression analysis of human NSCLC has also shown significant 
inter and intratumor heterogeneity, of gene signatures related to epithelial-to-mesenchymal transition 
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(EMT), and resistance to PD-1 checkpoint inhibitors (Lee et al., 2018). Furthermore, by doing multi-
region exome/whole genome sequencing of NSCLC patients, Swanton and colleagues showed spatial 
and temporal heterogeneity in driver gene alterations. They found decrease in smoking-associated 
mutations over time and increase in apolipoprotein-B mRNA editing catalytic polypeptide-like 
(APOBEC) cytidine deaminase mediated mutations, and this was more prevalent in lung ACs 
compared to SCC, suggesting histotype-specific regulatory effects of APOBEC (de Bruin et al., 2015). 
The process of tumorigenesis involves a complex interplay between tumor cells and the host immune 
system, in a way that favors tumor cells to escape from host immune surveillance. Tumor infiltrating 
immune cells can either be pro-tumorigenic, and this category includes tumor associated macrophages 
(TAMs), myeloid derived suppressor cells (MDSCs), and regulatory T cells (Tregs). Anti-tumorigenic 
immune cells include cytotoxic T cells (CTL) (CD8+) and natural killer cells (NK cells). The density 
of tumor-infiltrating lymphocytes, particularly CTL, is associated with response to chemotherapy and 
improved survival in patients with advanced NSCLC (Kilic et al., 2011; Liu et al., 2012a). On the 
contrary, an increase in MDSCs (CD14+HLA-DR-) in NSCLC patients is associated with metastasis 
and poor response to chemotherapy (Huang et al., 2013). Heterogeneity in signaling downstream of 
NSCLC driver genes has an impact on patient survival, therapeutic sensitivity and resistance 
mechanisms (Gerdes et al., 2013; Lee et al., 2013). However, intertumoral as well as spatial ITH in 
oncogenic signaling downstream of common driver genes, such as KRAS, EGFR, or loss of LKB1 has 
thus far not been extensively studied in NSCLC. 
 
1.7. Preclinical models of lung cancer 
Various in vivo and ex vivo models have been established to dissect the physiological and molecular 
mechanisms that drive lung cancer pathogenesis.  These models have also been used for preclinical 
investigation of promising monotherapy and drug combinations, and the discovery of potential new 
NSCLC targets. 
 
1.7.1. In vivo models 
In vivo mouse models can be categorized as xenografts, chemically-induced, syngeneic, and transgenic 
models (Kellar et al., 2015). Generation of classic xenograft models involves injection of established 
cancer cell lines into immunodeficient mice, either subcutaneously or orthotopically into the same 
organ from which cancer cells were derived. These classical models are mainly used for testing drug 
response in vivo prior to enrolling new compounds in clinical trials (Steiner et al., 2007). Recent efforts 
have however focused on the grafting of patient-derived tumor cells or tissue pieces (PDX models), 
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and these serve as an ideal model for personalized cancer therapy (Gao et al., 2015; Morgan et al., 
2017). However, besides lacking physiologically relevant immune system, PDX models have been 
shown to undergo genetic drift during later passages, and hence may not recapitulate molecular and 
functional heterogeneity of the in situ tumor (Julien et al., 2012). Chemically-induced mouse models 
require exposure to carcinogens to initiate tumorigenesis. Typically, carcinogen-induced mouse models 
are inbred mice strains such as A/J or SWR known to be susceptible for spontaneous tumor 
development (Gordon and Bosland, 2009). Among carcinogen-induced models, lung adenocarcinomas 
driven by urethane has been shown to harbor Kras and p53 mutations (Horio et al., 1996). Syngeneic 
mouse models enable the injection of immunologically compatible tumor cells into immunocompetent 
mice. Syngeneic mouse models of lung cancer are limited; one well-studied model is the lewis lung 
carcinoma (LLC), originally established by injecting primary LCC cells derived from the spontaneous 
lung tumor of  C57BL mouse into the lung of recipient C57BL mouse (Rask et al., 2013). Due to the 
aggressiveness of the cell line, this model is used to for metastasis studies and for in vivo testing of 
chemotherapeutic agents (Papageorgiou et al., 2000; Sakai et al., 2006). Genetically engineered mouse 
models (GEMMs) are transgenic models that carry conditional or inducible genetic alterations, and are 
created by microinjection of the desired DNA construct into fertilized mouse oocytes, followed by 
homology-based genomic recombination to generate genetically-modified offspring (Gordon et al., 
1980). Another method, developed by Oliver Smithies and Mario Capecchi, involves modifying 
embryonic stem cells (ES) with DNA constructs homologues to the gene of interest, followed by 
implantation of ES cells with the desired genomic DNA into murine blastocysts (Thomas and Capecchi, 
1987). A variety of GEMMs carrying clinically-relevant genetic alterations have been created to model 
human NSCLC, which will be discussed below. 
 
1.7.1.1. Transgenic mouse models of lung cancer 
Transgenic mice or GEMMs of lung cancer are powerful models to examine processes governing tumor 
initiation and progression (Meuwissen and Berns, 2005). Sophisticated genetic engineering tools have 
enabled the creation of a number of lung cancer models with somatic gene alterations, which can be 
activated or inactivated in a spatial and temporal manner. The widely used Cre/lox and FLP/frt 
recombinase system permits conditional activation of oncogenes or inactivation of tumor suppressors 
(Jackson et al., 2001; Lee et al., 2012; Meuwissen et al., 2001; Sadowski, 1995; Sternberg and 
Hamilton, 1981). The availability of intranasally or intratracheally deliverable adenoviral Cre (AdCre) 
particles, as well as lentiviral Cre (LentiCre) particles, can mediate pulmonary tissue-specific genetic 
recombination (Gierut et al., 2014). These particles also permit the study of the role of different lung 
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epithelial cells in tumor initiation and progression, through the incorporation of cell type-specific 
promoters to drive Cre expression (Sutherland et al., 2011; Sutherland et al., 2014).  
 
1.7.1.2. GEM models of lung adenocarcinoma 
A number of transgenic mouse models model AC, the most common subtype of lung cancer. The 
earliest transgenic mouse model developing AC was expressing simian virus large T-antigen 
(SV40Tag) under the control of the CC10 or SPC promoter (DeCaprio et al., 1988; Dobbelstein and 
Roth, 1998). Later, expression of the oncogene c-Myc under the control of SPC promoter was shown 
to drive bronchioalveolar adenoma and then AC, with an average latency of 9.2 months (Ehrhardt et 
al., 2001). On the other hand, when c-Myc was driven by CC10 promoter, only bronchioloalveolar 
hyperplasias were observed (Geick et al., 2001). Transgenic mice carrying genetic alterations that are 
commonly found in lung ACs include models with Egfr mutation and Eml4-Alk4 fusion genes; mice 
harboring human EGFR kinase domain mutations, the exon 19 deletion and the exon 21 point mutation 
L858R, under the CCSP promoter develop ACs (Ji et al., 2006a; Politi et al., 2006). Expression of the 
Eml4-Alk4 fusion gene in SPC+ cells leads to development of multiple ACs within a few weeks of birth 
(Soda et al., 2008). 
The first oncogenic Kras-driven lung AC models were developed by Jacks and colleagues, and one 
model used a latent allele of KrasG12D (KrasLA) which is activated by spontaneous recombination. In 
addition to lung ACs, these mice also developed intestinal crypt foci, and skin papilloma (Johnson et 
al., 2001). Two additional inducible KrasG12D/+ GEMMs were created, one with a reverse tetracycline-
controlled transactivator (rtTA), and the other one  with the KrasG12D stop codon flanked by Cre-loxP 
sites (Fisher et al., 2001; Jackson et al., 2001). Both these Kras models have been extensively used, 
and include the combination of KrasG12D together with genes involved in cell cycle regulations, such 
as p53fl/fl, Rb1fl/fl, Rb12fl/fl, and Map2k7fl/Δ, or genes involved in controlling cellular metabolism and 
polarity, such as Lkb1fl/fl, or genes that regulate cell growth and proliferation, such as Ptenfl/fl (Ho et al., 
2009; Iwanaga et al., 2008; Ji et al., 2007; Schramek et al., 2011). With exception of the model 
harboring concomitant KrasG12D activation and loss of Lkb1 (Kras G12D/+;Lkb1fl/fl, KL), which produces 
lung SCC, ASC, and NSCLC-NOS (previously known as large cell carcinoma) in addition to AC, all 
models exclusively develop AC histotype tumors. Recently, a GEM model carrying clinically common 
KRAS mutation, KRASG12C (hKRASG12C) has been established (Li et al., 2018). 
A transgenic model carrying the KrasG12V mutation commonly found in lung ACs, has been established 
(Meuwissen et al., 2001). To elucidate the bioequivalence of oncogenic functions of Kras and Hras 
isoforms, Barbacid and colleagues generated transgenic mice expressing HrasG12V under the Kras locus, 
40 
 
and demonstrated differential effects of oncogenic KrasG12V and HrasG12V in lung tumorigenesis. Unlike 
KrasG12V, lung-specific expression of HrasG12V from the Kras locus did not result in lung tumors due to 
overactivation of MAPK signaling, resulting in a senescent-like state. However, it was also shown that 
the expression of Kras locus-driven HrasG12V was 2.5 fold higher than that of KrasG12V, suggesting that 
differences could be due to differences in their expression levels (Drosten et al., 2017).  
The transcription factor NKX2-1 is a master regulator of cell fate determination during embryonic 
development of pulmonary tissue, and is frequently lost in poorly differentiated ACs (Herriges and 
Morrisey, 2014). Homozygous loss of Nkx2-1 alters AC differentiation in KrasG12D/+ mice, and deletion 
of Nkx2-1 leads to mucinous AC as well as gastric differentiation of lung ACs marked by expression 
of the transcription factor, Hnf4α (Hepatocyte nuclear factor 4-alpha) (Snyder et al., 2013). These 
results suggests that NKX 2-1 has an important role in determining tumor differentiation and 
establishment of the AC sub-histotypes.  
Homozygous loss of p53 (p53fl/fl) or expression of a mutant form of p53 (structural mutant; p53R172H/-, 
or contact mutant; p53R270H/-) accelerates KrasG12D-induced lung AC development, and increases 
metastasis to lymph nodes and distant organs (Table 3) (Jackson et al., 2005). Tumors in the 
KrasG12D;p53fl/fl,  KrasG12D;p53R172H/-, or KrasG12D;p53R270H/- GEMMs show characteristics of human 
tumors, including high grade ACs characterized by nuclear atypia, and desmoplastic stroma. 
Interestingly, AdCre-mediated loss of p53 (p53fl/fl) alone drives AC with a longer latency (1-1.5 years) 
suggesting that p53 alteration itself is not sufficient to initiate lung tumorigenesis; instead the oncogenic 








Genetic modifications Initiation method Tumor burden Reference  
Kras LSL-G12D/+ 
 





Kras LSL-G12D/+;Trp53 fl/fl Ad5-CMV-Cre Advanced AC 
with lymph node 
metastasis 
(Jackson et al., 
2005)  
Kras LSL-G12D/+;Trp53 LSL-R172H/-  Ad5-CMV-Cre Advanced AC 
with lymph node 
metastasis 
(Jackson et al., 
2005)  
Kras LSL-G12D/+;Trp53 LSL-R270H/- Ad5-CMV-Cre 
Advanced AC 
with lymph node 
metastasis 
(Jackson et al., 
2005) 
 
Kras LSL-G12D/+;Ptenfl/fl CC10-Cre Advanced AC (Iwanaga et al., 
2008) 
 
Kras LSL-G12D/+;Lkb1fl/fl Ad5-CMV-Cre AC (Ji et al., 2007)  








Ad5-CMV-Cre Decreased AC 
burden 
(Engelman et al., 
2008) 
 
Kras LSL-G12D/+;Tgfbr2fl/fl K5-CrePR Increased AC 
burden 
(Malkoski et al., 
2012) 
 
Kras LSL-G12V/+ CMV-Cre+/T Adenomas and 
AC 
(Meuwissen et al., 
2001) 
 
hKRAS LSL-G12C/+ Ad5-CMV-Cre AC (Li et al., 2018)  
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1.7.1.3. GEM models of lung squamous cell carcinoma  
Only very few GEMMs exist to model lung SCC. Lung-specific loss of Lkb1 together with bi-allelic 
inactivation of Pten (LP) leads to SCC formation (Xu et al., 2014). In addition, using bi-cistronic 
lentiviral vectors expressing Sox2 and Cre recombinase, it has been shown that Sox2 expression 
cooperates with Lkb1 loss (Sox2;Lkb1) to promote lung SCC formation (Mukhopadhyay et al., 2014). 
Concomitant loss of Pten and Tgfrb2 (transforming growth factor beta type II receptor) in airways by 
Cre recombinase under the control of K5 (keratin 5) promoter results in SCC with low incidence 
(Malkoski et al., 2012). A recent study by Berns and colleagues showed that SOX2, but not FGFR1, 
overexpression is critical for establishing squamous tumors in mice harboring conditional loss of Pten 
and Cdkn2ab (PC). This study demonstrated that both FGFR1 and SOX2 expression can drive lung 
tumorigenesis in PC mice but, only SOX2 (Sox2;PC model) overexpression promotes SCC formation, 
whereas FGFR1 overexpression results in sporadic SCCs (Ferone et al., 2016). These findings suggest 
that FGFR1, despite being frequently amplified (22%) and overexpressed (27%) in lung SCC, is not 
critical for driving SCC tumorigenesis, at least in the mouse (Table 4) (TCGA, 2012; Ferone et al., 
2016; Weiss et al., 2010). 
A lung cancer model harboring homozygous loss of Lkb1 was shown to cooperate with oncogenic 
KrasG12D to generate an expanded histopathology spectrum compared to KrasG12D mice, including SCC 
and ASC tumors. Furthermore, KL mice treated with AdCre exhibited a shorter latency compared to 
KrasG12D/+ mice (median survival, KL: 63 days vs Kras: 168 days). In addition, these mice also 
demonstrated enhanced metastasis to regional lymph node (61%), or axial cytoskeleton (7%) compared 
to KrasG12D/+ (0%) mice (Ji et al., 2007). Interestingly, KrasG12D activation or Lkb1 loss alone did not 
produce SCC, suggesting cooperative effects of oncogenic Kras and Lkb1 loss in SCC tumorigenesis 
(Ji et al., 2007). Furthermore, spontaneously arising SCCs in a mouse model harboring kinase dead 
IKKα (an inhibitor of the nuclear factor kappa-B kinase subunit alpha) showed significant 
downregulation of LKB1 compared to adjacent normal lung tissue, further supporting a mechanistic 
role of LKB1 loss in SCC differentiation and tumorigenesis (Xiao et al., 2013). In the KL model, 
transdifferentiation of AC to SCC via an ASC intermediate stage has been reported (Han et al., 2014), 
and suggested to mechanistically involve the extracellular matrix remodeling enzyme lox (lysal 
oxidase), the YAP (yes-associated protein) hippo pathway protein, as well as oxidative stress in 
regulating the AC-SCC transition (Gao et al., 2014; Han et al., 2014; Li et al., 2015a).  
Despite the low incidence of LKB1 genetic alterations in lung SCC (Table 1), above murine studies 
thus show that Lkb1 loss plays an important role in the establishment of SCC together with genes 
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predominantly altered in SCC, namely PTEN and SOX2, and that these tumors thus represent a small 
subset of clinical SCC. 
 
1.7.1.4. GEM models of lung adenosquamous cell carcinoma 
ASC is one of the rarest but most aggressive subtype of lung cancer, with poor patient prognosis 
(Nakagawa et al., 2003). Only limited mouse models have been shown to give rise to ASCs, with the 
already mentioned KL model being one of these (Ji et al., 2007) (Table 4). As mentioned, in the KL 
model, transdifferentiation of SPC+ cell-derived AC to SCC tentatively suggested to involve ASC as 
an intermediate stage (Han et al., 2014). In addition to the KL model, also loss of Pten and a 
transcription factor Smad4 in CC10 expressing airway epithelial cells results in ASCs, showing 
increased activation of AKT and ERBB2 compared to normal airway epithelium (Liu et al., 2015). 
Mechanistically, deletion of Pten and Smad4 led to transcriptional repression of Errfi1, a negative 
regulator of ERBB2 leading to increased ERBB2 signaling. Interestingly, transgenic expression of the 
mutant human HER2 gene (hHER2YVMA) in the lung epithelium drives ASC formation (Perera et al., 
2009), suggesting that ERBB2 receptor-mediated signaling suffices to initiate and establish ASC 








Genetic modifications Initiation 
method 
Tumor burden Reference 
 
Kras LSL-G12D/+; Lkb1fl/fl 
(KL) 
Ad5-CMV-Cre AC, SCC, ASC, and 
LCC 
(Ji et al., 2007) 
 
Lkb1fl/fl;Ptenfl/fl (LP) Ad5-CMV-Cre SCC (Xu et al., 2014)  
IkkaKA/KA  Spontaneous SCC (Xiao et al., 2013)  






Lenti-Sox2-Cre SCC (Mukhopadhyay 






SCC (Ferone et al., 
2016)  
Ptenfl/fl ;Cdkn2abfl/fl 
;LSL-Fgfr1K656E   
Ad5-K5-Cre 
Ad5-K14-Cre 




CCSPiCre ASC (Liu et al., 2015) 
 
hHER2YVMA CC10-rTA ASC and occasional 
AC 





1.8. Cellular origin(s) of lung cancer 
Tumorigenesis is a multistep process. Transforming events lead to alterations of stem/progenitor cell 
functions. In this,  the precise cell of origin has been suggested to define phenotypic heterogeneity of 
the tumor lesions (Blanpain, 2013). Thus, improved understanding of the tumor progenitor cell can 
help in uncovering the source of tumor heterogeneity. As mentioned, anatomically distinct 
stem/progenitor cells have been identified based on their ability to self-renew and/or differentiate into 
specific lung epithelial cells. These include tracheal basal cells and club cells, bronchiolar club cells, 
BASCs in the BADJ, and alveolar AT2 cells (Figure 2) (Leeman et al., 2014). To explore the role of 
progenitor cells in progression of NSCLC, two different approaches have been used in GEM models: 
i) adenoviruses that contain epithelial cell type-specific promoter to drive expression of the Cre 
recombinase (Ad5-CC10-Cre, Ad5-SPC-Cre, Ad5-K5-Cre,and Ad5-K14-Cre), and ii) inducible 
knock-in mouse models (Sftpc-CreER, or CC10-CreER), in which cell type-specific genetic 
recombination is achieved following tamoxifen treatment (Sutherland et al., 2011; Sutherland et al., 
2014; Xu et al., 2012)  
 
1.8.1. Studies on the cell of origin of NSCLC 
The progenitor cells of lung AC have been defined during recent years. Studies using the KrasG12D/+ 
and KrasG12D/+;p53fl/fl GEMMs have identified club cells, AT2 cells, and BASCs as progenitors of 
murine AC (Kim et al., 2005; Sutherland et al., 2014; Xu et al., 2012). By using Ad5-CC10-Cre and 
Ad5-SPC-Cre, Sutherland et al showed that both CC10+ and SPC+ cells can drive AC progression upon 
activation of KrasG12D/+ alone, or in combination with loss of p53 (Sutherland et al., 2014). Despite an 
absence in survival differences between KrasG12D/+ or KP mice infected with SPC-Cre or CC10-Cre 
viruses, Sutherland et al reported that CC10+ cell-derived ACs showed invasive characteristics and 
expressed Hmga2, a transcription factor involved in the regulation of proliferation, EMT, and 
metastasis in many cancers and also expressed in poorly differentiated tumors (Gao et al., 2017; 
Sutherland et al., 2014). Similarly, using tamoxifen-inducible SPC-Cre-ER or CC10-Cre-ER mouse 
models, Xu et al showed that both CC10+ and SPC+ positive cells are progenitors of AC in 
KrasG12D/+;p53fl/+ mouse model (Xu et al., 2012). The role of BASCs as  progenitors of AC is under 
debate: while Kim et al showed expansion of BASCs as measured by immunofluorescence (IF) 
staining, following Ad5-CMV-Cre mediated KrasG12D/+ expression, Sutherland et al did not observe 
SPC and CC10 dual positive cells in the BADJ/BASC region of Ad5-SPC-Cre infected KrasG12D/+ mice 
(Kim et al., 2005; Sutherland et al., 2014). Possible explanations could be that either the SPC promoter 
activity in SPC/CC10 dual positive BASC cells is too low to initiate KrasG12D activation, or BASCs are 
not AC progenitors. Interestingly, an AdCre-mediated inflammatory response, consisting of increased 
46 
 
infiltration of T and B cells, has been linked to CC10+-driven AC progression in the KrasG12V/+ model 
(Mainardi et al., 2014). This inflammatory response was essential for progression of epithelial 
hyperplasia to low grade adenomas, but not for progression to advanced ACs. These findings show that 
the tumor cell of origin, together with the genetic drivers and microenvironmental factors influence the 
tumor progression and aggressiveness of the established tumors. 
Recently, Ferone et al demonstrated that basal cells, club cells, and AT2 cells have the capacity to give 
rise to SCC in the Sox2;PC mouse model. While SCCs induced from basal cells using Ad5-K14-Cre 
were detected in the bronchi or bronchioles, leading to centrally-localized tumors, Ad5-CC10-Cre- or 
Ad5-SPC-Cre driven SCCs were distributed in the peripheral regions of the lung. In addition to 
morphological similarities, SCCs derived from different progenitors exhibited striking similarity in 
their gene expression profiles. The authors therefore concluded that peripheral SCCs in humans may 
originate from both SPC+ or CC10+ cells, and also that SOX2 expression is a determining factor for 
SCC tumorigenesis (Table 5). (Ferone et al., 2016). Using CC10 promoter-driven knock-in mice or 
AdCre viruses, previous studies have shown that CC10+ cells can drive ASC tumorigenesis (Liu et al., 
2015; Perera et al., 2009). However, the relative roles of progenitors in establishing lung ASC remains 
unclear. Moreover, in the study by Han et al addressing the transdifferentiation of KL AC to SCC via 
ASC, the human SPC promoter was used to drive Cre-ER expression, and this promoter has been shown 
to be active in bronchiolar and alveolar cells (Glasser et al., 1991; Han et al., 2014), suggesting that 
cellular origins of diverse NSCLC histotypes observed in the KL model are unlikely restricted to the 










Tumor burden Reference  
Kras LSL-G12D/+ Ad5-CC10-Cre Papillary hyperplasia, 
papilloma, and papillary 
carcinoma 
(Sutherland et al., 
2014) 
 
Kras LSL-G12D/+ Ad5-SPC-Cre AAH, mixed AC 
(Sutherland et al., 
2014) 
 
Kras LSL-G12D/+;Trp53 fl/fl  Ad5-CC10-Cre Invasive, metastatic 
Hmga2 positive AC 
(Sutherland et al., 
2014) 
 
Kras LSL-G12D/+;Trp53 fl/fl Ad5-SPC-Cre Mixed AC 
(Sutherland et al., 
2014) 
 
Kras LSL-G12D/+;Trp53+/fl CC10-CreER 
Hyperplasia at BADJ, AC 
in alveoli 
(Xu et al., 2012)  
Kras LSL-G12D/+;Trp53+/fl SPC-CreER AC in alveoli (Xu et al., 2012)  
Kras LSL-G12D/+; Lkb1fl/fl SPC-CreER AC which transdifferentiate 
into SCC via ASC 
(Han et al., 2014) 
 
Kras LSL-G12D/+; Lkb1fl/fl Ad5-SPC-Cre AC, SCC, and, ASC (Li et al., 2015a)  
Pten fl/fl;Cdkn2abfl/fl 
;LSL-Sox2 





Ad5-SPC-Cre Peripheral SCC  





Ad5-K14-Cre Central SCC  





1.9. Modeling of immune functions in lung cancer 
Tumorigenesis involves a complex interplay between malignant cells and the host environment, which 
consists of vasculature, stromal cells, and cells of the innate and adaptive immune system (Junttila and 
de Sauvage, 2013). The tumor immune contexture, which is defined as the functional identity, density, 
and spatial distribution of immune cells, is regarded as an important factor affecting patient prognosis 
and therapeutic efficacy (Fridman et al., 2013). Immunosurveillance is a mechanism by which the host 
immune system recognizes neoantigens, and destroys transformed cells. Some of the effector cells that 
mediate immunosurveillance are NK cells, macrophages, and tumor-infiltrating lymphocytes (TILs), 
mainly represented by CD8+ T cells and interferon gamma (IFN-γ)-producing γδ T cells (Figure 7) 
(Dunn et al., 2002). Conversely, tumors employ various strategies to escape from the host immune 
system, a process called immunoediting. Various soluble factors and cytokines secreted by the tumor 
cells favor the recruitment of cells with immunosuppressive functions, which includes MDSCs capable 
of inhibiting T cell-mediated immunosurveillance (Marvel and Gabrilovich, 2015). Another immune 
evasion mechanism is altered antigen presentation by downregulating expression of class I major 
histocompatibility complex (MHC) molecules, or alterations in the antigen-processing machineries, 
amounting to escape form CTL-mediated recognition and tumor attack (Garrido et al., 1997; Maeurer 
et al., 1996). A subset of CD4+ T cells called Tregs, marked by expression of the FoxP3 transcription 
factor, also act immunosuppressively, by suppression of antigen presentation and secretion of T cell 
inhibitory cytokines (Facciabene et al., 2012). Tregs have been implicated in lung cancer progression 
and metastasis (Marshall et al., 2016). In addition, significant enrichment of Tregs in lung ACs 
compared to SCCs has been observed in clinical samples suggesting histopathology-selective functions 
of Tregs and AC patients might benefit from anti-Treg therapies (Black et al., 2013). 
Hematopoietic stem cells give rise to myeloid progenitors, which then differentiate into immature 
myeloid cells (IMCs). Under normal conditions, IMCs are produced in the bone marrow, and these 
cells then differentiate into macrophages, dendritic cells (DCs) and granulocytes. However, in disease 
conditions including cancer, differentiation of IMCs can be blocked, resulting in the expansion of IMCs 
with immunosuppressive functions which are referred to as MDSCs (Gabrilovich and Nagaraj, 2009). 
In mice, MDSCs are identified based on cell surface expression of CD11b (integrin alpha M) and Gr-
1. A monoclonal antibody that binds to cell surface antigen Gr-1 recognizes two different epitopes, 
namely lymphocyte antigen 6 complex locus G and C (LY6G and LY6C), with higher affinity for 
LY6G (Fleming et al., 1993). Subsequently, development of isotope-specific antibodies led to the 
identification of two subsets of MDSCs, namely granulocytic MDSCs identified as 
CD11b+LY6G+LY6Clow, and monocytic MDSCs identified as CD11b+LY6G−LY6Chi (Youn et al., 
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2008). Importantly, granulocytic MDSCs share similarity with neutrophils/tumor-associated 
neutrophils (TANs) in terms of morphology and cell surface markers (Pillay et al., 2013). 
Human MDSCs are identified as cells that co-express CD11b and CD33, but lacking HLA-DR. The 
granulocytic counterpart of human MDSCs are CD15+, whereas monocytic MDSCs are CD14+. In 
recent years, molecules that regulate MSDC’s immune suppressive functions have been identified, 
including Arginase-1 (Arg-1), indoleamine 2, 3-dioxygenase (IDO1), reactive oxygen species (ROS), 
and nitric oxide synthase (NOS) (Elliott et al., 2017). Inflammatory signals, and the pro-inflammatory 
cytokines interleukin 1b (IL1β) and interleukin-6 (IL-6), as well as the bioactive lipid prostaglandin 
(PGE2), are known to induce MDSC accumulation and activation (Ostrand-Rosenberg and Sinha, 
2009; Song et al., 2005; Tu et al., 2008). In addition, the S100 Calcium Binding Proteins A8 and A9 
(S100A8 and S100A9) regulate MDSC mobilization (Sinha et al., 2008). One of the well-described 
mechanisms of MDSC-mediated immunosuppression relates to the metabolism of L-arginine, which 
acts as a substrate for two enzymes, iNOS (generating NO) and arginase 1 (converting L-arginine to 
urea and L-ornithine). MDSCs express high levels of both of these enzymes, and the specific T cell 
suppressive ability of MSDCs is attributed to depletion of extracellular arginine required for the 
proliferation and expansion of T cells (Munder et al., 2006; Rodriguez and Ochoa, 2008; Rodriguez et 
al., 2002). In addition to immunosuppressive functions, MDSCs can also assist in tumor invasion, 
angiogenesis and migration by secreting growth factors such as MMPs (matrix metalloproteinases) and 
VEGFA (vascular endothelial growth factor A) (Ye et al., 2010).  
Importantly, analysis of granulocytic MDSCs isolated from the peripheral blood of lung cancer patients 
showed an inverse relationship between the abundance of MSDC and CD3+CD8+ CTLs, and MDSC 
infiltration correlated with as poor patient prognosis (Liu et al., 2010). Furthermore, increases in 
monocytic MDSCs were reported in NSCLC patients treated with chemotherapy, and this was 
associated with disease progression and poor response to therapy (Koinis et al., 2016). Recently, it was 
shown that elevated neutrophil-to-lymphocyte ratio (NLR) negatively correlates with patient survival 
and response to anti-PD1 therapy in metastatic NSCLC patients (Diem et al., 2017). In addition, using 
murine breast cancer models, neutrophils have been shown to provide a pre-metastatic 
microenvironment in the lungs facilitating lung metastasis of breast cancer cells (Wculek and Malanchi, 
2015). These finding imply that targeting MDSCs and neutrophils may help in controlling primary and 
metastatic disease. Various strategies are being tested in preclinical and clinical settings to 
therapeutically target MDSC function, such as molecules affecting MDSC recruitment (anti-CSF-1 and 
anti-G-CSF antibodies), expansion (cyclooxygenase (COX-2 and PGE2), differentiation (trans-
Retinoics; ATRA, vitamin D3), and immune suppression (inhibitors of reactive nitrogen species) 
(Albeituni et al., 2013; Gabrilovich, 2017). 
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The role of the immune microenvironment in tumor progression has been extensively studied using 
GEMMs. For example, in the KP GEMM, exogenous expression of T cell antigens elicited a substantial 
anti-tumor immune response marked by increase in number of T and B cells (DuPage et al., 2011). 
This response was not sustained at later time points, due to loss of anti-tumor functional and memory 
T cells, as well as expression of the T cell exhaustion marker PD-1, and tumors eventually escaped 
from T cell attack. Despite lack of T cell response in the later phase, significant delay in the tumor 
development was observed in immunogenic KP mice compared to poorly immunogenic control mice, 
suggesting early anti-tumor responses can delay disease progression (DuPage et al., 2011). In addition, 
the role of Tregs in lung tumorigenesis has been studied using murine models, Foxp3+ Treg cells 
promote tumor growth in CC10-Tag transgenic lung AC mouse model. Specifically, anti-CD25-
mediated depletion of Tregs led to reduction in tumor burden accompanied by increased cleaved 
caspase-3-marked cell death and enhanced CD8+ T cell infiltration, indicating that in this model Tregs 
promote lung cancer development by restraining anti-tumor immunity (Ganesan et al., 2013).  
Tertiary lymphoid structures (TLS) are immune cell aggregates that are often found near the site of an 
inflammatory infection, or near cancerous tissue. TLSs contain T and B lymphocytes, and dendritic 
cells. The role of tumor associated (TA)-TLS in tumor development has been deeply studied in the KP 
NSCLC GEMM. Specifically, Joshi et al demonstrated that depletion of Tregs located in TA-TLS 
resulted in an increased number of tumor infiltrating CD8+ lymphocytes and triggered an anti-tumor 
immune response against established ACs (Joshi et al., 2015).  
Profiling of the immune cell phenotypes in ACs driven by mutant Kras, mutant Egfr or mutant Kras 
with p53 loss, revealed immune cell signatures unique to each of these models. Specifically, flow 
cytometry and IHC analysis showed expansion of CD8+ lymphocytes in mutant Kras- and KP-driven 
tumors, but not in Egfr mutant tumors, and this was further validated in human KRAS and EGFR mutant 
NSCLC. On the contrary, murine Kras and KP ACs, but not Egfr mutant ACs, showed a significant 
decrease in NKG2D (natural killer group 2, member D receptor) expression required for suppression 
of NK cell-mediated cytotoxicity, suggesting NSCLC subtype-specific immune cell composition 
(Busch et al., 2016). 
A recent study by Faget et al reported that particularly the large and advanced tumors in the KP model 
exhibited high Gr-1+ neutrophil and low CD8+ T cell infiltration, and Gr-1+ neutrophils were shown to 
promote tumor progression by enhancing tumor hypoxia and Snail expression (a transcription factor 
involved in EMT) by the cancer cells. Anti-Gr1-mediated neutrophil depletion reversed hypoxia, 
decreased Snail expression, and sensitized tumors for PD-1 inhibition, resulting in tumor regression. 
Authors further validated this finding in human NSCLC samples, by showing that patients with low 
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CD8+ T cell and high CD15+ neutrophils showed reduced overall survival (Faget et al., 2017). These 
findings suggest that immune cell signatures correlate with the histological grade or aggressiveness of 
the tumor, and that immunosuppression by neutrophils is predominant in advanced lung ACs.  
In a mouse model harboring kinase dead IKKα, which develops spontaneous SCC, macrophage-
induced inflammation was shown to regulate the development of SCC (Xiao et al., 2013). Another lung 
SCC model driven by loss of Lkb1 and Pten showed immunosuppressive features marked by PD-L1 
expression and high tumor-associated neutrophil (TAN) infiltration (Xu et al., 2014). Similarly, SCCs 
in the Sox2;PC model showed abundant LY6G and myeloperoxidase (MPO) positive TANs, and 
conversely, TAMs were poorly represented in these tumors. Furthermore, while membranous PD-L1 
expression was variable in human SCC, Sox2;PC-derived SCCs showed strong PD-L1 positivity, 
suggesting immunosuppression in SOX2;PC-driven SCC (Ferone et al., 2016). Together, these reports 
indicate that TAN infiltration might be characteristic of lung SCC and advanced ACs, while 
lymphocyte functions vary depending on the AC subtype. 
Loss of Lkb1 has also been linked to an immunosuppressive microenvironment, characterized by pro-
inflammatory cytokine and chemokine production favorable for TAN infiltration. Koyama et al 
reported that tumors from the KL model show increased CD11b+ Gr-1+ TANs and decreased PD-L1 
expression compared to Kras tumors. In addition, expression of the pro-inflammatory cytokine Il6 was 
higher in TANs isolated from KL tumors compared to neutrophils from the normal lung. Therapeutic 
benefit was observed only upon TAN inhibition via IL-6 neutralizing antibody, whereas treatment with 
anti-PD1 antibody did not show measurable response in KL mice. This study also reported that LKB1 
inactivating mutations in human NSCLC were associated with reduced PD-L1 expression and low 
CD3+/CD8+ T cells compared to Kras mutant tumors (Koyama et al., 2016). Given the observation that 
SCCs as well as advanced ACs in the KP model exhibit TAN infiltration, it remains to be investigated 












1.10. Oncogenic signaling heterogeneity in murine NSCLC  
Deregulation of signaling pathways that govern cell proliferation, survival, and migration such as 
MAPK and PI3K/AKT pathways are frequently found in cancers (McCubrey et al., 2012). Surprisingly, 
oncogenic signaling heterogeneity has been studied only to a limited extent using lung cancer GEMMs. 
Integrative genomic and proteomic analysis identified activation of SRC (proto-oncogene tyrosine-
protein kinase) and FAK (focal adhesion kinase) in primary and metastatic KL tumors compared to 
KrasG12D tumors. This was suggested to have functional consequences, as interference with SRC and 
FAK signaling in LKB1 wild type and LKB1 null human NSCLC cell lines using the small molecule 
inhibitors dasatinib (SRC inhibitor) or PF573228 (FAK inhibitor) resulted in decreased cell adhesion 
and migration. Furthermore, LKB1 null cell lines grew faster as subcutaneous xenografts compared to 
wild type cells, and showed vimentin positivity in the tumor periphery, suggesting that loss of LKB1 
could promote EMT. These findings indicate that activation of SRC and FAK signaling could be one 
possible mechanism by which LKB1 loss activates cell migration and promotes metastasis (Carretero 
et al., 2010).  
Loss of PTEN is generally known to activate PI3K/AKT pathway. Interestingly, however, Curry et al 
showed that, depending on the bronchiolar or alveolar origins, KrasG12D-driven Pten-null murine 
tumors showed differential AKT activation and resistance to dietary restriction. Pten lacking, 
bronchiolar, high-grade tumors showed AKT activity and resistance to dietary restriction. On the other 
Figure 7. The balance between anti-tumor and tumor promoting functions of the immune 
system. Both innate and adaptive immune cells mediate anti-tumor immunity, and these include B 
cells, CD4+ T cells, CTLs, and NK cells that can be activated by interferon gamma (IFN-γ). On the 
other hand, tumor promoting immune cells, including Tregs, MDSCs, TANs, TAMs, and IDO+-
dendritic cells are activated by pro-inflammatory cytokines IL-6, and TNF- α (tumor necrosis factor 




hand, alveolar tumors were sensitive to dietary restriction and displayed low AKT activity. This 
difference was attributed to bronchiolar cells intrinsically expressing high levels of IGF-IR (insulin-
like growth factor-I receptor) and the enzyme ENTPD5 (endoplasmic reticulum enzyme, 
ectonucleoside triphosphate diphosphohydrolase 5), known to modulate growth factor receptor levels 
(Curry et al., 2013). These findings imply that cell autonomous growth factor signaling in the 
bronchiolar vs alveolar compartments of the lungs may influence signaling activities in the tumors 
derived from different progenitors. 
Murine squamous tumors in the LP model exhibited high AKT activity, as well as low ERK activity 
compared to KrasG12D-driven tumors, suggesting that LP SCC tumors rely on PI3K/AKT signaling, 
while KrasG12D-driven AC tumors are more dependent on MEK/ERK signaling (Xu et al., 2014). 
Similarly, SCCs in the Sox2;Lkb1 model showed weak activation of ERK compared to KrasG12D and 
KL tumors. However, AKT activation was found to be variable in KL tumors as well as in SCCs in the 
Sox2;Lkb1 model.  Furthermore, Sox2;Lkb1-driven SCCs showed significantly higher nuclear pSTAT3 
compared to AC or SCC tumors in the KrasG12D or KL model, respectively (Mukhopadhyay et al., 
2014). These studies linked PI3K/AKT and MAPK signaling heterogeneity to tumor genotype. 
However, oncogenic signaling heterogeneity in a genetically homogeneous KL model with mixed 
NSCLC pathologies remained to be investigated. 
 
1.11. Organotypic tumor slice cultures as a preclinical model 
Predicting patient responses to anticancer therapies remains as a major challenge, especially for solid 
tumors such as lung cancer, where pronounced genetic, phenotypic and microenvironmental 
heterogeneity influences treatment efficacy (Mumenthaler et al., 2015; Xue et al., 2017). As opposed 
to conventional two-dimensional (2D) and three-dimensional (3D) models, in which tumor 
complexities can be partially retained, organotypic cultures known as precision-cut slices retain the 
complexities of the in situ tumors such that intact tumor-stroma interactions which can be studied in a 
spatial manner (Meijer et al., 2017). In addition, tumor tissue slices offer a low-throughput but high-
content platform for pharmacological drug testing. The first organotypic cultures were generated from 
heart and brain tissues of chick embryos and adult rats, respectively (Bousquet and Meunier, 1962; 
Loffredo Sampaolo, 1956). Initially, precision-cut slices were generated using a Krumdieck tissue slice 
machine that punches cylindrical tissue cores, which are further sliced by a rotating knife (Krumdieck, 
2013). More recently, a vibratome machine Leica VT1200 S, which uses a vibrating blade microtome 
to generate precision-cut slices has been developed. The latter generates reproducible and more precise 
slices compared to the Krumdieck tissue slicer, and also enables to follow the order of slicing 
(Zimmermann et al., 2009). 
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The most widely used tissue slice culture method is the air-liquid interphase, which involves placing 
the slices on top of 0.4 μm pore size membrane inserts immersed in the culture medium. Some studies 
have cultivated slices on top of titanium grids inserted into culture medium in rotating 6-well plates, 
and this method ensures intermittent exposure of tissue slices to oxygen and nutrients (Kiviharju-af 
Hallstrom et al., 2007). Careful optimization of the tissue slice culture conditions is a prerequisite for 
long-term culturing. Slices with varying thickness (250 μm -500 μm) have been shown to preserve the 
morphological and histological tissue features up to 16 days (Das et al., 2015; Davies et al., 2015; 
Kiviharju-af Hallstrom et al., 2007; Merz et al., 2013; Naipal et al., 2016; Vaira et al., 2010). Davies et 
al performed a systematic comparison of culture conditions using tumor slices derived from lung, breast 
and prostate cancer models. This showed that atmospheric oxygen and membranous supports are 
required for the preservation of the tissue slice viability. They further showed that stress response genes 
were elevated in cultured slices compared to freshly section uncultured 0 h slices, and that an intra-
slice gradient in viability, proliferation and biomarkers formed during cultivation; the region of the 
slice exposed to the culture medium had reduced viability, and accumulated HIF1α as a result of poor 
oxygenation. This suggests that intra-slice viability gradients, as well as DNA damage responses, likely 
affecting tumor-specific biological functions, and should be taken into consideration when performing 
perturbation studies on slice cultures (Davies et al., 2015).  
Precision-cut tumor slices from a variety of tumor tissues have been established for testing anti-cancer 
agents (Carranza-Torres et al., 2015; Gerlach et al., 2014; Koerfer et al., 2016; Vaira et al., 2010). 
Breast cancer-derived tissue slices were established for ex vivo diagnostics to test RAD51 accumulation 
at DNA double strand breaks, and authors suggest that this assay could be used to guide selection of 
patients for treatment with PARP inhibitors (Naipal et al., 2014). In addition, Muzumder et al developed 
an ex vivo tumor slice model established from clinical biopsies of Head and neck squamous cell 
carcinoma (HNSCC), or colorectal cancer, this model composed of slices cultured with tumor grade-
matched matrix and autologous patient serum. They evaluated the functional drug response (viability, 
and proliferation) to targeted drug (cetuximab) and or chemotherapy agents on these cultures and 
integrated the responses obtained in ex vivo engineered cultures with response from matched patients. 
This permitted the development of an algorithm that could accurately predict clinical response in a new 
group of 55 patients (Majumder et al., 2015). Furthermore, Vaira et al established tissue slices from 
human lung, colon, and prostate cancers, and showed that viability and proliferation in these cultures 
are preserved up to 4 days. Pharmacological inhibition of the PI3K/AKT pathway in slices effectively 
inhibited phosphorylation of AKT and S6RP (S6 ribosomal protein), and resulted in a partial reduction 
in viability and proliferation (Vaira et al., 2010). The authors also show an increase in the levels of 
phosphorylated S6RP (pS6RP) in cultured slices as compared to uncultured T0 tissue slices, suggesting 
altered signaling in the cultured slices. This highlights the importance of careful analysis of the cultured 
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slices for the preservation of targeted pathway activities of in situ tumors before evaluating ex vivo drug 
responses. The utility of slice cultures has also been extended for the prediction of response to 
combination treatments; slices established from clinical glioblastoma tumors from patients harboring 
the ROS1-FIG fusion gene showed a synergistic response to combination treatment with crizotinib and 
the chemotherapy agent temozolomide (Das et al., 2015). Together, these findings suggest that 
precision-cut tumor slices could be a valuable tool for evaluating functional drug response.  
 
1.12. Preclinical studies using in vivo models 
The utility of in vivo and ex vivo cancer models extends from understanding disease biology to testing 
the efficacy of anticancer regimens prior to their clinical application. Preclinical studies have been 
carried out with lung cancer GEMMs, human NSCLC cell lines, and more recently also with patient-
derived primary cells. A study conducted by Johnson and colleagues showed that combination of 
chemotherapy  (carboplatin) and erlotinib has no effect on the survival of KP mice, and this 
observation was in line with the response to same combination in Kras mutant NSCLC patients. In 
addition, they also showed that similar to human NSCLC, KP mice obtain significant survival 
benefit from combination of chemotherapy with anti-VEGFR therapy compared to chemotherapy 
alone (Singh et al., 2010). This highlights the preclinical utility of lung cancer GEMM in predicting 
therapeutic responses and identifying novel drug combinations. TKIs were shown to be effective in 
an Egfr mutant transgenic lung cancer model (Ji et al., 2006b; Politi et al., 2006). In addition, the anti-
EGFR mAb cetuximab was shown to mediate effective tumor regression in a mutant Egfr-driven lung 
AC model (Ji et al., 2006a). Another lung AC GEM model, driven by expression of the H1047R kinase 
domain mutation of the PI3K p110α catalytic subunit (PIK3CA), was used to show that treatment with 
the dual PI3K and mTOR inhibitor NVP-BEZ235 (dactolisib) effectively caused tumor regression. 
Interestingly, while the same inhibitor was not effective in KrasG12D mice, combined treatment with 
NVP-BEZ235 and the MEK inhibitor ARRY-142886 caused efficient tumor regression, suggesting 
that two major effector pathways downstream of KRAS need to be perturbed to achieve tumor 
regression in mutant Kras-driven murine lung tumors (Engelman et al., 2008). On the other hand, KL 
tumors were found to be unresponsive to combined PI3K/mTOR and MEK inhibition 
(dactolicib+AZD2644/selumetinib) (Carretero et al., 2010). Based on the observation that KL tumors 
showed increased SRC and FAK activation, Carretero et al hypothesized that interference with SRC 
signaling might restore sensitivity in KL tumors. In line with this hypothesis, they observed that the 
triple combination of dactolisib, selumetinib, and the SRC inhibitor dasatinib caused tumor regression 
in KL mice. These findings imply that KL tumors are resistant to combined PI3K/mTOR and MEK 
inhibition, at least partly due to activation of SRC (Carretero et al., 2010). Another murine study 
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conducted in parallel with an ongoing human clinical trial, comparing the response of standard-of-care 
docetaxel monotherapy with the combination of docetaxel and the MEK inhibitor selumetinib in Kras 
mutant NSCLC patients (Chen et al., 2012). This co-clinical study used tumor-bearing KrasG12D, KP, 
and KL mice. Similar to the observations by Carretero et al, KL tumors were shown to be non-
responsive to docetaxel/selumetinib combination therapy, while significant decreases in tumor volume 
accompanied by increased apoptosis and decreased proliferation were detected in KrasG12D and KP 
tumors. These authors thus suggested that resistance to combination therapy in KL tumors could be 
associated with low MAPK activity and increased AKT and SRC activity, indicating that multiple 
pathways in addition to MAPK appear to drive proliferation of KL tumors (Chen et al., 2012). In 
addition, hKRASG12D mice showed prolonged progression-free survival to combination of selumetinib 
and chemotherapy, while the same combination was not effective in hKRASG12D; p53R270H mice. These 
results suggests that the KRAS and p53 mutation status may define sensitivity to MEK inhibition plus 
chemotherapy (Li et al., 2018). 
Resistance to targeted therapies can be categorized as:  i) primary resistance, where some of the tumor-
inherent features in pose resistance to therapy, for example KRAS mutation confers resistance to anti-
EGFR therapies, ii) adaptive resistance in which bypass signaling is activated upon blockade of driver-
gene induced oncogenic signaling, iii) acquired resistance occurs when cancer cells obtain additional 
mutations following therapy. Towards the identification of effective combination therapies to treat Kras 
mutant lung cancer, and to understand adaptive resistance mechanisms, Manchado et al employed an 
in vitro shRNA screen on Kras mutant NSCLC cell lines to identify genes whose downregulation 
sensitizes to MEK inhibition following trametinib treatment. This showed that feedback activation of 
RTKs, via activation of FGFR1-mediated signaling, was involved in adaptive resistance to MEK 
inhibition. Subsequent in vivo treatment using combinatorial treatment with trametinib and the FGFR1 
inhibitor ponatinib in KP mice showed significantly increased tumor regression compared to single 
treatment (Manchado et al., 2016), implying FGFR activation is an adaptive signal mediating resistance 
to MEK inhibition. 
Metabolic rewiring is considered as one of the hallmarks of cancer in which cancer cells continue to 
grow and survive in harsh environmental condition by altering their metabolism and nutrient 
requirements (Hanahan and Weinberg, 2011). Martins and colleagues reported that high grade, but not 
low grade, tumors in the KP model exhibit KrasG12D allelic amplification, which results in metabolic 
rewiring accompanied by altered glucose and glutathione metabolism. Combined inhibition of 
glycolysis, using the glucose analogue 2-deoxy-d-glucose (2DG), and inhibition of glutathione using 
buthionine sulfoximine (BSO, an inhibitor of gamma-glutamylcysteine synthetase, an enzyme required 
for glutathione synthesis), proved to be effective in advanced KP tumors (Kerr et al., 2016). LKB1-
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deficient NSCLC cell lines and tumors in the KL model are sensitive to the anti-diabetic drug 
phenformin (Shackelford et al., 2013). Under normal conditions, phenformin mediates its effect by 
inhibiting the mitochondrial complex I, and thereby increases intracellular AMP levels, which results 
in LKB1-dependent phosphorylation of AMPK. Activated AMPK in turn directs defective 
mitochondria towards autophagy (Dykens et al., 2008; Egan et al., 2011; Hawley et al., 2010; Owen et 
al., 2000). Shackelford et al demonstrated that lack of AMPK activation in KL tumors confers 
sensitivity to phenformin due to defective mitochondria and autophagy, but not in KrasG12D and KP 
tumors. In addition, long-term treatment with phenformin also provided survival benefit to KL, but not 
KP, mice (Shackelford et al., 2013). Interestingly, it was found that AC and SCC tumors in KL mice 
responded differently to combination treatment with phenformin and the mTOR inhibitor MLN0128: 
while this combination induced apoptosis and inhibited proliferation in KL-derived ACs (KL;ACs), 
squamous tumors in the same mice were resistant to combination therapy. MLN0128 treatment induced 
AKT activation in KL-derived SCCs, suggesting a possible resistance mechanism (Momcilovic et al., 
2015). This suggests that combinatorial strategies involving AKT inhibition could be effective 
specifically in KL squamous tumors. 
As discussed previously, transgenic mice expressing an inducible form of human mutant HER2YVMA in 
mouse airway epithelium give rise to ASCs (Perera et al., 2009). Combinatorial treatment with the 
irreversible dual EGFR/HER2 inhibitor BIBW2992/afatinib and rapamycin caused effective tumor 
shrinkage, suggesting possible therapeutic combinations for HER2 mutant NSCLC. Similarly, ASCs 
in the Pten;Smad4 conditional mouse model, which showed ERBB2 and AKT activation, were found 
to regress following combinatorial treatment with the PI3K inhibitor GDC-094 and the ERBB2/EGFR 
dual kinase inhibitor lapatinib (Liu et al., 2015). 
Collectively, these preclinical studies utilizing lung cancer GEMMs have addressed tumor genotype 
and signaling pathway activity directed therapeutic responses. In KL mice, Momcilovic et al identified 
AC histotype-selective sensitivity to combination of phenformin and mTOR inhibitor (Momcilovic et 
al., 2015). However, in the KL model, histotype-specific drug sensitivity and resistance mechanisms 
including drugs targeting PI3K/mTOR, MAPK, or SRC pathways have not been investigated. 
Moreover, it is unknown if the previously described PI3K/mTOR and SRC pathway signatures in the 
KL model are selective to a particular histotype, or whether histotype-selective signaling differences 
confer differential drug sensitivities. Furthermore, spatial ITH in oncogenic signaling and its 




1.13. Preclinical studies using in vitro models 
Despite the fact that two-dimensional (2D) monolayer cell cultures fail to represent the complexities 
of the in situ tumors, cancer cell lines have been extensively used in preclinical studies to identify new 
targets and gene signatures predicting drug response (Greshock et al., 2010; Sos et al., 2009). Compared 
to complex in vivo models, 2D models are advantageous due to the fact that they are amenable to i) 
high-throughput functional assays, including drug sensitivity screening, ii) relatively straightforward 
investigation of mechanisms of drug resistance, and iii) easier genetic manipulation compared with in 
vivo models.  
Pharmacological targeting of mutant KRAS remains challenging. Alternatively, inhibition of the RAS 
effector pathways including MAPK pathway has been considered in clinical settings. However, 
targeting MEK a downstream effector of the KRAS has proven to be ineffective, due to adaptive 
activation of several other pathways including PI3K/AKT (Blumenschein et al., 2015; Cox et al., 2014; 
Janne et al., 2013) . Furthermore, MEK inhibition relieves the negative feedback regulation of upstream 
RTKs leading to survival and proliferation of cancer cells (Turke et al., 2012). Towards identification 
of adaptive resistance to MEK inhibition in KRAS mutant lung cancer cells, Kitai et al demonstrated 
epithelial or mesenchymal cell-specific adaptive activation of RTKs leads to resistance to MEK 
inhibition. While epithelial-like cell lines showed activation of ERBB3 as a feedback mechanism, 
mesenchymal-like cell lines showed FGFR1 activation as a resistance mechanism upon trametinib 
treatment. Furthermore, combination treatment with the pan-ERBB inhibitor afatinib and MEK 
inhibitor trametinib was found to be effective only in epithelial-like cell lines and corresponding 
xenograft models, whereas mesenchymal-like cell lines and xenograft tumors were sensitive to 
combinatorial blockade of MEK together with FGFR inhibitor NVP-BGJ398 (Kitai et al., 2016). 
Similarly, Sun et al identified synergistic effects of the MEK inhibitor AZD6244 and the pan-ERBB 
inhibitor afatinib in KRAS mutant NSCLC and colon cancer cell lines. Mechanistically, they showed 
that AZD6244 treatment relieves MYC-mediated transcriptional repression of ERBB2 and ERBB3, 
leading to their increased expression, and resistance to MEK inhibition (Sun et al., 2014). Collectively 
these studies imply that feedback activation of ERBB and FGFR1 RTKs is one of the mechanisms of 
resistance to MEK inhibition in KRAS mutant lung cancer cells (Figure 8).  
While establishment of  conventional 2D cell cultures derived from patient lung tumors have been 
reported, the success rate was low at 2.6% (Sugaya et al., 2002). Primary cultures have also been 
derived from murine NSCLCs, although in this case mice were always crossed with the p53fl/fl GEMM 
to derive KP or KPL tumor-derived cell lines (Koyama et al., 2016; Liu et al., 2013; Meylan et al., 
2009; Pfirschke et al., 2016). However, promising recent advancements in cell culture technology have 
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improved the ability to establish primary epithelial cell cultures from a variety of normal and tumor 
tissues. This method was originally developed by Schlegel and colleagues, known as the conditional 
reprogramming (CR) protocol (Liu et al., 2012b). This methodology involves the culturing of primary 
cells together with irradiated 3T3 feeder cells, in the presence of media containing the Rho-associated 
protein kinase inhibitor or ROCK inhibitor Y-27632. This protocol has been suggested to achieve cell 
immortalization by: i) induction of telomerase expression by factors secreted by the feeder cells, and 
ii) ROCK inhibitor-mediated deregulation of cytoskeleton and Rb/p16 pathway (Liu et al., 2012b). 
Various studies have identified novel therapies, even applied to clinical translation, using the CR 
technology (Beglyarova et al., 2016; Crystal et al., 2014; Liu et al., 2017; Liu et al., 2012b; Saeed et 
al., 2017; Yuan et al., 2012). Crystal et al established conditionally reprogrammed cells (CRCs) from 
biopsies of lung cancer patients treated with EGFR or ALK TKIs, following acquired resistance to 
therapy. By combining genetic analysis with pharmacological screens on patient-derived CRCs, they 
were able to identify effective combinations against resistant tumors and validated their findings in 
PDX in vivo models (Crystal et al., 2014). For example, they showed that an ALK-positive resistant 
tumor with MAP2K1 activating mutation was sensitive to combination treatment with ALK and MEK 
inhibitors. Similarly, combinatorial treatment with EGFR and FGFR inhibitors was effective in EGFR 
mutant resistant CRCs that had acquired a novel FGFR3 mutation. This suggests that CRCs may offer 
a unique tool for use in precision medicine, to identify lesion-specific therapeutic sensitivities. 
However, it remains unaddressed in how far the in vitro drug responses observed in CRCs are predictive 
of response of native tumors. In addition, lung cancer GEMM tumor-derived CRC cultures have not 
been established thus far.  
 
 
Figure 8.  Feedback RTK activation following 
MEK inhibition. In KRAS mutant NSCLC cell lines, 
MEK inhibitor treatment relieves negative regulation 
of ERBB and FGFR receptors by Myc and Sprouty 
(SPRY), respectively. This in turn leads to activation 
of PI3K/AKT signaling and adaptive resistance to 
MAPK inhibition. Modified from (Sun et al., 2014). 
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Taken together, cancer genome analyses have revolutionized our understanding of lung cancer at the 
genetic level, and this information has been integrated in the development of targeted therapies against 
a set of driver genes. So far, targeted therapies, particularly tyrosine kinase inhibitors against EGFR or 
ALK1, are however mainly been directed towards AC histotype tumors, in which these genetic 
alterations are predominantly detected. Despite gained understanding of the genetic landscape of SCC 
and ASC histotype tumors, effective therapies to treat these subtypes are still underway. Moreover, 
resistance to targeted therapies occur eventually leading to poor clinical outcomes. Therefore, better 
understanding of intrinsic and adaptive resistance mechanisms as well as the investigation of predictive 
markers beyond genetic drivers is necessary to design effective single or combination therapies. The 
evolution of cancer from pre-malignant lesions to heterogeneous tumors is a multistep process, and 
various factors, including the nature of cancer-initiating oncogenic events and the tumor cell of origin, 
determine the fate of end-stage tumors (Blanpain, 2013). Furthermore, the complex interplay between 
malignant cells, stromal and immune cells can also influence therapy response (Junttila and de Sauvage, 
2013). Hence, understanding of tumor immunity, particularly tumor immune suppression, is necessary 
for guiding optimal immunotherapy. Therefore, in addition to understanding of the heterogeneity at 
genetic level, improved understanding of the phenotypic and functional heterogeneity may help in 
designing lung cancer subtype-specific effective therapies. Despite the development and utilization of 
various ex vivo models for testing drug responses, their ability to maintain molecular and functional 
features of the native tumor remains poorly characterized. This highlights the importance of careful 









2. AIMS OF THE STUDY 
Genetic alterations in cancer cells of origin lay the foundation for initiation and establishment of 
tumors. In addition, intrinsic and extrinsic factors related to the tumor cell of origin influence the 
heterogeneity of the established tumors. Hence, it is important to investigate the niche-specific tumor 
progenitors of different cancer subtypes. Using mouse models driven by oncogenic KrasG12D alone, or 
in combination with loss of the tumor suppressor p53, it has been established that multiple cells of 
origin, namely CC10+ and SPC+ cells, serve as progenitors of lung ACs. However, the relative roles of 
different lung progenitors in establishing other NSCLC histotype tumors has remained obscure. Given 
that a mouse model harboring conditional expression of KrasG12D together with loss of the tumor 
suppressor Lkb1 (KL) produces all four subtypes of NSCLC, it serves as an excellent model to study 
the etiology of NSCLC histotypes. Furthermore, as all of the histotypes in this model are derived from 
common genetic drivers, the model allows the investigation of histotype-specific functions of lung 
cancer.  
 
Tumor heterogeneity plays an important role in drug sensitivity and resistance; therefore, understanding 
the cellular and molecular basis of tumor heterogeneity is fundamental in disease control. However, 
the investigation of tumor heterogeneity, including intratumor spatial heterogeneity, is challenging in 
surgically-resected clinical samples or small biopsies. GEMMs that mimic the genetic and biological 
aspects of patient tumors offer an excellent opportunities to expand our knowledge on tumor 
heterogeneity, and to investigate effective drugs or drug combinations. Furthermore, the balance 
between pro-tumorigenic and anti-tumor tumor immune functions influence on disease outcome, as 
well as the response to immunotherapies. The objectives of this thesis were to unravel how the cell of 
origin influences histotype spectra and immune function heterogeneity. In addition, this thesis work 
also set out to investigate intertumoral and intratumoral spatial heterogeneities and associated drug 
sensitivities. These aims were addressed using the KL and KP lung cancer GEMMs, representing a 
range of NSCLC histotypes, as well as ex vivo tumor slices and primary cell cultures derived from KL 




     Specific aims of this thesis were: 
I. To investigate the role of the cell of origin in determining NSCLC histopathology and 
associated immune function heterogeneity upon activation of KrasG12D together with loss 
of the tumor suppressor Lkb1. 
II. To set up a methodology for the establishment and analysis of precision-cut murine 
NSCLC slice cultures as a prerequisite for drug testing 
 
III. To investigate oncogenic signaling heterogeneity in Kras-driven murine NSCLC, and test 
signaling heterogeneity-related functional drug responses, using tumor tissue slice 
cultures. 
IV. To identify histotype-specific drug sensitivities using murine NSCLC cell cultures, and 




3.  MATERIALS AND METHODS 
 
3.1. Materials used in this thesis work 
 
3.1.1. Mouse strains 
 
Mouse Strain Description Reference Study 
KrasLSL-G12D/+ Mice carrying conditional allele of 
mutant Kras 
(Jackson et al., 2001) I, II, III, & 
IV 
Lkb1fl/fl Mice carrying conditional allele for 
Lkb1 
(Bardeesy et al., 2002) I, II, III, & 
IV  
p53fl/fl                                 Mice carrying conditional allele for 
p53 
(Marino et al., 2000) I, III, & 
IV 
 




(Muzumder et al., 2007) I, III, & 
IV 
PtenLoxP/LoxP                 Mice carrying conditional allele for 
Pten loss-of-function 
 
(Marino et al., 2002) III 
 
PSA-Cre              Mice carrying Cre recombinase under 
the control of PSA promoter 
 







3.1.2. Primary antibodies  
 
Antibody Description Reference Study 
GFP Rabbit polyclonal Verschuren Laboratory I 
SPC Rabbit polyclonal Millipore, Ab3786 I 
CC10 Rabbit polyclonal Millipore, AB-07632 I 
NKX 2-1 (TTF1) Rabbit monoclonal Abcam, ab133638 
I, II, III, & 
IV 
p63 Rabbit polyclonal Abcam, ab124762 I, III, & IV 
Ki67 Rabbit monoclonal 
Thermo Fischer scientific, 
 RM-9106-S0 
I, III, & IV 
LKB1 Rabbit monoclonal Cell Signaling Technology, 13031 I, & IV 
SOX2 Goat polyclonal 
Santa Cruz Biotechnology,  
sc-17320 
I 
Cytokeratin 5 Rabbit monoclonal Abcam ab52635 
 
I 
HMGA2 Rabbit polyclonal Biocheck, BC-59210AP I 
Gr-1 (Ly6G) Rat monoclonal E-Bioscience, 145931 I 
CD11b Rabbit monoclonal BioSB, BSB6441 I 
CD3 Rabbit polyclonal Abcam ab5690 I 
CD45 Rabbit monoclonal Cell Signaling Technology, 13917 I 
CD8 Mouse monoclonal Dako, M7103 I 
CD4 Rabbit monoclonal Abcam, 133616 I 
CD33 Mouse monoclonal LSbio, C338084 I 
HLA-DR Mouse monoclonal Abcam, 20181 I 
p44/22 (Erk1/2) Rabbit monoclonal Cell Signaling Technology, 4370 II, III, & IV 
p4EBP1 Rabbit monoclonal Cell Signaling Technology, 2855 II, III, & IV 
pAMPK Rabbit monoclonal Cell Signaling Technology, 2535 III 
pSRC(Y416) Rabbit polyclonal Cell Signaling Technology, 2101 III 
E-cadherin Rabbit monoclonal Cell Signaling Technology, 3195 I, III, & IV 
Vimentin Rabbit monoclonal Abcam, ab92547  IV 
γ-H2AX Rabbit monoclonal Millipore,MABE205 III 
CIdU Rat monoclonal Biorad, OBT0030 IV 
pEGFR (Tyr 1068) Rabbit polyclonal Cell Signaling Technology, 2234S IV 
pERBB2 
(Tyr1211/1222) 
Rabbit monoclonal Cell Signaling Technology, 2243 IV 
pERBB3 (Tyr1289) Rabbit monoclonal Cell Signaling Technology, 4791  
 
IV 
Cleaved Caspase-3 Rabbit monoclonal Cell Signaling Technology, Y9664 IV 
CD45-PE Rat monoclonal E-Biosciences, 12-0451-82 I 
CD3-APC Mouse monoclonal Biolegend, 100236 I 
CD4-PerCP Mouse monoclonal BD Biosciences, 553052 I 
CD8-FITC Rat monoclonal E-Biosciences, 11-0083-81 I 
CD11b-FITC Rat monoclonal Biolegend, 101206 I 
Ly-6c-PerCP Mouse monoclonal Biolegend,128027 I 





3.1.3. Quantitative PCR (q-PCR) probes and primers 
 
Q-PCR probe Nucleotide sequence  Source Study 
Mouse l1b  fwd 5’TGCCACCTTTTGACAGTGATGAGA3’  Verschuren 
laboratory 
I 





5’TCGTGTACATTGGCTTGCGA3’  Verschuren 
laboratory 
I 


































3.1.4. Human NSCLC samples (I, III, and IV) 
Tissue microarrays (TMAs) were prepared from human NSCLC tissue blocks, and consisted of ASCs 
(n=13), ACs (n=25), and SCCs (n=28) operated during 2000-2015 at the Hospital District of Helsinki 

























3.1.6. Selected small molecule inhibitors used in study II, III and IV.  List of all the compounds 
used in study IV can be found from supplementary Table S1 (IV) 
Name                                 Description  Source Study 
Insulin 




   IV 
EGF 




354052       IV 
Hydrocortisone   Sigma, H4001    IV 
Adenine  
 Sigma: 
A2786        IV 




100B    IV 
ROCK inhibitor  
 ENZO, ALX-
270-333 IV 
  Name Mechanism/Target 
Approval 
status 














































3.2.1. Mouse cohort and adenovirus infections (I, II, III, and IV) 
All mice experiments conducted in this thesis followed the guidelines from the Finnish National Board 
of Animal Experimentation and were approved by the Experimental Animal committee of the 
University of Helsinki and the State Provincial Office of Southern Finland (permit number 
ESAVI/9752/04.10.07/2015). Cohorts of KrasLSL-G12D/+;Lkb1fl/fl (KL) were generated by breeding 
KrasLSL-G12D/+ mice (C57Bl/6J background) with Lkb1fl/fl mice on a mixed genetic background (F4 
ICR;BALB/cByJ;FVB/N). KL mice were also bred with Rosa26mT/mG reporter mice resulting in 
cohorts with mixed genetic background (C57Bl/6J, F4 ICR;BALB/cByJ;FVB/N, 29X1/SvJ;ICR). 
KrasLSL-G12D/+ mice were also crossed with Trp53fl/fl mice to generate KrasLSL-G12D/+; Trp53fl/fl mice. Eight 
to ten weeks old KL or KP mice were intranasally or intratracheally treated with 1-20 x107 pfu of Ad5-
CC10-Cre or 2.5-7.5 x109 pfu of Ad5-SPC-Cre viruses under isofluorane anaesthesia (Viral Vector 
Core Facility, University of Iowa, USA). Animal experiments performed using Pten mice were 
approved by the animal experimentation committee of the Erasmus Medical Center (DEC-consult, 
permit number 106-05-11). Cohorts of PSA-Cre;Pten-loxP/loxP (Pten) mice, were generated by 
crossing PSA-Cre mice (strain FVB) with mice carrying Pten-loxP allele (strain 129Ola). 
 
3.2.2. Tissue preparation immunohistochemistry and quantification (I, III, & IV) 
Tumor bearing lungs from moribund mice were fixed in 4% formaldehyde overnight at 4°C followed 
by processing into paraffin blocks. Formalin-fixed paraffin-embedded (FFPE) lungs were sectioned 
into 4-5µm thickness and then processed for H&E staining or IHC analysis. IHC on murine paraffin 
sections were performed as follows: rehydrated sections were subjected to antigen retrieval method 
(either citrate buffer, pH 6.0 or tris-EDTA, pH 9.0) to expose antigenic epitopes. To block non-specific 
binding of primary antibody, sections were blocked with 1% BSA and 10% normal goat serum (NGS) 
in 1x PBS. Primary antibodies were stained for 1-1.5 h at ambient temperature or overnight at 4°C. 
Secondary antibodies, BrightVision poly-HRP Goat anti-rabbit (IL ImmunoLogic, AD Duiven, the 
Netherlands) or Peroxidase Goat anti-rat IgG (H+L) (Invitrogen Corporation, Camarillo, CA) were 
incubated for 30 min at ambient temperature. Immunodetection was done using DAB (Bright DAB, IL 
ImmunoLogic, Duiven, The Netherlands). IHC stained sections were scanned using Panoramic 250 
3DHISTECH (3DHISTECH Kft., Budapest, Hungary) digital slide scanner using a 20x objective. 
Quantitation for H&E or IHC stained whole slide scans were performed using the Tissue StudioTM 




3.2.3. Immunohistochemistry quantification using CellProfiler (II) 
Whole slide scans of the IHC-stained samples were acquired using Pannoramic 250 3DHISTECH 
scanner, and TIFF images were acquired using Pannoramic Viewer 3DHISTECH. Using Fiji-ImageJ, 
the images were converted into 16-bit images, and uploaded to CellProfilerTM ( http://cellprofiler.org) 
2.0.0 for analysis. The following pipeline was used for quantification: Identify Primary Objects -> 
Measuring Object Intensity -> Filter Objects (minimal value=0.0025) -> Calculate Math. The results 
were represented as percentages of DAB-stained nuclei of the total number of nuclei. 
3.2.4. Immunofluorescence and quantification of human NSCLC TMA (I) 
For fluorescent triple multiplex staining on human NSCLC TMA, tissue sections were rehydrated 
followed by antigen retrieval using 10mM Tris/1mM EDTA pH 9.0 buffer in a PT heating module 
(Thermo Scientific).  Endogenous peroxidase activity was blocked using 0.9% H2O2 in TBS, followed 
by blocking with TBS containing 0.05% Tween-20 and 10% normal goat serum. Sections were 
incubated with primary antibodies for 1-2 h at ambient temperatures. The 488 fluorescent signal was 
developed first by applying HRP (1:10 diluted) conjugated secondary (Bright Vision, Immunologic, 
Duiven, the Netherlands) followed by enhancement of signal using the TSA-Alexa Fluor-488 substrate 
(Life Technologies). After this, slides were immersed in TBS containing 0.9% H2O2 and 15mM NaN3 
to block remaining peroxidase reactivity. The second primary antibody was probed for 1 h at ambient 
temperature and 555 fluorescent signal was obtained by adding HRP conjugated secondary antibody 
for 30 min and the signal was enhanced by using the TSA-555 substrate (Life Technologies). 
Previously bound antibodies were denatured by immersing the slides in 10mM Tris/1mM EDTA pH 
9.0 in a PT module at 99°C for 20 min. Finally, the third primary antibody was incubated for 2 h at 
ambient temperature and secondary Alexa fluor-647 conjugated goat anti-mouse or -rabbit antibodies 
(Life Technologies) were used and sections were counterstained with DAPI (Roche, Mannheim, 
Germany. 
Fluorescent multiplex stained TMA slides were scanned using Axio Imager.Z2 (Zeiss, Germany) with 
the Metafer 4 slide scanning system (MetaSystems GmbH, Germany), and quantifications were 
performed using Tissue StudioTM IF image analysis solution of the Definiens Developer XD 64 2.1 





3.2.5. Microarray gene expression and quantitative PCR analysis (I) 
Lung tumors were snap frozen and RNA was extracted using NucleoSpin RNA II kit (MACHEREY-
NAGEL, Duren, Germany). Gene expression profiling was done with Illumina Mouse WT-6 version 2 
expression arrays (Illumina, San Diego, CA, USA). For the quantitative real-time PCR (qPCR) 
analysis, cDNA was extracted from high-capacity cDNA reverse transcription kit (Life technologies, 
Waltham, USA), and qPCR reactions were run and analyzed on a CFX384 TouchTM Real-Time PCR 
Detection System (Bio-Rad, Hercules, USA). 
 
3.2.6. Flow cytometry analysis (I) 
Lung tumors were incubated with HBSS/2mg/ml collagenase 1A (Sigma Aldrich, USA) and 0,3 mg/ml 
dispase (Life Technologies, Thermo Fisher Scientific, USA) for 30 min at 37°C, resulting tissue 
homogenate was digested using gentle MACS Dissociator (Miltenyi Biotec, Germany) in 
DMEM/20mM Hepes and 5U/ml DNAse (Promega, USA). Thus obtained single cell suspensions were 
incubated with antibodies in HBSS/2%BSA buffer for 30 min at 4°C. Propidium Iodide (Sigma 
Aldrich, USA) was used to stain dead cells and the analysis was performed using BD Accuri flow 
cytometer, data analysis was done using BD Accuri C6 software (Becton, Dickinson and Company, 
USA). 
 
3.2.7. Preparation and culturing of murine and human tissue slices (II, & III) 
Mouse and human tumor tissue slices were prepared using vibrating blade microtome (Leica 
VT1200S), to ensure better quality slices vibrocheck was performed prior to slicing. Tumor-containing 
lung tissue was attached to the magnetic specimen holder of a Leica VT1200S, using cyanoacrylate 
adhesive. Lung tumor tissues were either sliced as 160 µm, or 200 µm, or 250 µm thick using speed at 
0.12 mm/s and 2.5-2.7 amplitude settings. Sliced tissues were collected into 24-well plates with cold 
HBSS, and then placed in an inclined position on top of titanium grids inserted into culture medium in 
6-well plates, which were then placed in rotating incubation units. Importantly, slices were collected in 
the order of slicing, and neighboring slices were compared for experimental purposes. Tumor slices 
were cultivated at 37°C and 5% CO2, in a humidified incubator under normoxic condition (21%). 
Uncultured (0 h) slices as well as those cultivated for different time points were snap frozen (Pten 
tumor slices) for western blot analysis, or fixed in 4% formaldehyde overnight at +4°C, for paraffin 




3.2.8. Drug treatments on murine NSCLC tissue slices (II, & III) 
Precision-cut (200 µm) murine and human NSCLC tissue slices were placed on rotating incubation 
units, and were drug treated in the following medium:  F-12 medium (Thermo Fisher, Waltham, MA, 
USA) supplemented with 2mM glutamax (Gibco), 100 U/mL penicillin, 100 µg/mL streptomycin 
(Gibco), and 22 mM glucose (Sigma-Aldrich, St. Louis, MO, USA). At the end of treatment period, 
slices were fixed in 4% formaldehyde overnight at +4°C and processed for FFPE sections, which were 
processed for H&E and IHC analysis. 
 
3.3.9. Quantification of necrosis and overlapping signaling areas in tissue slices (II, & III) 
Necrotic areas in the H&E stained tissue slices were analyzed by a pathologist followed by drawing of 
the masks on necrotic tumor regions using Adobe Photoshop CS6, as described (Davies et al., 2015). 
The following formula was used to calculate relative decrease in viability of the drug treated slices: (1 
– viability in drug-treated/viability in DMSO control) * 100%. Analysis of phosphoprotein overlapping 
areas was done by drawing masks on the single stained regions in Photoshop CS6, and these masks 
were overlapped, and the overlapping regions were recolored using the magic wand tool in Photoshop 
CS6. Thus, the obtained overlapping regions were measured normalized to the total tumor area using 
the Photoshop histogram tool. 
 
3.2.10. Tissue dissociation and epithelial cell isolation (IV) 
Tumors were separated from the surrounding normal lung tissue, minced into small pieces and then 
subjected to enzymatic digestion in HBSS buffer containing 1% bovine serum albumin (BSA), 2 mg/ml 
collagenase (Sigma), and 0.3 mg/ml dispase (ThermoFisher Scientific; 17105-041) at 37ºC for 30 min 
with continuous rotation. Digested tissue was subjected to mechanical dissociation using 
gentleMACSTM dissociator, and filtered through a 70 µm cell strainer. The resulting single cell 
suspensions were used for epithelial cell isolation using EpCAM MicroBeads (MACS Miltenyi biotec; 
130-105-958). 
 
3.2.11. Cell culture (IV) 
Tumor-derived epithelial cells were either cultured on plastic with RPMI containing 10% FBS, 10mM 
glutamine, and penstrep, or as conditionally reprogrammed cells (CRC) as described before (Liu et al., 
2012b). In brief, tumor cells were plated on 3T3 cells (feeder cells) irradiated with 11 gray in F-medium 
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1:3 v/v DMEM: F-12 nutrient HAM) supplemented with, 5% FBS, and reagents listed in growth factors 
and supplements table. 3T3 cells were maintained in DMEM supplemented with 10%FBS/10mM 
glutamine/penstrep. CRC cultures were passaged by differential trypsinization, first to remove the 
feeder cells, followed by trypsinization of the epithelial cells.  
 
3.2.12. Colony formation assays (IV) 
Murine NSCLC CRCs or normal lung (NL) CRCs at passage 7 were plated in a 6-well plates as 500 
cells per well, either in CRC media or with F-media without Y-27632. To evaluate long-term effect of 
drugs, compounds or vehicle were added 48 h following cell seeding. At day 11 for regular assays, or 
day 13 for drug treated cells, colonies were fixed using a mixture of acetic acid and methanol (1:7 
vol/vol) and stained with 0.5% crystal violet in methanol. For regular assays, colonies were counted 
manually, and the colony formation rate was calculated as the percentage of cells forming colonies per 
500 cells. For drug treatment studies, analysis was done as percentage of area covered by colonies using 
the ‘ColonyArea’ Image J plugin (Guzman et al., 2014), and normalized to DMSO controls.  
 
3.2.13. Immunofluorescence analysis (IV) 
Cells cultures as CRCs were plated on top of glass coverslips, and fixed with 4% paraformaldehyde 
(PFA) for 15 min at ambient temperature. Fixed cells were blocked with PBS containing 3 % BSA, 
0.1M Glycine, and 0.1% TritonX-100, followed by incubation with primary antibodies for 1 h. Alexa 
goat anti-rabbit secondary antibody (Thermo Fisher Scientific; A21244) was incubated for 30 min. at 
ambient temperature, followed by nuclear staining with Hoechst (1 ug/ml, Thermo Fisher Scientific). 
Images were acquired using a Nikon Eclipse 90i fluorescence microscope; quantifications were done 
using CellProfiler software. 
FFPE sections (4 µm) of murine lungs treated with vehicle and CIdU or trametinib and CIdU were 
rehydrated, and permeabilized with 0.2% TritonX-100 in PBS. Sections were subjected to antigen 
retrieval using 10mM citric acid buffer (pH6) in a PT heating module (ThermoFisher Scientific) for 20 
min at 99°C. To expose antigenic epitopes, DNA was denaturated using 1.5N hydrochloric acid for 40 
min. at ambient temperature, followed by blocking with PBS containing 1% BSA, 10% NGS. Primary 
rat anti-CIdU (Biorad; OBT0030) antibody was incubated overnight at +4°C, and then with secondary 
anti-rat Alexa 488 (Invitrogen; A11006), and Hoechst (0,5 mg/ml). Whole slide scans of the stained 
samples were obtained using a Pannoramic 250 3DHISTECH digital slide scanner. Quantification of 




3.2.14. CRC 3-dimensional cultures (IV) 
Tumor or NL CRCs at passage 6 or 7 were plated on top of matrigel (Corning) in chambered cover 
glass (Lab-Tek) at a concentration of  2.5x104 cells per well in F-media (100 µl) without Y-67632. On 
the second day, a layer of collagen (of 2 mg/ml, Corning) was added on top of the spheroids, and 
allowed to solidify at 37°C for 1 h. 100 µl of F-media without Y-27632 was added on top of the 
solidified collagen. On the fourth day after seeding the cells, matrigel-collagen sandwich cultures were 
fixed with 4% PFA, processed using the Cytoblock kit (Thermo Fisher Scientific), paraffin embedded, 
and sectioned at 4 µm for further IHC processing. 
 
3.2.15. Immunoblotting (I, & IV) 
Snap frozen tissue references or CRC pellets were lysed using RIPA buffer, protein concentrations 
from the resulting protein lysate were measured using BCA kit (G Biosciences; 786-570). Western 
blotting was done using 20 µg of protein lysate. Membranes were blocked with Odyssey® Blocking 
Buffer (927-40000), and probed with primary antibody for 1 h at ambient temperature or overnight at 
+4°C followed by incubation with odyssey IRDye secondary antibodies. Membranes were scanned 
using an odyssey infrared imager. 
 
3.2.16. Drug Sensitivity and Resistance Testing (DSRT) (IV) 
Murine NSCLC tumor-derived or normal lung CRCs were subjected to DSRT according to previously 
published procedure (Yadav et al., 2014). For DSRT analysis a library of 299 compounds listed in 
Table S1 (III) was used. Drugs were dispensed using an Echo 550 Liquid Handler (Labcyte) into clear 
bottom 384-well plate (Corning #3712), at five different concentrations. Cells (1500 per well) were 
seeded into pre-plated DSRT plates using a MultiDrop Combi dispenser (Thermo Fisher Scientific), in 
F-media (25 ul) with or without Y-27632. Cell viability was measured using CellTiter-Glo® reagent 
(25 µl) (Promega) at 72 h post plating the cells using a PheraStar plate reader (BMG Labtech). 
 
3.2.17. DSRT data analysis and interpretation (IV) 
Quality assessment of DSRT screen data was done using the Z’-factors value, calculated as the raw 
luminescence values of drug-treated wells normalized against positive and negative controls (Yadav et 
al. 2015). Data from screens that passed the data quality test were used to determine the percentage 
inhibition of viability per drug concentration, plotted as dose-response curves by applying the 
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Marquardt-Levenberg algorithm implemented in an in-house developed bioinformatic pipeline 
‘Breeze’. Multiple parameters of each dose-response curve, including the IC50, slope, top, and lower 
asymptotes, were used to calculate the Drug Sensitivity Score (DSS), as described (Yadav et al, 2015). 
The average DSS values following treatment of normal lung cultures were used to normalize the DSS 
values for each tumor-derived culture, to calculate cancer cell-specific DSS (selective DSS). The sDSS 
values for each culture type were plotted using unsupervised hierarchical clustering with the Cluster 
3.0 application (http://bonsai.hgc.jp/~mdehoon/software/cluster/), and using Euclidean distance 
measures of the CRC profile. Heat maps were plotted in Java TreeView (http://jtreeview.- 
sourceforge.net/). 
 
3.2.18. In vivo drug treatments (IV) 
KL or KP mice infected with Ad5-CC10-Cre or Ad5-SPC-Cre viruses were randomly assigned for 
treatment groups at 11-14 (for KL) or 13-25 (for KP) weeks post infection. For 24 h trametinib 
treatment, mice were intra peritonially (IP) treated with 1 mg/ kg trametinib in 0.9 % saline or with 
vehicle (1.6% DMSO in 0.9% saline). At 20 h post trametinib treatment, mice were administered with 
2 mg chloro-deoxyuridine (CldU; Sigma C6891) via IP and 4 h later they were sacrificed by cervical 
dislocation. For combination treatments, mice were treated with vehicle equivalent of trametinib and 
afatinib, or with 1 mg/ kg trametinib alone in 0.9% saline via IP or with 12.5 mg/kg afatinib alone in 
0.5% hydroxyl propyl methyl cellulose (HPMC), 0.1% Tween 80 in H2O by oral gavage. Mice treated 
with both drugs received 1 mg/ kg trametinib and 12.5 mg/kg afatinib by IP or oral gavage, respectively. 
Treatment was done once daily for 3 days, and mice were sacrificed by cervical dislocation 24 h 
following the third treatment. 
 
3.2.19. Statistical analysis (I, III, & IV) 
Quantitative data are represented as +/- standard deviation or standard error of mean. Statistical 
significance calculated using t-tests were performed using two-tailed student’s t-test. Survival analysis 
(study I) was done using the Gehan-Breslow-Wilcoxon Test. Fisher’s exact test was used for the 
comparison of two categorical variables (human TMA analyses in study III and IV). One –way 
ANOVA was used for statistical comparison of more than two groups (study III). Spearman’s 
correlation coefficient (study III) or Pearson correlation coefficient (study IV) was used to evaluate the 
correlations between two variables. For the data which did not pass D'Agostino-Pearson omnibus 




4.  RESULTS AND DISCUSSION 
 
4.1. Cell of origin determines histotype spectrum and immune functions in NSCLC driven by 
mutant KrasG12D and loss of Lkb1 
Towards investigating the role of the cell of origin in establishing NSCLC subtypes, previous reports 
have utilized cell type-specific AdCre viruses or Cre-ER driven mouse strains to target CC10+ club 
cells in the airways or SPC+ AT2 cells in the alveoli and shown that both of these progenitor cell types 
can give rise to ACs (Mainardi et al., 2014; Sutherland et al., 2011; Sutherland et al., 2014; Xu et al., 
2012). Furthermore, GEMM studies have also shown that airway basal cell-specific deletion of Pten 
together with Tgfbr2 gives rise to SCC, however with low incidence (10-20%) and long latency (52 
weeks) (Malkoski et al., 2014). In addition, using the SOX2;PC model, recent work by Berns and 
colleagues suggested that multiple progenitors can give rise to SCC, namely K14+ cells in the bronchi, 
and SPC+ and CC10+ cells in the more distal lungs (Ferone et al., 2016). Using the KL model, Han et 
al showed that SPC+ cells can initiate ACs, which they suggest to transdifferentiate into SCC via an 
ASC intermediate state. In the latter study, the human SPC promoter was used to drive Cre recombinase 
expression (Han et al., 2014). However, this promoter was reported to be active also in bronchiolar 
cells (Glasser et al., 1991), suggesting the possible involvement of bronchiolar cells in establishing 
tumors in the KL model. Moreover, the role of CC10+ club cells in producing NSCLC histotypes, 
particularly in KL model which develop AC, SCC, and ASC histotype tumors, remained largely 
unknown. Hence, we decided to use KL mouse model to better understand the role of CC10+ and SPC+ 
lung progenitors in establishing histotype diversity and functional heterogeneity. 
 
4.1.1. The cell of origin defines NSCLC histotype spectra and mouse survival upon activation of 
KrasG12D and loss of Lkb1 
Previous work using the KP model has shown that both CC10+ and SPC+ cells similarly influence the 
survival of the mice following AdCre infection (Sutherland et al., 2014). We asked if the progenitor 
cell of origin has an effect on survival of mice in the KL model. To do this, we intranasally infected 8-
12 weeks old KL mice with adenovirus expressing Cre recombinase under control of the CC10 or SPC 
promoter: Ad5-CC10-Cre or Ad5-SPC-Cre. To confirm accurate targeting of the cell type-specific 
AdCre viruses, KL mice were crossed with the Rosa26mT/mG reporter strain, to locate Cre-targeted cells 
based on membrane GFP (mGFP) expression. Consistent with previous results, IHC analysis of mGFP 
on lung sections following 2 and 4 weeks of Ad5-CC10-Cre and Ad5-SPC-Cre infection revealed 
mGFP positivity in bronchiolar and alveolar compartments, respectively. In addition, Ad5-CC10-Cre, 
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but not Ad5-SPC-Cre infection, also resulted in mGFP positivity in the BADJ (I, Fig. S1A). Virus titers 
were set at 1 x 107 pfu for Ad5-CC10-Cre and 2.5 x 109 pfu for Ad5-SPC-Cre to archive comparable 
infection rates. The numbers of mGFP+, CC10+ or SPC+ cells were quantified on sequential lung 
sections. With these amounts of viruses, approximately 0.8% of the total lung cells were targeted at 3 
and 4 weeks following Ad5-CC10-Cre and Ad5-SPC-cre infection, respectively (I, Fig. S1B). KL mice 
intranasally infected with Ad5-CC10-Cre or Ad5-SPC-Cre (n=9 for each group) were sacrificed when 
they showed disease symptoms (breathing difficulties and loss of body weight). Interestingly, KL mice 
infected with Ad5-CC10-Cre showed a significantly shorter latency compared with Ad5-SPC-Cre 
infected mice (median survival of 79 and 120 days respectively) (I, Fig. 1A), suggesting that CC10+ 
cells may produce faster growing tumors. Next, we performed a detailed histopathological analyses of 
the lesions from full lung lobes of infected mice (n=5 per virus). The commonly used histotype-specific 
clinical biomarkers TTF1, also known as NKX 2-1, and p63 were analyzed to classify lesions into 
different histopathology subtypes of AC or ASC (I, Fig 1B) (Travis et al., 2011). Using LKB1 IHC, 
we first confirmed that all the lesions in KL mice originated following Ad5-CC10-Cre or Ad5-SPC-
Cre infection lacked LKB1 expression, using tumors from KP mice as positive reference tissue (I, Fig. 
S1C).  
Interestingly, quantification of lesions revealed that the incidence of ASCs was higher in Ad5-CC10-
Cre infected mice (20/60 lesions from 5 mice) than in Ad5-SPC-Cre infected mice (3/171 lesion from 
5 mice). On the other hand, Ad5-SPC-Cre infection resulted in invasive AC (IAC) (117/171), or 
papillary AC (PAC) (26/171) as the predominant histotypes. Of note, mucinous AC (MAC) and acinar 
AC (AAC) subtypes were detected specifically in Ad5-CC10-Cre infected mice (I, Fig. 1C, S1D, S1G 
and Table S1). Collectively, these results suggested that progenitor cells influence histotype spectra in 
KL mice, and that CC10+ cells are the predominant origins of ASC. 
Analysis of tumor proliferation using Ki67 IHC showed that lesions that originated from CC10+ cells, 
more specifically PAC and AIS, showed higher proliferation compared to those derived from SPC+ 
cells. In addition, the SCC regions of ASC tumors showed higher proliferation compared to the AC 
regions of ASCs (I, Fig. 1B and 1D) Analysis of tumor size revealed that ASCs were the largest (20-
30 mm2) of all the lesions (I, Fig. 1E). Consistent with published results, ASCs showed keratin 5 
(KRT5) positivity and low or absence of SOX2 expression (Mukhopadhyay et al., 2014). Assessment 
of SOX2 positivity in human ASCs showed positivity in 8/12 samples, and more specifically in SCC 
components of ASCs. Furthermore, 7/12 ASCs showed LKB1 negativity, including 2/4 SOX2 negative 
tumors, indicating that SOX2 negative KL ASCs may represent a subset of clinical ASCs (I, Fig. S1E-
F, and Table S1). To determine the precursors of end-stage tumors, we assessed the KL lungs at 6 and 
9 weeks post AdCre infection. Ad5-CC10-Cre infection resulted in bronchiolar hyperplasias at 6 weeks, 
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and adenocarcinoma in situ (AIS), IAC, PAC, MAC, and ASC at 9 weeks post infection (w.p.i). Of 
note, 1/ 4 Ad5-CC10-Cre infected mice showed SCC lesions at 9 w.p.i. On the other hand, Ad5-SPC-
Cre infection resulted mainly in AIS or PACs at 6 or 9 w.p.i, respectively (I, Fig. S1 I). We also 
confirmed the MAC histotype using Periodic acid-Schiff (PAS) staining, and showed that, similar to 
published results, PAS positive MAC tumors contained reduced numbers of NKX 2-1 positive cells 
compared to PACs (I, Fig. 1F-1G, and S2C-E) (Snyder et al., 2013). The expression of high mobility 
group AT-hook 2 (HMGA2), a transcription factor associated with poorly differentiated tumors 
(Sutherland et al., 2014), was found to be homogeneously expressed in ASCs, while other histotypes 
showed negative or mosaic staining (I, Fig. 2B). Together these results suggested that the shorter 
survival of Ad5-CC10-Cre infected KL mice was most likely due to the increased tendency of CC10+ 
progenitors to form fast growing, larger and more poorly differentiated ASC tumors. 
 
4.1.2. Mutant KrasG12D and Lkb1 loss-driven tumors show histotype-specific gene expression 
signatures 
To investigate tumor histotype-associated molecular heterogeneity, we performed gene expression 
analysis of Ad5-CC10-Cre induced ASCs and Ad5-SPC-Cre induced PACs from KL mice. We decided 
to use PACs, as they were the largest and second most frequently detected lesion upon Ad5-SPC-Cre 
infection. In addition, other AC subtypes including MAC, AAC, and PACs (from Ad5-CC10-Cre 
infected mice) were detected in low frequency compared to ASCs, and hence could not be isolated in 
sufficient numbers. We isolated six tumors, two each from 3 mice infected with Ad5-CC10-Cre or 
Ad5-SPC-Cre viruses. Each tumor was processed for RNA isolation, protein lysates and histological 
analyses. We confirmed the ASC histotype of tumors by western blot analysis using anti-p63 antibody 
(I, Fig. S3B). Unsupervised clustering of the microarray results with cut-off adjusted p-value<0.01, 
LogFC>1 revealed 340 genes that were differentially expressed between ASCs and PACs (I, Fig. 2A).  
We further assessed commonalities in histotype-specific gene signatures between our data and 
published datasets. Since there are no human ASC gene expression data available, we used human SCC 
vs AC comparative data and Lkb1;Pten loss (LP) mouse model-derived SCC vs Kras-AC comparative 
data (Kuner et al., 2009; Xu et al., 2014). Venn diagram representation of comparative gene expression 
analysis revealed 40 genes (29 upregulated 11 downregulated) to be commonly altered in a histotype-
specific manner (I. Fig. 2B). Among 29 upregulated genes were SCC markers, Trp63, and a set of 
cytokeratins including Krt5. As expected, one of the downregulated genes included one of the AC 
marker napsin A (Napsa) (I, Fig. 2C). Given that ASCs showed SCC-specific gene signatures, we next 
assessed the similarities between the KL ASC vs PAC comparison and murine basal cell expression 
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(Rock et al., 2009). This analysis revealed 75 or 33 genes to be commonly up- or downregulated, 
respectively, in these two data sets (I, Fig. S3C and Table S2). Upregulated genes were related to basal 
cell differentiation, namely Trp63, basonuclin 1 (Bnc1), stratifin (Sfn), snail family zinc finger 2 
(Snai2), and cytokeratins. In addition, pro-inflammatory cytokine interleukin 1b (Il1b) and its type II 
interleukin 1 receptor (Illr2) were found to be commonly upregulated in ASCs and basal cells (I, Table 
S2). Finally, we compared KL ASC vs PAC data with published data from Ad5-CMV-Cre-induced KL 
AC vs ASCs transcriptional analyses (Ji et al., 2007). This comparison resulted in 23 commonly 
deregulated genes, including SCC-specific Trp63 and cytokeratins (I, Fig. S3C and Table S2). 
 
4.1.3. Murine NSCLC show histotype-specific immune gene signature 
It has been reported that Ad5-CMV-Cre induced tumors from KL mice harbor immunosuppressive 
microenvironment characterized by the presence of TANs and production of pro-inflammatory 
cytokines that suppress CTL recruitment (Koyama et al., 2016). Since our gene expression analysis 
showed histotype-dependent gene expression signatures, we asked if there exist histotype-specific 
immune gene signatures in the KL model. Ingenuity Pathway Analysis (IPA) of KL;ASC vs KL;PAC 
gene expression with a cut-off log FC>2 identified granulocyte adhesion and diapedesis (upregulated 
in ASCs: Cxcl15, Itga2, Ccl6, Ccl7, Cldn18), and antigen presentation (downregulated in ASCs: Cd74, 
Ciita, H2-D1, H2-DMa, H2-DMb1) as altered canonical pathways (I, Fig. 3A). It has been reported 
that in the KrasG12V/+ model, adenovirus-induced inflammation can contribute to inflammatory 
infiltrates and promotes tumorigenesis (Mainardi et al., 2014). To confirm that the observed histotype-
specific immune gene signature was not due to AdCre-induced inflammation, we performed gene 
expression analysis of selected immune genes in KL;ASCs, and PACs together with KP;ACs derived 
from Ad5-CC10-Cre or Ad5-SPC-Cre infection. Our results showed that indeed certain immune genes 
were expressed in a histotype- but not genotype-dependent manner (I, Fig. 3B), and excluded the 
possible effect of AdCre on immune gene signatures. Histotype-specific immune genes included ASC-
specific upregulation of pro-inflammatory genes related to neutrophil recruitment, namely cytokine 
Il1b, S100a8 and S100a9, and Arg1, an enzyme mediating T-cell suppression (Munder et al., 2006; 
Ryckman et al., 2003). Additionally, antigen presentation genes including the expression of class I 
major histocompatibility complex (MHC) genes (H2-M2, and H2-D1), class II MHC genes (H2-DMa, 
H2-Ab1, H2-DMb1) and class II MHC associated gene Cd74 were downregulated in ASCs, and also 
the lymphocyte and monocyte chemoattractant genes Ccl17 and Ccl6 were downregulated in ASCs 
compared to ACs (I, Fig. 3B). Furthermore ASC histotype-specific downregulation of class I MHC 
genes and up regulation of Arg1 was confirmed by quantitative real-time PCR (qPCR) (I, Fig. 3C). 
Expression of Il1b, one of the neutrophil chemoattractants was not statistically significant between 
ASCs and KP;ACs (I, Fig. 3C). This could possibly relate to tumor grade, as Gr-1+ neutrophils have 
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been reported to be higher in high grade KP;ACs (Faget et al., 2017). These results indicate that KL 
tumors show histotype-specific immune gene signatures suggestive of immunosuppression in ASCs 
compared to ACs  
 
4.1.4. ASC histotype-specific recruitment of Gr-1+ CD11b+ TANs   
The finding that ASCs showed gene expression signatures favorable for neutrophil recruitment 
prompted us to investigate the abundance of TANs in KL;ASC and KL;PACs. For this purpose, we 
performed quantitative IHC-based analysis for neutrophil markers, Gr-1 and Cd11b, on full lung lesions 
from KL Ad5-CC10-Cre or Ad5-SPC-Cre infected mice (n=5 for both groups). The results showed a 
clear enrichment of Gr-1+ and CD11b+ cells in ASCs compared to PACs. Furthermore, increased TAN 
recruitment in ASCs was accompanied with a reduced number of CD3+ T cells, suggesting pro-
tumorigenic effect of TANs in ASCs (I, Fig. 4A-B, and S3E). Additionally, we confirmed Gr-1 and 
Cd11b double positive cells (TANs) by flow cytometry, and the results confirmed ASC-specific 
recruitment of TANs. Conversely, flow cytometry analysis also showed an ASC-specific reduction in 
CD3+ T cells (I, Fig. 4C-D). Consistent with varying expression of Il1b, IHC analysis on KP;ACs 
showed variability in the percentage of  Gr-1+  and CD11b+ cells (I, Fig. S4A-B), supporting the finding 
that that tumor grade in KP;ACs influences TAN infiltration.  
To investigate the translational relevance of our findings, we next analyzed a set of human NSCLC 
tumors, in a TMA comprised of ASC (N=12), PAC (N=25), and SCC (N=28) tumors, for TAN 
infiltration. Quantification of fluorescent multiplex staining for human TANs, CD11b+CD33+HLA-Dr-
, did not show statistically significant difference among histotypes (I, Fig 4F-G and S4C-D). However, 
we observed a trend towards SCC subregion-specific infiltration of TANs in ASC tumors (I, Fig 4H 
and S4E). Consistent with the murine findings, the status of LKB1 in human NSCLC tumors did not 
correlate with TAN infiltration (I, Fig S4F-G). Taken together, these results showed an KL;ASC-
specific immunosuppressive microenvironment, accompanied by increased TAN recruitment and a 












Figure 9. Schematic illustration summarizing of the role of cell of origin in determining survival of 
mice, histotype spectrum and histotype-specific immune microenvironment in the KL GEMM. (A) 
Different cell types in the distinct compartments of the adult mouse lungs. Intranasal or intratracheal 
administration of Ad5-CC10-Cre or Ad5-SPC-Cre viruses into KL lungs restricts genetic recombination 
to either CC10+ or SPC+ cells, respectively. (B) Ad5-CC10-Cre infected KL mice show a shorter survival 
compared to Ad5-SPC-Cre infected mice. (C) CC10+ cells are the predominant progenitors of ASC, MAC, 
and AAC tumors, while both CC10+ and SPC+ cells can produce PAC, IAC, and AIS lesions (D) KL;ASCs 
show immunosuppressive features, consisting of reduced antigen presentation molecules, increased TAN 
infiltration and reduced intratumoral T cells. 
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4.2. A protocol for the generation, cultivation and analysis of precision-cut murine NSCLC tissue 
slices 
 
In an IMI-funded consortium project PREDECT (http://www.predect.eu), we described an optimized 
workflow for the establishment, and analysis of precision-cut tumor slices derived from lung, breast, 
and prostate cancer models (Davies et al., 2015). We showed that, compared to filter-supports where 
sliced are cultivated on air-liquid interphase, rotating incubation units improved viability of short-term 
NSCLC slice cultures by intermittent exposure of tumor slices to oxygen and nutrients (Davies et al., 
2015). However, slice cultivation on rotating incubation units is technically challenging and requires 
constant monitoring. We therefore developed a protocol for the generation of precision-cut murine 
NSCLC tissue slices using the Leica VT1200 S vibratome machine, which includes a practical video 
demonstration showing how to handle the rotating incubation unit followed by H&E staining and 
quantitative IHC analysis of cultured slices (II, Fig. 1). We also showed that thickness influences the 
viability of short-term (24 h) slice cultures. H&E analysis of 160 µm, 200 µm, and 250 µm thick tumor 
slice cultures showed that 160 µm thin slices harbor necrotic regions across the slices, likely because 
they are too fragile and tend to damage during slice handling. Slices of 250 µm thickness showed 
necrotic gradients across the slice when compared to 200 µm thin slices (II, Fig. 2A). The poor viability 
of thicker 250 µm slices is possibly related to insufficient oxygen and nutrient diffusion across the 
slices compared with thinner 200 µm slices. Due to differences in tissue stiffness, hypoxia or matrix 
composition, each tissue type is therefore likely to require slice thickness optimization. In addition, we 
demonstrated how to execute quantitative IHC analysis for well-differentiated lung AC marker, NKX2-
1. This showed that, compared to 0 h slices, NKX2-1 expression was not altered in samples cultured 
up to 72 h, suggesting that the AC differentiation status is not affected during short-term slice 
cultivation (II, Fig. 2B-C). Given our findings that Kras mutant murine ACs exhibit high pERK1/2 
compared to ASCs, with p4EBP1 is similarly expressed in both ACs and ASCs (III, Fig. 2A-B), we 
targeted these pathways to demonstrate how to select optimal drug concentrations prior to slice 
treatment studies. To evaluate a dose-dependent effect on targeted pathway inhibition, KL;AC slices 
were treated with DMSO or titrated amounts of compounds, namely 0.1 µM -1 µM dactolisib (to inhibit 
p4EBP1) or 0.05 µM - 0.5 µM selumetinib (to inhibit pERK1/2). The results showed that 1 µM 
dactolisib or 0.5 µM of selumetinib was effective in inhibiting 4EBP1 or ERK1/2 phosphorylation, 
respectively. In addition, as a technical bonus, such selective regulation of phosphoprotein expression 
indicates that tumor slices can be used to validate phosphorylation-specific antibodies. Together, this 
protocol demonstrated the critical steps in obtaining maximum viability of the tumor slice cultures, and 




4.3. KrasG12D-driven murine NSCLC show histotype-specific spatial heterogeneity in oncogenic 
signaling  
Despite advancements in cancer therapy, successful treatments are compromised by intra- and 
intertumoral heterogeneity (Xue et al., 2017). Research during the past few decades have established 
multiple levels of tumor heterogeneity, namely genetic, phenotypic, functional, and 
microenvironmental heterogeneity (de Bruin et al., 2015; Turner and Reis-Filho, 2012; Xue et al., 
2017). For solid cancers, an important question remains how the spatiality of oncogenic signaling 
activities determine functional response to therapies. Since our previous work using the KL GEMM 
showed a histotype-dependent immune phenotype, we next asked if the histotypes also determine 
oncogenic signaling. We analyzed a set of KL and KP tumors initiated by Ad5-CC10-Cre or Ad5-SPC-
Cre viruses for oncogenic signaling downstream of KRAS or LKB1 (III, Fig. S1A). We demonstrated 
that certain oncogenic signaling pathways are expressed in a histotype-specific manner, with 
phosphorylation of AKT (pAKT; indicating PI3K pathway activity) selectively detected in ASCs and 
phosphorylation of ERK (pERK; indicating MAPK pathway activity) predominantly detected in ACs. 
Furthermore, we found that oncogenic phosphoproteins, namely pAKT, and pSRC were predominantly 
detected in the SCC subregions of ASCs, suggesting intratumoral spatial heterogeneity in oncogenic 
signaling (III, Fig. 2A-B). Interestingly, consistent with our murine finding, human NSCLC analysis 
revealed that ASC (5/13), and SCC (8/28) showed predominant pAKT expression compared to AC 
(1/25) (ASC comparison to AC, Fisher’s test p-0.012, SCC comparison to AC, Fisher’s test p-0.026), 
whereas pERK was more commonly detected in ACs (20/25) compared to ASC (9/13), or SCC (13/28) 
tumors (AC comparison to SCC, Fisher’s test p-0.02). Examination of the LKB1 or TP53 status in 
human NSCLCs by IHC revealed that the majority of the tumors contained nuclear TP53, suggesting 
alteration in the TP53 pathway, while LKB1 expression varied in all the pathologies (III, Fig. S1B, 
and Table S1). In summary, these results indicated that oncogenic signaling tends to stratify according 
to tumor histotype and exhibits intratumoral spatial heterogeneity in murine and human NSCLC. 
 
4.3.1. Establishment and characterization of KrasG12D-driven murine NSCLC tissue slices to study 
drug responses 
The fact that we identified marked intra- and intertumoral heterogeneity in PI3K/mTOR and MAPK 
pathway activities led us to investigate how this affects sensitivity to targeted therapies. Precision-cut 
tumor tissue slices are an attractive preclinical model for functional drug testing, due to the presence 
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of intact tumor-stroma interactions, and, more importantly, spatial aspects of drug response can be 
better modelled in tumor tissue slices. As a part of the PREDECT consortium project (www.predect.eu) 
we established KL and KP tumor tissue slices, optimized the culture conditions and assessed viability, 
proliferation, DNA damage, and phosphoprotein levels in uncultured (0 h) and in slices cultured up to 
72 h (III, Fig. S2A). Slices were cultured on rotator incubation units to ensure uniform exposure to 
oxygen and nutrients. Assessment of the viability by H&E in cultured slices showed that viability was 
better maintained in the top section of the tissue (III, Fig. S2B and S2C). Hence, in the following 
experiments, all quantitative analyses were done on the top section of the tumor slices (III, Fig. S2A). 
We interrogated the slicing and culture-induced changes on cellular proliferation, DNA damage, and 
phosphoprotein expression. Proliferation of 0 h uncultured slices were similar to native tumors with 
respect to Ki67 IHC; hence we compared the proliferation in cultured samples to that of 0 h samples 
(III, Fig. S3B). While cultured AC slices showed a decrease in Ki67 positivity, ASCs showed region-
specific changes: SCC regions showed a decrease in proliferation already at 24 h, and AC regions of 
ASCs showed an increase in proliferation after 48 h (III, Fig. S3C). Cultured slices accumulated more 
DNA damage compared to 0 h slices, as demonstrated by γH2AX positivity (III, Fig. S3A). Analyses 
of oncogenic phosphoproteins showed no significant change in 0 h slices compared to in situ tumors. 
However, ASC-specific induction of pAKT was observed in ASC slices cultivated for 24 h. While 
pERK1/2 showed alterations in both directions, p4EBP1 and pSRC showed a significant induction in 
slices of both ASC and ACs (III, Fig. S5A). Furthermore, PTEN loss-driven murine prostate cancer 
slices also showed similar changes in pERK1/2 upon cultivation (III, Fig. S7A). In addition, altered 
p4EBP1 and pERK1/2 expression was also seen in freshly resected human NSCLC and prostate tumors 
(III, Fig. S5B and S7B). Taken together, these results suggested that murine NSCLC tissue slices are 
vulnerable for culture-induced changes in proliferation and oncogenic signaling, while freshly cut (0 
h) uncultured slices preserving proliferation and oncogenic functions of in situ tumors. Therefore, drug 
treatments on tumor slices must be conducted at the onset of culturing.  
 
4.3.2. Cytotoxic response to combinatorial inhibition of the PI3K/mTOR and MAPK pathways 
is determined by co-expression of targeted phosphoproteins 
Next, we set out to investigate how histotype-specific spatial heterogeneity in oncogenic signaling 
influences on sensitivity to small molecule inhibitors, namely the dual PI3K/mTOR inhibitor NVP-
BEZ235 or dactolisib (dact), the MEK inhibitors AZD6244 or selumetinib (sel), and the SRC inhibitor 
saracatinib (sar) (III, Fig. 3A). Assessment of viability in neighboring DMSO and drug-treated slices 
(24 h) did not show significant cytotoxic responses in any of the single compound treated samples (III, 
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Fig. 3B-C). Interestingly, of the tested double combinations, only dact+sel showed considerable 
cytotoxic, but not cytostatic, response (III, Fig. 3C-D, and S10A). Since SRC activity is enriched in 
the SCC compartment of ASCs, we reasoned that addition of sar to the dact+sel may show SCC-specific 
increased sensitivity. However, our results showed that the effect of dact+sel and dact+sel+sar was 
very similar, and that inhibition of SRC did not increase cytotoxic effect in any of the groups tested 
(III, Fig. S10B). These results suggest that KL- and KP- derived NSCLC slices show sensitivity to 
combined inhibition of PI3K/mTOR and MAPK pathways. We reasoned that sensitivity to combination 
of dact+sel could possibly relate to prevalence of targeted pathways in the treated tissue slices. To test 
this, we determined baseline signaling activities, p4EBP1 and pERK1/2 (% area) in the 0 h uncultured 
slices, and correlated this with relative decreases in viability following 24 h dact+sel treatment. There 
was a significant correlation between p4EPB1 and pERK1/2 positivity in 0 h slices with cytotoxic 
response (p<0.001 for p4EBP1, and p<0.05 for pERK1/2) in neighboring treated slices (III, Fig. 4A 
and Table S2). Furthermore, deeper investigation of responding vs non-responding slices revealed the 
concomitant expression of p4EBP1 and pERK was required to elicit significant cytotoxic response 
(>20 decrease in viability), while expression of either of these phosphoproteins alone failed to induce 
cytotoxicity in treated slices (III, Fig 4C). 
To convincingly show that co-expression of p4EBP1 and pERK1/2 guides sensitivity to dact+sel, we 
correlated the percentages of overlapping p4EBP1 and pERK1/2 expression areas in 0 h slices with 
viability decreases in dact+sel-treated samples. As expected, there was a positive correlation between 
the % overlapping area and viability (III, Fig 5A-B). Furthermore, the AC regions of ASC tumors 
showed increased sensitivity to dact+sel compared to SCC regions (III, Fig. S10C), suggesting a SCC-
specific intrinsic resistance mechanism. Taken together, these results showed that in Kras-driven 
murine NSCLC slices, cytotoxic response to combined inhibition of the PI3K/mTOR and MAPK 
pathways depended on the co-activation of the targeted signaling pathways. In addition, the 





















Figure 10.  Kras-mutant murine NSCLCs show histotype-specific oncogenic signaling, and co-
expression of the targeted phosphoproteins determine sensitivity to combined drug treatment. 
Spatially distributed signaling activities correlate with sensitivity to drug combinations in Kras mutant 
NSCLC tissue slice cultures. Oncogenic phosphoproteins pAKT and pSRC are predominant in the SCC 
region of ASCs, while pERK is predominant in ACs. Short-term treatment of ASC or AC tissue slice 
cultures with a combination of PI3K/mTOR and MEK inhibitors leads to cytotoxic response in the 
regions showing concomitant activation of both p4EBP1 (indicative of PI3K/mTOR pathway) and 




4.4. Histotype-specific oncogenic signaling defines sensitivity to combinatorial MEK inhibition in 
KrasG12D-driven NSCLC 
Since our previous work using KL and KP GEMMs identified that tumor histotype determines immune 
microenvironmental heterogeneity and oncogenic signaling, we asked how in vivo pathology-specific 
functional heterogeneity informs on histotype-selective drug vulnerabilities. We hereto set out to 
establish KL- and KP tumor-derived cell cultures, to investigate the ability of in vitro cultures to model 
drug response of in vivo tumors. 
 
4.4.1. A conditional reprogramming (CR) protocol is necessary for the establishment of KL cell 
cultures 
To investigate NSCLC subtype-specific drug sensitivities, we first set out to establish murine NSCLC 
cell cultures. Epithelial cells from Ad5-CC10-Cre-induced KL;ASC (N=4), Ad5-SPC-Cre-induced 
KL;AC (N=3), or Ad5-CC10-Cre- or Ad5-SPC-Cre-induced KP;AC (N=4) tumors were cultured on 
plastic using RPMI medium, or on top of irradiated 3T3 feeder cells using F-medium supplemented 
with Rho kinase inhibitor (Y-27632). The latter cultures are referred to as conditionally reprogrammed 
cells (CRCs). Using IHC, we confirmed the histotype of the source tumors from which the cell cultures 
were established, by performing NKX2-1 (AC & ASC marker) and p63 (ASC marker) staining, and 
confirmed the lack of LKB1 expression in KL source tumors (IV, Fig. S1A). While KP  cultures were 
readily established in RPMI as well as in the CR condition, establishment of KL tumor cell cultures 
(both ASC and AC histotypes), required the CR protocol (IV, Fig. 1A and S1B), indicating that tumor 
genotype (KL vs KP) is the major determinant influencing whether the CR protocol is required for 
culture establishment.  
Using immunoblot analysis, we confirmed that KL- and KP-CRCs lacked LKB1 or p53, respectively, 
and retained features of epithelial cells (IV, Fig. 1B, and 1C). Interestingly, all KP-CRCs showed both 
vimentin and E-Cadherin positivity, while KL-CRCs were E-cadherin positive. Of note, one of the 
KL;ASC-CRCs, established without EpCAM purification, showed positivity for LKB1 and the stromal 
marker vimentin, suggesting epithelial purification is required to establish pure epithelial cultures (IV, 
Fig. 1B-1C and S1C-S1D). Next, we assessed the growth rates of the established CRCs at passage 6. 
In line with differential growth rates observed in vivo, KL;ASCs grew faster than KL;ACs (IV, Fig. 
S1E). We examined if cultures also showed a differential clonogenic potential in the presence of 
absence of Y-27632. This showed that KL cultures were dependent on the presence of Y-27632 for 
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colony formation, and exhibited a variable yet higher clonogenic potential than KL;AC cultures (IV, 
Fig. 1D and 1E). On the contrary, inclusion of Y-27632 negatively affected the clonogenic ability of 
KP;AC cultures (IV, Fig. 1D and 1E). These results suggested that murine NSCLC CRCs represent the 
genotype and growth characteristics of in vivo tumors. 
To assess the representativity of CRCs to that of source tumors, we analyzed histotype-specific marker 
expression in CRC 2D and three dimensional (3D) cultures. Comparison of NKX2-1 and p63 
expression in 2D or 3D cultures to that of the source tumors showed that p63 expression was variable 
yet sustained in 2D and 3D cultures of ASCs, but was absent in ACs. On the other hand, NKX2-1 
expression was reduced in 2D and 3D cultures of ASCs, while it was completely lost in ACs. (III, Fig. 
S1F-H). These results suggested that AC-CRCs undergo de-differentiation by losing NKX2-1 
expression, while ASC-CRCs maintain their differentiated state. 
 
4.4.2. Identification of NSCLC subtype-specific drug vulnerabilities using drug sensitivity and 
resistance testing (DSRT) 
To validate the robustness of the CRCs in identifying pathology- or genotype-specific drug responses, 
we first tested the effect of idasanutlin, an activator of p53 and inhibitor of mdm2-p53 interaction, in 
KL and KP cultures. Drug Sensitivity Scores (DSSs) were used to measure the drug response 
(Pemovska et al, 2013).  As expected, KL cultures showed increased sensitivity to idasanutlin compared 
to KP;ACs (IV, Fig. S2A). Next, we performed DSRT on murine NSCLC CRCs representing KL;ASCs 
(N=2), KL;ACs (N=2), and KP;ACs (N=2), and on NL cultures (N=3). For each drug, tumor cell-
specific sensitivities were identified by subtracting the DSS of individual tumor-derived CRCs from 
average DSS scores of NL;CRCs (n=3), determining selective drug sensitivity scores (sDSS) 
(Pemovska et al., 2013; Yadav et al., 2014). Sensitivity or resistance to a particular drug was identified 
as those with sDSS greater than 5 or lesser than 5, respectively (IV, Fig. 2A). Analysis of the DSRT 
data revealed that ASC cells were sensitive to 19 compounds, while ACs from both genotypes showed 
sensitivity to fewer drugs (IV, Fig. S2D). The second screening phase (phase II) included the 61 
compounds for which at least one of the CRCs showed a sDSS ≥5 and ≤-5 in the initial screen (IV, Fig. 
2A). Unsupervised hierarchical clustering of the sDSS from the phase II screen revealed four distinct 
compound groups (IV, Fig. 2B). Consistent with higher proliferative capacity, KL;ASC cultures 
showed increase sensitivity to antimitotic and chemotherapeutic agents. In addition, also compounds 
targeting proliferation, topoisomerase, BET inhibitors and HDAC inhibitors were found to be 
specifically effective in KL;ASC cultures (IV, Fig. 2B). In line with published findings, KL cultures 
87 
 
showed higher sensitivity to HSP90 inhibitors compared to KP cells (IV, Fig. 2C) (Skoulidis et al., 
2015). These results tentatively suggested that murine NSCLC CRCs showed both histotype and 
genotype-selective drug sensitivities. 
 
4.4.3. AC histotype-selective sensitivity to MEK inhibition 
Comprehensive drug screening on GEMM tumor-derived CRCs across different genotypes and 
histotypes revealed that compared to other subtypes, KL;AC cultures were more sensitive to the MEK 
inhibitors (IV, Fig. 2C and S2D). To further validate this finding, eight different doses (0.5-500 nM) 
of MEK inhibitor trametinib were tested in all the cultures. Consistent with the previous results, 
KL;ACs showed increased sensitivity to trametinib among the culture subtypes tested (IV, Fig. 3A). 
To investigate signaling changes following MEK inhibition, we assessed pERK1/2 and pAKT 
expression in cells treated with 50 nM trametinib for 4-72 h, or with a titrated amount of trametinib (5 
to 50 nM) for 48h (dose-dependent). ERK phosphorylation was successfully inhibited with 50 nM 
trametinib already at 4 h post treatment, and this was accompanied by increased AKT phosphorylation 
in all the cultures, suggesting adaptive responses to MAPK inhibition (IV, Fig. 3B-C and S3A-B). 
Consistent with our in vivo IHC analysis (II, Fig. 2A-B), western blot analysis of the source tumor 
tissues showed pERK to be predominant in ACs, while pAKT was higher in ASCs (IV, Fig. S3E). 
These results partially explained KL;AC-selective sensitivity to MEK inhibition. 
Next, we assessed if the in vitro subtype-specific sensitivity to MEK inhibition was also recapitulated 
in in situ tumors. Short-term treatment (24 h) of KL and KP tumor-bearing mice with trametinib showed 
that ACs of both culture genotypes exhibited sensitivity to trametinib as evidenced by decreases in the 
percentage of proliferating cells (chloro-deoxyuridine; CIdU or Ki67 positive nuclei). Consistent with 
the in vitro results, KL;ASC tumors (both their SCC and AC subregions) were insensitive to trametinib 
(IV, Fig. 3D-H), and  this could be explained by the observation that ASCs showed lower ERK activity 
compared to ACs (IV, Fig. S3C-D). Together, these result showed that, despite the presence of Kras 
mutation in all culture subtypes, murine NSCLCs showed AC-specific cytostatic effects to short-term 




4.4.4. Inhibition of MEK together with RTKs identifies NSCLC subtype-specific drug 
combinations  
The finding that KL;ASCs were non-responsive to trametinib, and all the culture subtypes showed 
adaptive activation of the PI3K/mTOR pathway following MAPK inhibition, prompted us to explore 
subtype-specific effective drug combinations. Several studies using KRAS mutant NSCLC cell lines 
have shown adaptive activation of various RTKs, including ERBBs, and FGFR following MAPK 
inhibition (Anderson et al., 2017; Kim et al., 2016; Kitai et al., 2016; Manchado et al., 2016; Massarelli 
et al., 2007). These adaptive pathways promote pro-survival signaling via induction of pAKT. To 
investigate which RTKs were involved in adaptive activation PI3K/AKT signaling, we treated cultures 
with pan-ERBB, FGFR, IGF1R, Axl or Met inhibitors, either alone or in combination with trametinib. 
This approach revealed a KL-specific (both ASC and AC cultures) sensitivity to combination treatment 
with MEK and pan-ERBB inhibitor (trametinib + afatinib) (IV, Fig. 4A-B). On the other hand, all the 
cultures were insensitive to MEK and FGFR inhibitor (trametinib + ponatinib) combination (IV. Fig. 
S4A-B). Together, these results indicate NSCLC subtype-specific sensitivity to combinatorial MEK 
and RTK inhibition, with selective sensitivity of KL cultures to combinatorial inhibition of MEK and 
ERBB pathways. 
 
Combination treatment of trametinib together with ponatinib was previously shown to cause tumor 
regression in the KP lung cancer model (Manchado et al., 2016). Hence, the finding that none of the 
culture subtypes showed response to trametinib + ponatinib combination treatment, prompted us to 
investigate the long-term response to this combination. In addition, we asked if the culture subtype-
specific response to MEK and ERBB inhibition showed durable response. Therefore, we selected the 
trametinib + afatinib and trametinib + ponatinib combinations to perform clonogenicity assays for 
NSCLC culture subtypes, and treated with single compound trametinib (5 nM), afatinib (250 nM), or 
ponatinib (250 nM) or their combinations. Consistent with previous results, the trametinib + afatinib 
combination significantly reduced the colony forming ability of KL;ASC and KL;AC, but not KP;AC 
cultures. Interestingly, the ponatinib combination, which was ineffective in short-term assays (IV, Fig. 
4A and S4A-B), showed a significant reduction in colony formation exclusively in AC cultures (IV, 
Fig. 4C-D). Together, these results suggested the role of ERBBs and FGFR in KL genotype-selective 




To determine if KL-specific sensitivity to afatinib combination treatment was explained by activation 
of ERBB family receptors, we assessed pEGFR, pERBB2, and pERBB3 expression by 
immunoblotting, before and after trametinib treatment. In KL;ASCs, ERBB3 phosphorylation was 
found to be present in untreated cells, as well as following trametinib treatment. Furthermore, 
phosphorylation of EGFR, was found to be induced in KL cultures following trametinib treatment. In 
contrast, KL;AC cultures lacked pERBB3, but pERBB2 was induced following trametinib treatment. 
Interestingly, KP;AC cultures lacked pERBB3 expression, and baseline phosphorylation of EGFR and 
ERBB2 was lost upon trametinib treatment (IV, Fig. 4E-F and S4C-D). In line with the AC-specific 
sensitivity to combination MEK and FGFR inhibition, pFRS2, one of the adaptor proteins of activated 
FGFR1, was found to be expressed specifically in ACs, either at baseline or following trametinib 
treatment in KP;ACs and KL;ACs respectively (IV, Fig. 4E-F and S4C-D). Finally, to assess if the 
combinatorial inhibition of the MEK and ERBB pathways also affected cell survival, we analyzed 
expression of cleaved caspase-3 (CC3), a marker of apoptosis, in samples treated with trametinib (50 
nM), afatinib (1000 nM), or trametinib + afatinib for 48 h. Combination treatment with trametinib + 
afatinib induced cell death specifically in KL cultures (IV, Fig. 4G). These results suggested that 
combinatorial inhibition of MEK together with subtype-specific RTKs effectively blocked the survival 
and proliferation of NSCLC cultures. Collectively, these results indicated NSCLC subtype-specific 
RTK activation, with intrinsic or adaptive ERBB activation being KL-selective, and AC-selective 
adaptive FGFR activation following MEK inhibition determining sensitivity to combinatorial MEK 
inhibition.  
 
4.4.5. Histotype-specific differences in ERBB receptor activation in murine and human NSCLC 
To assess if in vitro sensitivity to combinatorial inhibition of the MEK and ERBB pathways was 
explained by the activation of ERBB receptors in in situ tumors, we profiled in vivo KL;ASC (N=4 
mice), KL;AC (N=3-6 mice), and KP;AC (N=7-8 mice) tumors for pEGFR, pERBB2, and pERBB3 
expression. Interestingly, quantitative IHC analysis showed that activation of all three ERBB receptors 
was predominant in the SCC subregions of ASC tumors compared to AC tumors (IV, Fig. 5A-B). To 
determine if the pathology-specific activation of ERBB receptors was also found in clinical samples, 
we performed IHC for pERBBs on human NSCLC TMAs comprised of ASCs (N=13), ACs (N=25), 
and SCCs (N=28). In line with the murine findings, pERBB3 in human samples was predominant in 
ASC (4/13) and SCC (7/28) histotype lesions compared to ACs (0/25) (Fisher’s test p=0.009 for ASC 
vs AC, p=0.02 for SCC vs AC.) In addition, activation of EGFR was significantly higher in SCCs 
compared to ACs, Fisher’s test p=0.03 SCC vs AC (IV, Fig. 5C-D). Replicate cores taken from 
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different subregions of the same tumor showed varying positivity for activation of all tested ERBB 
receptors, indicating that spatial heterogeneity is also detected in human tumors (IV, Fig. 5D). These 
results suggested that NSCLCs show histotype-specific spatial heterogeneity in activation of ERBB 
receptors. More specifically, the SCC subregions of murine ASCs showed predominance of ERBB 
receptor activation compared to AC tumors. 
 
4.4.6. Spatially-defined ERBB receptor activation determines acute cytotoxic response to 
combinatorial inhibition of the MAPK and ERBB pathways 
Given that ERBB activation in vivo was prevalent in SCC subregion of ASCs, we reasoned that SCCs 
may show increased response to inhibition of ERBB signaling. To investigate the NSCLC subtype-
specific acute response to combinatorial MEK + ERBB inhibition in in vivo settings, we treated KL or 
KP mice with TR, or AF as single agents or in combination, once daily for three days. Quantitative 
IHC comparisons of proliferation (Ki67), or cell death (CC3) was performed between four groups 
(KL;SCC of ASC, KL;AC of ASC, KL;AC, or KP;AC) of vehicle, trametinib, afatinib, or trametininb 
+ afatinib-treated KL or KP mice. As opposed to 24 h in vivo trametinib treatment, MEK inhibition did 
not show cytostatic response in all tumor subtypes (IV, Fig. 3E-H and 6A-B), suggesting adaptive 
resistance mechanisms following MEK inhibition. However, a significant decrease in Ki67 positive 
proliferating cells was observed upon combinatorial MAPK and ERBB pathway inhibition in all the 
groups (IV, Fig. 6A-B). In line with the Ki67 results, residual pERK1/2 expression was detected 
following 72 h trametinib treatment, while combination trametinib plus afatinib treatment caused 
significant inhibition of pERK1/2 in all subtypes (IV, Fig S5A-B).  
 
Next we assessed cytotoxic responses short-term combination treatment, using CC3 IHC. Of note, the 
CC3 antibody was found to stain inherent necrotic areas in vehicle-treated ASC tumors, and drug-
induced or inherent-necrotic regions were indistinguishable. Hence, the percentages of CC3 positivity, 
marking both necrotic and apoptotic regions, per tumor area were quantified in both control and treated 
samples. Interestingly, the SCC regions of ASCs exhibited varying but significant cytotoxic response 
upon trametinib treatment (IV, Fig. 6C-D). Importantly, combination treatment elicited stronger 
cytotoxic response selectively in SCC subregion of ASCs as measured by CC3 positivity (% area) (IV, 
Fig. 6C-D). Lack of a cytotoxic response to combination treatment in ACs suggested that survival 
pathways in these tumors are independent of ERBB signaling. In summary, these results suggest that 
the in situ ERBB activation status associates with acute cytotoxic response to combination treatment 





Figure 11.  Subtype-specific intrinsic and 
adaptive signaling activities determine 
sensitivity to combinatorial MEK inhibition in 
Kras mutant NSCLC. MEK inhibition in ex vivo 
cultures of KL;ASC, KL;AC, or KP;AC leads to 
adaptive activation of the AKT in all culture 
subtypes. However, cultures show subtype-specific 
differential activation of RTKs: adaptive EGFR and 
intrinsic ERBB3 activation in KL;ASCs, and 
adaptive ERBB2, EGFR, and FGFR activation in 
KL;ACs, or adaptive FGFR activation in KP;ACs. 
Combinatorial ERBB + MAPK or FGFR1 + MAPK 
inhibition results in KL genotype-specific or AC 
histotype-specific inhibition of proliferation or 
survival, respectively. In contrast, short-term (72 h) 
combinatorial inhibition of the MAPK + ERBB 
pathways in KL and KP tumors results in KL;ASC- 
selective acute responses in terms of proliferation 
and survival, which is in line with the predominance 
of ERBB receptor activation in KL;ASC tumors 
compared to ACs. The dotted line represents 
absence or lower PI3K/AKT pathway activity in 
ACs compared to KL;ASC tumors. Red and blue 
arrows indicate predominant and lower activation of 




5. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
5.1. The cell of origin defines NSCLC histotype spectra and immune microenvironment 
heterogeneity upon activation of KrasG12D and loss of Lkb1 
This thesis work demonstrates that the tumor cell of origin is crucial in determining the survival of 
mice, and the histotype fate of the lesions following KrasG12D activation together with loss of Lkb1. 
Importantly, this work showed that ASCs, the most aggressive NSCLC subtype, are initiated from 
CC10+ progenitors. The occasional ASCs produced from SPC+ cells indicated possible 
transdifferentiation of AC-SCC via an ASC intermediate state, as reported previously (Han et al., 
2014). Alternatively, rare CC10 and SPC co-expressing alveolar cells or BASCs could serve as 
progenitors of Ad5-SPC-Cre-derived ASCs (Rawlins et al., 2009). The finding that CC10+ cells 
uniquely gave rise to mucinous and acinar AC subtypes could be explained by the presence of CC10+ 
cells in different compartments of the lung, for instance a rare SPC and CC10 dual positive alveolar 
cells (Rawlins et al., 2009), or CC10 and mucin co-expressing bronchiolar cells (Boers et al., 1999; 
Rawlins et al., 2009) could serve as progenitors of Ad5-CC10-Cre-derived acinar or mucinous AC 
tumors, respectively. Investigation of markers specific to subsets of CC10+ cells residing in 
anatomically distinct compartment of the lung would help in lineage-tracing the cellular origin of the 
diverse histotypes originated upon Ad5-CC10-Cre infection in KL mice. In addition, future studies 
focusing on targeting of other lung progenitors, including p63+K5+ cells or integrin α6+β4+ and SPC- 
cells, would expand our knowledge on NSCLC subtype-specific cellular origin(s) in the KL model. 
The ASCs produced from CC10+ cells showed gene expression signatures similar to SCC. This finding 
was further supported by published reports showing the ability of club cells to form p63+ cells in the 
lung parenchyma following influenza infection, but not bleomycin injury, and suggests a unique 
capacity of club cells to differentiate into basal-like cells in a context-dependent manner (Zheng et al., 
2014). A study by Koyama et al suggested that immunosuppression mediated by increased TANs was 
specific to loss of LKB1 in the KL model (Koyama et al., 2016). Our study deepened this finding by 
showing that TAN infiltration and immunosuppression in KL mice is in fact ASC histotype-specific. 
The fast generation and bigger size of ASCs could partially be due to modulation of the immune 
microenvironment favorable for TAN recruitment, and reduced anti-tumor surveillance by CD3+ T 
cells. In addition, ASCs may escape from anti-tumor immune response by downregulating antigen 
presentation genes, enabling faster growth of tumors. Our attempts to investigate ASC-specific 
expression of TANs in clinical samples did not yield convincing results due to the low number of 
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clinical ASCs, and possibly also because of the varied clinical history of patients with respect to co-
existence of other inflammatory diseases such as COPD (Chronic obstructive pulmonary disease) and 
prior clinical treatments. Moreover, this study investigated myeloid cell populations in human NSCLC, 
and further analysis using granulocytic and monocytic MDSC-specific markers are warranted. Finally, 
to obtain reliable translational relevance for such TAN analyses, immune cell analysis in human 
NSCLC must be correlated to clinical parameters such as previous treatment history and consider the 
option to follow neutrophil abundance in liquid biopsies taken from the blood, so to enable the temporal 
tracing of immune suppressive cells. In addition, further development of strategies to specifically target 
TAN functions in Ad5-CC10-Cre infected KL mice, as well as in patients, is necessary to reveal if the 
previously observed therapeutic benefit upon TAN inhibition in KL mice is specific to ASCs (Koyama 
et al., 2016).  
 
5.2. Tumor histotype but not driver genotype defines oncogenic signaling heterogeneity in 
KrasG12D-driven murine NSCLC 
Previous studies using murine models of lung cancer suggest that pERK activity is lower in lung SCC 
driven by Lkb1;Pten or Sox2;Lkb1 compared to KrasG12D-driven tumors, and this difference was 
attributed to absence of oncogenic Kras-driven MAPK pathway in SCCs (Mukhopadhyay et al., 2014; 
Xu et al., 2014). However, our quantitative IHC analysis of murine KL and KP tumors showed that 
despite being driven by oncogenic KrasG12D, signaling downstream of Kras is stratified according to 
tumor histotype, rather than genotype. Our results demonstrated that in both murine and human 
NSCLCs, pAKT expression is predominant in SCC/ASC histotype lesions, while pERK is enriched in 
ACs. In addition, pSRC and pAKT show intratumor spatial distribution within KL;ASCs, with 
predominant activation in SCC subregions compared to AC. These results suggested that increased 
AKT and SRC activities previously observed in the KL model were mostly specific to ASC and SCC 
histotypes (Ji et al., 2007). Together, we demonstrated that, despite being driven by the same 




5.2.1. Spatially active co-occurrence of signaling activities define cytotoxic response to 
combinatorial inhibition of the PI3K/mTOR and MAPK pathways in KrasG12D-driven NSCLC 
tissue slices 
We demonstrated that precision-cut organotypic murine NSCLC slice cultures are valuable only for 
short-term therapeutic studies, as the tumor slice cultures showed dynamic alterations in proliferation 
and signaling, particularly hyperactivation of mTORC1. By doing short-term treatment on tumor tissue 
slices, we showed that cytotoxic response to combined inhibition of the PI3K/mTOR and MAPK 
pathways was dependent on co-expression of both of the pathways being targeted. These results 
demonstrate the utility of tumor tissue slices in modelling spatial response to targeted therapies. 
Furthermore, these findings imply that spatial heterogeneity in oncogenic signaling must be taken into 
consideration as predictive markers in clinical settings.  
Establishment of tissue slices cultures from freshly resected clinical NSCLCs is technically 
challenging, and in our preliminary experience, successful generation of good quality slices depends 
on the stiffness of the tumor tissue: harder tissues provide better quality slices, while softer tissues were 
not suitable for slicing. Thus, further technical refinements in slicing softer tumor tissues are needed to 
establish clinical tumor tissue slice cultures. Furthermore, future studies comparing the responses 
between tumor tissue slices established from lung cancer biopsies with that of matched patient response 
to the same drugs or drug combinations will reveal the applicability of this model in routine clinical 
settings.   
 
5.3. Stratification of KrasG12D-driven murine NSCLC based on in situ signaling activities and 
sensitivity to combinatorial MEK inhibition  
In search of NSCLC lesion-specific drug sensitivities, we set out to establish Kras-driven murine 
NSCLC cell cultures. However, our attempts to establish conventional KL cultures was not successful, 
possibly due to p53-mediated growth arrest. The conditional reprograming method proved to be 
successful in establishing long-term KL and KP cultures with the preservation of genotype and growth 
properties of native tumors. DSRT analysis on murine NSCLC CRCs followed by in vivo validation 
demonstrated that KL;AC cultures and AC tumors showed increased sensitivity to the MEK inhibitor 
trametinib. While in vivo response to MEK inhibition was accurately modelled in KL;AC cultures, 
KP;ACs were found to be resistant to trametinib-mediated MAPK inhibition as opposed to in situ 
KP;ACs. Differential sensitivity to MEK inhibition between in vitro KP;AC cultures vs in vivo KP;AC 
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tumors could possibly be due to differences in end-point readout, as assessment of in vitro viability is 
based on cellular ATP levels, whereas in vivo effects of trametinib were measured on cell proliferation 
using nuclear markers. Increased sensitivity of AC tumors upon 24 h MEK inhibition could be 
explained by previous data showing that Kras copy number gain in KP tumors leads to increased 
dependency on the MAPK pathway (Junttila et al., 2010; Kerr et al., 2016). 
A number of studies on Kras mutant NSCLC cell lines or in vivo models have reported that adaptive 
resistance to MEK inhibition is associated with activation of  RTKs, namely ERBBs and  FGFR (Kitai 
et al., 2016; Manchado et al., 2016; Pang and Liu, 2016; Sun et al., 2014). Our study extrapolated this 
finding and demonstrated that Kras mutant NSCLC subtype-selective intrinsic or feedback RTK 
activation is associated with resistance to MEK inhibition. Cell intrinsic or adaptive activation of 
ERBBs in KL cultures, and adaptive FGFR activation in AC cultures, is associated with resistance to 
MEK inhibition, and that this can be overcome by combinatorial inhibition of the MEK + ERBB 
pathways or MEK + FGFR1 pathways, respectively. Previously, the combined blockade of the MEK 
and FGFR pathways was shown to effectively induce tumor regression in the KP model (Manchado et 
al., 2016). However, the effect of the same combination in the KL model was not explored. Our results 
showed that, in addition to KP;ACs, KL-derived ACs were also responsive to this combination, 
indicating an AC histotype-specific sensitivity to combinatorial inhibition of the MAPK and FGFR 
pathways. These results highlight the utility of CRCs for the identification of NSCLC subtype-specific 
drug sensitivities. 
It has been shown that ERBB3 has high affinity for the PI3K regulatory subunit, and is a potent 
activator of  PI3K/AKT pathway (Hellyer et al., 1998). Our finding of absence or lower activation of 
ERBB3 in murine and human ACs possibly explains the lack of AKT activation in ACs, and that 
alternative survival pathways in tumor with low levels of ERBB3 phosphorylation may exist. 
Interestingly, two recent studies demonstrated the role of ERBBs in Kras-driven murine lung 
tumorigenesis, and showed an impressive anti-tumorigenic effect of long-term treatment with ERBB 
inhibitor alone or in combination with MEK inhibitor (Kruspig et al., 2018; Moll et al., 2018).  These 
findings complement our finding of in vivo acute cytotoxic response to combinatorial MAPK and 
ERBB pathway inhibition, and extends this response to the SCC histopathology. Given that ASCs 
showed acute cytotoxic response to short-term trametinib plus afatinib combination treatment, long-
term treatment with the same combination will likely show therapeutic responses in ASCs. However, 
long-term treatment studies are warranted to fully understand the potential of this treatment strategy in 
the context of Kras-driven mixed NSCLC histopathology models. A clinical study investigating the 
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combination of afatinib and MEK inhibitor selumetinib in KRAS mutant NSCLC is ongoing 
(NCT02450656), and given these findings, the outcome of this will be very interesting (Bennouna and 
Moreno Vera, 2016). Together, our work suggests that coupling of in vitro drug sensitivities with the 
analysis of oncogenic signaling and therapeutic responses in in situ tumors will aid in the selection of 
tumor-specific effective drug combinations 
 
In summary, the work presented in this thesis demonstrates that while being targeted by the same 
genetic alterations, particularly KrasG12D activation and Lkb1 loss, niche-specific lung progenitors 
exhibit a differential ability to establish phenotypic and immune microenvironmental heterogeneity. In 
addition, this work also establishes ex vivo models of Kras mutant murine NSCLCs, and demonstrates 
their utility in modeling spatial responses to targeted therapies, as well as in the identification of 
subtype-selective drug combinations. Furthermore, this work highlights that beyond understanding 
lung cancer at the genetic level, it is important to consider histotype-specific functions, including spatial 
oncogenic signaling heterogeneity, in guiding selection of effective therapies. As such, our studies start 
to point at an alternative way in which NSCLCs, and possibly also other tumor types, can be stratified 






This thesis work was carried out at the Institute for Molecular Medicine Finland (FIMM). I am grateful 
to the current and former directors of FIMM, Prof. Mark Daly, Prof. Jaakko Kaprio and Prof. Olli 
Kallioniemi, for providing excellent infrastructure and state-of-the-art research facilities. I thank HR 
and the administrative staff for supporting me all these years. I am thankful for the financial support 
received from the Doctoral Programme in Biomedicine (DPBM), IMI-PREDECT, Academy of 
Finland, K. Albin Johanssons Stiftelse Foundation, Biomedicum Helsinki Foundation, Cancer Society 
of Finland, Orion Research Foundation, and Maud Kuistila Foundation. 
I would like to extend my deepest gratitude to my supervisor Dr. Emmy Verschuren for her generous 
support and encouragement throughout my PhD. Thank you, Emmy, for accepting me into your group 
and always leaving your door open for me no matter how busy you were. I am grateful to you for giving 
me the freedom to explore my ideas and making sure that I had the best possible resources to pursue 
my scientific questions. Your dedication, enthusiasm and positive attitude towards your work has 
always been an inspiration for me. This journey has been extremely educational for me because of the 
opportunities you made available for collaborations within and outside the lab. I am also grateful to 
you for fostering the transformation of myself into an independent scientist. 
I would sincerely like to thank my opponent Dr. David Dankort for kindly agreeing to serve as an 
opponent for my thesis and for being cooperative with the defense date. I would like to thank Prof. 
Jaakko Kaprio for taking time out of his busy schedule to serve as the Custos for my dissertation. I am 
grateful to my thesis advisory members Prof. Elina Ikonen and Docent Brendan Battersby for their 
encouragement and support throughout my PhD. I also thank my thesis reviewers Docent Aki 
Manninen, and Prof. Anna-Liisa Levonen for their encouraging feedback on my thesis. 
I am immensely grateful to Dr. Denis Kainov for introducing me to the FIMM research community. 
Thank you, Denis, for the opportunity to work with you. I could not have started my PhD if you had 
not recruited me in the first place. I really appreciate your help during the course of my PhD as well as 
during the thesis submission process. 
This thesis work would not have been possible without the fruitful collaborations with my colleagues. 
Many thanks to Jenni Lahtela for helping me during early stages of my PhD and for providing 
emotional support during the difficult times. Thank you, Jenni, for being an excellent team mate on our 
shared publication. I am grateful to our former postdoc Katja Närhi for setting up the mouse colony 
and the protocols. Thank you, Katja, for guiding me through the mouse work, histology analysis and 
98 
 
establishment of the tumor slice cultures. I could not have completed this thesis work without learning 
these techniques from you. I appreciated your help outside the lab as well for our family get-togethers. 
I am thankful to Sarang Talwelkar for the opportunity to collaborate on the mouse CRC project. It has 
been very exciting to work on this project. I am very fortunate to have worked with our former postdoc 
Jennifer Devlin, who is one of the most organized, brilliant and kind scientists I have ever met. Thank 
you, Jennifer, for your generous help during my manuscript preparations and submissions, and for your 
continued support even after you have moved on! A big thank you to Annabrita Hemmes, I can’t 
imagine, Anna, how I would have survived my PhD without your support. I would like to thank 
pathologists, Dr. Kaisa Salmenkivi, for guidance with the murine lung cancer histopathology analysis, 
and Dr. Mikko Mäyräpää, for helping us with the generation of human lung cancer tissue microarrays. 
My sincere thanks to Prof. Krister Wennerberg for advising on the CRC project. I am grateful to Dr. 
Simon Anders for providing valuable and critical comments on my manuscripts. I extend my thanks to 
Teijo Pellinen for taking the time to guide me with the 3D cell cultures. Though some of these results 
could not be part of my thesis, it will definitely be interesting to pursue this in future. I am thankful to 
Sami Blom for supporting me with the image analysis. I would also like to thank Elina Kiss for being 
helpful and accommodating with the in vivo drug treatments. 
Many thanks to Margarita Walliander and Olle Hansson for helping me to troubleshoot a series of 
problems with Definiens. I am grateful to Kalid Saeed for helping me set up the CRC protocol in our 
lab. I am thankful to Susanne Hultsch for letting me use the IPA software and for guiding me with the 
bureaucracy of the thesis work.  I would like to thank Astrid Murumägi and Katja Välimäki for kindly 
providing antibodies for my experiments. Special thanks to Dr. Gretchen Repasky for her advice and 
support during my PhD. I would like to thank current and former lab members Jie Bao, Rita C. Matos, 
Dat Nguyen and Erasmus student Carolina Pereira. I thank my former E-wing neighbors: Masha, 
Laura, Oxana, Daria, Manu, Pauliina and Yuexi for the great company. I am grateful to the Laboratory 
Animal Centre for breeding and maintenance of the mice, the FIMM webmicroscope facility for 
scanning histological slides, the FIMM High-Throughput Biomedicine facility for support with the 
drug screening, and the HUSLAB/Helsinki biobank for providing the human NSCLC tissue blocks. 
Many thanks to my Indian friends (Helsinki Family) for the wonderful get-togethers and celebrations. 
Special thanks to Disha, Poojitha, Yashu, Ashwini and Dipti for organizing my surprise baby shower, 
and for your warmth and friendship. I thank current and former members of “desi lunch”: Swapnil, 
Ashwini, Himanshu, Raghu, Sarang, Mahesh, Disha, Poojitha, Bala, for the delicious food, as well as 
for discussions on a wide range of topics. I would like to thank Sreesha and Abhilash for their friendship 
and for helping my family on various occasions. I am thankful to Yashu and Raghu for their company 
99 
 
and for being there for my family through thick and thin. I thank all the friends from Finland Kannada 
Association (FINKA) for the memorable gatherings. I truly appreciate your efforts to keep our language 
and culture alive even when we are far away from home. 
My sincere thanks to all my teachers for the sharing their knowledge and guiding me through various 
stages of my education. I am grateful to Prof. R. Manjunath from department of Biochemistry, Indian 
Institute of Science (IISc), Bangalore for the opportunity to work in his research group and for the 
valuable research experience. 
My heartfelt gratitude to my parents for their unconditional love, having faith in me and for supporting 
all my decisions. I am forever indebted to you for all the sacrifices you made to ensure I got the best 
possible education. ಅಪ್ಪ , ಅಮ್ಮ  ನಿಮ್ಮ  ನಿಸ್ವಾ ರ್ಥ ಪ್ರ ೀತಿ, ನನನ ಲಿಟ್ಟ  ನಂಬಿಕೆ ಹಾಗು ನನನ  ಎಲ್ಲ  
ನಿರ್ಧಥರಗಳಿಗೆ ನಿೀವು ಕೊಟ್ಟ  ಪ್ರ ೀತ್ಸಾ ಹವೇ ನಾನು ಈ ಹಂತಕೆೆ  ಬರಲುಕಾರಣ. ನನನ  ಬೆಳವಣಿಗೆ ಮ್ತ್ತು  
ಉತು ಮ್ಮ  ಶಿಕ್ಷಣಕೆಾ ಗಿ ನಿೀವು ಮಾಡಿದ ತ್ಸಾ ಗಕೆೆ  ನಾನು ಸದಾ ಚಿರಋಣಿ. My sincere thanks to Radha atte and 
Mohan mava for supporting my education for two years. ರಾರ್ಧ ಅತ್ತು  ಮ್ತ್ತು  ಮೀಹನ್ ಮಾವ, ನನನ  
ಉನನ ತ ಶಿಕ್ಷಣಕೆಾ ಗಿ ನಿೀವು ಮಾಡಿದ ಸಹಾಯಕೆೆ  ನಾನು ಸದಾ ಕೃತಜ್ಞ ಳಾಗಿರುತ್ತು ೀನೆ. I am immensely grateful 
to Lakshmi doddamma and Seetaramu doddappa for supporting my education and for taking care of 
me for 5 long years. ಲ್ಕ್ಷ್ಮ ಮ  ದೊಡ್ಡ ಮ್ಮ  ಮ್ತ್ತು  ಸೀತ್ಸರಾಮು ದೊಡ್ಡ ಪ್ಪ  ನಿಮ್ಮ  ಪ್ರ ೀತಿ, ಸಹಾಯ ಹಾಗು 
ಪ್ರ ೀತ್ಸಾ ಹಕೆೆ  ನಾನು ಸದಾ ಕೃತಜ್ಞ ಳಾಗಿರುತ್ತು ೀನೆ. I am grateful to my late grandmothers Bhavanamma and 
Ranganayakamma for their love and affection. ಪ್ರ ೀತಿ, ಮ್ಮ್ತ್ತ, ಹಾಗು ಆರೈಯೆ್ಕ  ಇಂದ ನನನ ನುನ  ಬೆಳಸದ 
ನನನ  ಅಜಿ್ಜಯರಾದ, ದಿ. ಭವಾನಮ್ಮ  ಮ್ತ್ತು  ದಿ. ರಂಗನಾಯಕಮ್ಮ ನಿಗೆ ನನನ  ಅನಂತ ನಮ್ನಗಳು. I would like 
to thank all my aunts and uncles from Kottige family as well as form Kalasapura family. ನನನ  
ಬೆಳವಣಿಗೆಗೆ ಪ್ರ ೀತ್ಸಾ ಹಿಸದ ಕೊಟ್ಟಟ ಗೆ ಕುಟಂಬ ಹಾಗು ಕಳಸ್ವಪುರ ಕುಟಂಬದ ದೊಡ್ಡ ಪ್ಪ  ದೊಡ್ಡ ಮ್ಮ ದಿರಿಗೆ, 
ಚಿಕೆಪ್ಪ  ಚಿಕೆಮ್ಮ ಂದಿರಿಗೆ, ಹಾಗು ಅತ್ತು  ಮಾವಂದಿರಿಗೆ ನನನ  ಅನಂತ ನಮ್ನಗಳು. I would like to thank all my 
cousins for the good times, and for the childhood memories that I will cherish forever. Many thanks to 
my in-laws, kaka, chikkamma, and late Aayi for making me feel welcome to their family and for all 
the support and encouragement. ತಮ್ಮ  ಕುಟಂಬಕೆೆ  ನನನ ನುನ  ಸ್ವಾ ಗತಿಸ ಪ್ರ ೀತಿ, ವಿಶ್ವಾ ಸದಿಂದ 
ಪ್ರ ೀತ್ಸಾ ಹಿಸರುವ ನನನ  ಅತ್ತು  ಮಾವ, ಕಾಕಾ, ಚಿಕೆಮ್ಮ , ತಂಗಿ ಮ್ತ್ತು  ದಿ. ಆಯಿಗೆ ನನನ  ಕೃತಜ್ಞ ತ್ತಗಳು. I thank 
my extended family members of Hasyagar family and Bommanahalli family. ಹಾಸಾ ಗಾರ್ ಕುಟಂಬ 
ಹಾಗು ಬೊಮ್ಮ ನಹಳಿಿ  ಕುಟಂಬಕೆೆ  ನನನ  ಅನಂತ ನಮ್ನಗಳು. I thank my lovely daughter Inchara for 
bringing a positive change into our lives and for keeping the joy alive. Heartfelt thanks to my beloved 
husband Kiran, you are the man behind my success. Thank you for your patience and understanding. 
Success and failure, joy and sorrow, let’s sail through them together forever, love you. 
 







(2012). Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 
519-525. 
(2014). Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550. 
Adjei, A.A., Mauer, A., Bruzek, L., Marks, R.S., Hillman, S., Geyer, S., Hanson, L.J., Wright, 
J.J., Erlichman, C., Kaufmann, S.H., et al. (2003). Phase II study of the farnesyl 
transferase inhibitor R115777 in patients with advanced non-small-cell lung 
cancer. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology 21, 1760-1766. 
Ahrendt, S.A., Decker, P.A., Alawi, E.A., Zhu Yr, Y.R., Sanchez-Cespedes, M., Yang, S.C., 
Haasler, G.B., Kajdacsy-Balla, A., Demeure, M.J., and Sidransky, D. (2001). 
Cigarette smoking is strongly associated with mutation of the K-ras gene in 
patients with primary adenocarcinoma of the lung. Cancer 92, 1525-1530. 
Ahrendt, S.A., Hu, Y., Buta, M., McDermott, M.P., Benoit, N., Yang, S.C., Wu, L., and 
Sidransky, D. (2003). p53 mutations and survival in stage I non-small-cell lung 
cancer: results of a prospective study. Journal of the National Cancer Institute 95, 
961-970. 
Albeituni, S.H., Ding, C., and Yan, J. (2013). Hampering immune suppressors: therapeutic 
targeting of myeloid-derived suppressor cells in cancer. Cancer journal (Sudbury, 
Mass) 19, 490-501. 
Alexander, A., and Walker, C.L. (2011). The role of LKB1 and AMPK in cellular responses to 
stress and damage. FEBS letters 585, 952-957. 
Anand, P., Kunnumakkara, A.B., Sundaram, C., Harikumar, K.B., Tharakan, S.T., Lai, O.S., 
Sung, B., and Aggarwal, B.B. (2008). Cancer is a preventable disease that requires 
major lifestyle changes. Pharmaceutical research 25, 2097-2116. 
Anderson, G.R., Winter, P.S., Lin, K.H., Nussbaum, D.P., Cakir, M., Stein, E.M., Soderquist, 
R.S., Crawford, L., Leeds, J.C., Newcomb, R., et al. (2017). A Landscape of 
Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for 
Controlling Tumor Evolution. Cell reports 20, 999-1015. 
Appella, E., and Anderson, C.W. (2001). Post-translational modifications and activation of p53 
by genotoxic stresses. European journal of biochemistry 268, 2764-2772. 
Arteaga, C.L., and Engelman, J.A. (2014). ERBB receptors: from oncogene discovery to basic 
science to mechanism-based cancer therapeutics. Cancer cell 25, 282-303. 
Baas, A.F., Boudeau, J., Sapkota, G.P., Smit, L., Medema, R., Morrice, N.A., Alessi, D.R., and 
Clevers, H.C. (2003). Activation of the tumour suppressor kinase LKB1 by the 
STE20-like pseudokinase STRAD. The EMBO journal 22, 3062-3072. 
Baas, A.F., Kuipers, J., van der Wel, N.N., Batlle, E., Koerten, H.K., Peters, P.J., and Clevers, 
H.C. (2004). Complete polarization of single intestinal epithelial cells upon 
activation of LKB1 by STRAD. Cell 116, 457-466. 
Balmain, A. (2001). Cancer genetics: from Boveri and Mendel to microarrays. Nature reviews 
Cancer 1, 77-82. 
Bass, A.J., Watanabe, H., Mermel, C.H., Yu, S., Perner, S., Verhaak, R.G., Kim, S.Y., Wardwell, 
L., Tamayo, P., Gat-Viks, I., et al. (2009). SOX2 is an amplified lineage-survival 
oncogene in lung and esophageal squamous cell carcinomas. Nature genetics 41, 
1238-1242. 
Beglyarova, N., Banina, E., Zhou, Y., Mukhamadeeva, R., Andrianov, G., Bobrov, E., Lysenko, 
E., Skobeleva, N., Gabitova, L., Restifo, D., et al. (2016). Screening of 
Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies 
101 
 
ERCC3-MYC Interactions as a Target in Pancreatic Cancer. Clinical cancer 
research : an official journal of the American Association for Cancer Research 22, 
6153-6163. 
Bennouna, J., and Moreno Vera, S.R. (2016). Afatinib-based combination regimens for the 
treatment of solid tumors: rationale, emerging strategies and recent progress. 
Future oncology (London, England) 12, 355-372. 
Berger, A.H., Brooks, A.N., Wu, X., Shrestha, Y., Chouinard, C., Piccioni, F., Bagul, M., 
Kamburov, A., Imielinski, M., Hogstrom, L., et al. (2017). High-throughput 
Phenotyping of Lung Cancer Somatic Mutations. Cancer cell 32, 884. 
Bergethon, K., Shaw, A.T., Ou, S.H., Katayama, R., Lovly, C.M., McDonald, N.T., Massion, 
P.P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012). ROS1 rearrangements 
define a unique molecular class of lung cancers. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology 30, 863-870. 
Bernhardt, E.B., and Jalal, S.I. (2016). Small Cell Lung Cancer. Cancer treatment and research 
170, 301-322. 
Bieging, K.T., Mello, S.S., and Attardi, L.D. (2014). Unravelling mechanisms of p53-mediated 
tumour suppression. Nature reviews Cancer 14, 359-370. 
Bishop, J.A., Teruya-Feldstein, J., Westra, W.H., Pelosi, G., Travis, W.D., and Rekhtman, N. 
(2012). p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary 
squamous cell carcinoma. Modern pathology : an official journal of the United 
States and Canadian Academy of Pathology, Inc 25, 405-415. 
Black, C.C., Turk, M.J., Dragnev, K., and Rigas, J.R. (2013). Adenocarcinoma contains more 
immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in 
non-small-cell lung cancer. Lung 191, 265-270. 
Blanpain, C. (2013). Tracing the cellular origin of cancer. Nature cell biology 15, 126-134. 
Blumenschein, G.R., Jr., Smit, E.F., Planchard, D., Kim, D.W., Cadranel, J., De Pas, T., Dunphy, 
F., Udud, K., Ahn, M.J., Hanna, N.H., et al. (2015). A randomized phase II study 
of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel 
in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)dagger. Annals 
of oncology : official journal of the European Society for Medical Oncology 26, 
894-901. 
Boch, C., Kollmeier, J., Roth, A., Stephan-Falkenau, S., Misch, D., Gruning, W., Bauer, T.T., 
and Mairinger, T. (2013). The frequency of EGFR and KRAS mutations in non-
small cell lung cancer (NSCLC): routine screening data for central Europe from a 
cohort study. BMJ Open 3. 
Boers, J.E., Ambergen, A.W., and Thunnissen, F.B. (1999). Number and proliferation of clara 
cells in normal human airway epithelium. American journal of respiratory and 
critical care medicine 159, 1585-1591. 
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., Vokes, 
E.E., Felip, E., Holgado, E., et al. (2015). Nivolumab versus Docetaxel in 
Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England journal 
of medicine 373, 1627-1639. 
Boudeau, J., Baas, A.F., Deak, M., Morrice, N.A., Kieloch, A., Schutkowski, M., Prescott, A.R., 
Clevers, H.C., and Alessi, D.R. (2003). MO25alpha/beta interact with 
STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in 
the cytoplasm. The EMBO journal 22, 5102-5114. 
Bousquet, J., and Meunier, J.M. (1962). [Organotypic culture, on natural and artificial media, of 
fragments of the adult rat hypophysis]. Comptes rendus des seances de la Societe 
de biologie et de ses filiales 156, 65-67. 
102 
 
Brahmer, J., Reckamp, K.L., Baas, P., Crino, L., Eberhardt, W.E., Poddubskaya, E., Antonia, S., 
Pluzanski, A., Vokes, E.E., Holgado, E., et al. (2015). Nivolumab versus 
Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New 
England journal of medicine 373, 123-135. 
Bronte, G., Rizzo, S., La Paglia, L., Adamo, V., Siragusa, S., Ficorella, C., Santini, D., Bazan, 
V., Colucci, G., Gebbia, N., et al. (2010). Driver mutations and differential 
sensitivity to targeted therapies: a new approach to the treatment of lung 
adenocarcinoma. Cancer Treat Rev 36 Suppl 3, S21-29. 
Brugarolas, J., Chandrasekaran, C., Gordon, J.I., Beach, D., Jacks, T., and Hannon, G.J. (1995). 
Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377, 
552-557. 
Buckpitt, A., Chang, A.M., Weir, A., Van Winkle, L., Duan, X., Philpot, R., and Plopper, C. 
(1995). Relationship of cytochrome P450 activity to Clara cell cytotoxicity. IV. 
Metabolism of naphthalene and naphthalene oxide in microdissected airways from 
mice, rats, and hamsters. Molecular pharmacology 47, 74-81. 
Busch, S.E., Hanke, M.L., Kargl, J., Metz, H.E., MacPherson, D., and Houghton, A.M. (2016). 
Lung Cancer Subtypes Generate Unique Immune Responses. Journal of 
immunology (Baltimore, Md : 1950) 197, 4493-4503. 
Calles, A., Sholl, L.M., Rodig, S.J., Pelton, A.K., Hornick, J.L., Butaney, M., Lydon, C., 
Dahlberg, S.E., Oxnard, G.R., Jackman, D.M., et al. (2015). 
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology 
in KRAS-Mutant Lung Adenocarcinoma. Clinical cancer research : an official 
journal of the American Association for Cancer Research 21, 2851-2860. 
Campbell, J.D., Alexandrov, A., Kim, J., Wala, J., Berger, A.H., Pedamallu, C.S., Shukla, S.A., 
Guo, G., Brooks, A.N., Murray, B.A., et al. (2016). Distinct patterns of somatic 
genome alterations in lung adenocarcinomas and squamous cell carcinomas. 
Nature genetics 48, 607-616. 
Carranza-Torres, I.E., Guzman-Delgado, N.E., Coronado-Martinez, C., Banuelos-Garcia, J.I., 
Viveros-Valdez, E., Moran-Martinez, J., and Carranza-Rosales, P. (2015). 
Organotypic culture of breast tumor explants as a multicellular system for the 
screening of natural compounds with antineoplastic potential. BioMed research 
international 2015, 618021. 
Carretero, J., Shimamura, T., Rikova, K., Jackson, A.L., Wilkerson, M.D., Borgman, C.L., 
Buttarazzi, M.S., Sanofsky, B.A., McNamara, K.L., Brandstetter, K.A., et al. 
(2010). Integrative genomic and proteomic analyses identify targets for Lkb1-
deficient metastatic lung tumors. Cancer cell 17, 547-559. 
Carter, C.A., Rajan, A., Keen, C., Szabo, E., Khozin, S., Thomas, A., Brzezniak, C., Guha, U., 
Doyle, L.A., Steinberg, S.M., et al. (2016). Selumetinib with and without erlotinib 
in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. 
Annals of oncology : official journal of the European Society for Medical 
Oncology 27, 693-699. 
Casey, P.J., Solski, P.A., Der, C.J., and Buss, J.E. (1989). p21ras is modified by a farnesyl 
isoprenoid. Proceedings of the National Academy of Sciences of the United States 
of America 86, 8323-8327. 
Casey, S.C., Vaccari, M., Al-Mulla, F., Al-Temaimi, R., Amedei, A., Barcellos-Hoff, M.H., 
Brown, D.G., Chapellier, M., Christopher, J., Curran, C.S., et al. (2015). The effect 
of environmental chemicals on the tumor microenvironment. Carcinogenesis 36 
Suppl 1, S160-183. 
Castellano, E., and Santos, E. (2011). Functional specificity of ras isoforms: so similar but so 
different. Genes & cancer 2, 216-231. 
103 
 
Chakrabarty, A., Sanchez, V., Kuba, M.G., Rinehart, C., and Arteaga, C.L. (2012). Feedback 
upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect 
of PI3K inhibitors. Proceedings of the National Academy of Sciences of the United 
States of America 109, 2718-2723. 
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, 
V., Majumder, P.K., Baselga, J., and Rosen, N. (2011). AKT inhibition relieves 
feedback suppression of receptor tyrosine kinase expression and activity. Cancer 
cell 19, 58-71. 
Chapman, H.A., Li, X., Alexander, J.P., Brumwell, A., Lorizio, W., Tan, K., Sonnenberg, A., 
Wei, Y., and Vu, T.H. (2011). Integrin alpha6beta4 identifies an adult distal lung 
epithelial population with regenerative potential in mice. The Journal of clinical 
investigation 121, 2855-2862. 
Chen, F., and Fine, A. (2016). Stem Cells in Lung Injury and Repair. The American journal of 
pathology 186, 2544-2550. 
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, 
J., Li, J., et al. (2012). A murine lung cancer co-clinical trial identifies genetic 
modifiers of therapeutic response. Nature 483, 613-617. 
Chen, Z., Fillmore, C.M., Hammerman, P.S., Kim, C.F., and Wong, K.K. (2014). Non-small-cell 
lung cancers: a heterogeneous set of diseases. Nature reviews Cancer 14, 535-546. 
Choi, Y.L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., 
Takeuchi, K., Hamada, T., Haruta, H., et al. (2010). EML4-ALK mutations in lung 
cancer that confer resistance to ALK inhibitors. The New England journal of 
medicine 363, 1734-1739. 
Citri, A., Skaria, K.B., and Yarden, Y. (2003). The deaf and the dumb: the biology of ErbB-2 and 
ErbB-3. Experimental cell research 284, 54-65. 
Corcoran, R.B., Ebi, H., Turke, A.B., Coffee, E.M., Nishino, M., Cogdill, A.P., Brown, R.D., 
Della Pelle, P., Dias-Santagata, D., Hung, K.E., et al. (2012). EGFR-mediated re-
activation of MAPK signaling contributes to insensitivity of BRAF mutant 
colorectal cancers to RAF inhibition with vemurafenib. Cancer discovery 2, 227-
235. 
Costa, D.B., Shaw, A.T., Ou, S.H., Solomon, B.J., Riely, G.J., Ahn, M.J., Zhou, C., Shreeve, 
S.M., Selaru, P., Polli, A., et al. (2015). Clinical Experience With Crizotinib in 
Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and 
Brain Metastases. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology 33, 1881-1888. 
Cox, A.D., Fesik, S.W., Kimmelman, A.C., Luo, J., and Der, C.J. (2014). Drugging the 
undruggable RAS: Mission possible? Nature reviews Drug discovery 13, 828-851. 
Crystal, A.S., Shaw, A.T., Sequist, L.V., Friboulet, L., Niederst, M.J., Lockerman, E.L., Frias, 
R.L., Gainor, J.F., Amzallag, A., Greninger, P., et al. (2014). Patient-derived 
models of acquired resistance can identify effective drug combinations for cancer. 
Science (New York, NY) 346, 1480-1486. 
Curry, N.L., Mino-Kenudson, M., Oliver, T.G., Yilmaz, O.H., Yilmaz, V.O., Moon, J.Y., Jacks, 
T., Sabatini, D.M., and Kalaany, N.Y. (2013). Pten-null tumors cohabiting the 
same lung display differential AKT activation and sensitivity to dietary restriction. 
Cancer discovery 3, 908-921. 
D'Amico, D., Carbone, D., Mitsudomi, T., Nau, M., Fedorko, J., Russell, E., Johnson, B., 
Buchhagen, D., Bodner, S., Phelps, R., et al. (1992). High frequency of 
somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. 
Oncogene 7, 339-346. 
104 
 
Dankort, D., Filenova, E., Collado, M., Serrano, M., Jones, K., and McMahon, M. (2007). A new 
mouse model to explore the initiation, progression, and therapy of BRAFV600E-
induced lung tumors. Genes & development 21, 379-384. 
Das, A., Cheng, R.R., Hilbert, M.L., Dixon-Moh, Y.N., Decandio, M., Vandergrift, W.A., 3rd, 
Banik, N.L., Lindhorst, S.M., Cachia, D., Varma, A.K., et al. (2015). Synergistic 
Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-
Positive Glioblastoma. Cancer growth and metastasis 8, 51-60. 
Davies, E.J., Dong, M., Gutekunst, M., Narhi, K., van Zoggel, H.J., Blom, S., Nagaraj, A., 
Metsalu, T., Oswald, E., Erkens-Schulze, S., et al. (2015). Capturing complex 
tumour biology in vitro: histological and molecular characterisation of precision 
cut slices. Scientific reports 5, 17187. 
de Bruin, E.C., McGranahan, N., and Swanton, C. (2015). Analysis of intratumor heterogeneity 
unravels lung cancer evolution. Molecular & cellular oncology 2, e985549. 
DeCaprio, J.A., Ludlow, J.W., Figge, J., Shew, J.Y., Huang, C.M., Lee, W.H., Marsilio, E., 
Paucha, E., and Livingston, D.M. (1988). SV40 large tumor antigen forms a 
specific complex with the product of the retinoblastoma susceptibility gene. Cell 
54, 275-283. 
Denissenko, M.F., Pao, A., Tang, M., and Pfeifer, G.P. (1996). Preferential formation of 
benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science (New 
York, NY) 274, 430-432. 
Der, C.J., Krontiris, T.G., and Cooper, G.M. (1982). Transforming genes of human bladder and 
lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten 
sarcoma viruses. Proceedings of the National Academy of Sciences of the United 
States of America 79, 3637-3640. 
Dhanasekaran, S.M., Balbin, O.A., Chen, G., Nadal, E., Kalyana-Sundaram, S., Pan, J., 
Veeneman, B., Cao, X., Malik, R., Vats, P., et al. (2014). Transcriptome meta-
analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway 
genes. Nature communications 5, 5893. 
Diem, S., Schmid, S., Krapf, M., Flatz, L., Born, D., Jochum, W., Templeton, A.J., and Fruh, M. 
(2017). Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio 
(PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) 
treated with nivolumab. Lung cancer (Amsterdam, Netherlands) 111, 176-181. 
Dietz, S., Harms, A., Endris, V., Eichhorn, F., Kriegsmann, M., Longuespee, R., Stenzinger, A., 
Sultmann, H., Warth, A., and Kazdal, D. (2017). Spatial distribution of EGFR and 
KRAS mutation frequencies correlates with histological growth patterns of lung 
adenocarcinomas. International journal of cancer 141, 1841-1848. 
Dobbelstein, M., and Roth, J. (1998). The large T antigen of simian virus 40 binds and inactivates 
p53 but not p73. The Journal of general virology 79 ( Pt 12), 3079-3083. 
Doebele, R.C., Pilling, A.B., Aisner, D.L., Kutateladze, T.G., Le, A.T., Weickhardt, A.J., Kondo, 
K.L., Linderman, D.J., Heasley, L.E., Franklin, W.A., et al. (2012). Mechanisms 
of resistance to crizotinib in patients with ALK gene rearranged non-small cell 
lung cancer. Clinical cancer research : an official journal of the American 
Association for Cancer Research 18, 1472-1482. 
Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery, C.A., Jr., Butel, J.S., 
and Bradley, A. (1992). Mice deficient for p53 are developmentally normal but 
susceptible to spontaneous tumours. Nature 356, 215-221. 
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., 
Schlessinger, J., and Waterfield, M.D. (1984). Close similarity of epidermal 




Drosten, M., Simon-Carrasco, L., Hernandez-Porras, I., Lechuga, C.G., Blasco, M.T., Jacob, 
H.K., Fabbiano, S., Potenza, N., Bustelo, X.R., Guerra, C., et al. (2017). H-Ras 
and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the 
Same Regulatory Sequences. Cancer research 77, 707-718. 
Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., and Schreiber, R.D. (2002). Cancer immunoediting: 
from immunosurveillance to tumor escape. Nature immunology 3, 991-998. 
DuPage, M., Cheung, A.F., Mazumdar, C., Winslow, M.M., Bronson, R., Schmidt, L.M., 
Crowley, D., Chen, J., and Jacks, T. (2011). Endogenous T cell responses to 
antigens expressed in lung adenocarcinomas delay malignant tumor progression. 
Cancer cell 19, 72-85. 
Dykens, J.A., Jamieson, J., Marroquin, L., Nadanaciva, S., Billis, P.A., and Will, Y. (2008). 
Biguanide-induced mitochondrial dysfunction yields increased lactate production 
and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in 
vitro. Toxicology and applied pharmacology 233, 203-210. 
Eberhard, D.A., Johnson, B.E., Amler, L.C., Goddard, A.D., Heldens, S.L., Herbst, R.S., Ince, 
W.L., Janne, P.A., Januario, T., Johnson, D.H., et al. (2005). Mutations in the 
epidermal growth factor receptor and in KRAS are predictive and prognostic 
indicators in patients with non-small-cell lung cancer treated with chemotherapy 
alone and in combination with erlotinib. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology 23, 5900-5909. 
Egan, D.F., Shackelford, D.B., Mihaylova, M.M., Gelino, S., Kohnz, R.A., Mair, W., Vasquez, 
D.S., Joshi, A., Gwinn, D.M., Taylor, R., et al. (2011). Phosphorylation of ULK1 
(hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. 
Science (New York, NY) 331, 456-461. 
Ehrhardt, A., Bartels, T., Geick, A., Klocke, R., Paul, D., and Halter, R. (2001). Development of 
pulmonary bronchiolo-alveolar adenocarcinomas in transgenic mice 
overexpressing murine c-myc and epidermal growth factor in alveolar type II 
pneumocytes. British journal of cancer 84, 813-818. 
el-Deiry, W.S., Kern, S.E., Pietenpol, J.A., Kinzler, K.W., and Vogelstein, B. (1992). Definition of 
a consensus binding site for p53. Nature genetics 1, 45-49. 
Elliott, L.A., Doherty, G.A., Sheahan, K., and Ryan, E.J. (2017). Human Tumor-Infiltrating Myeloid 
Cells: Phenotypic and Functional Diversity. Frontiers in immunology 8, 86. 
Engelman, J.A., Chen, L., Tan, X., Crosby, K., Guimaraes, A.R., Upadhyay, R., Maira, M., 
McNamara, K., Perera, S.A., Song, Y., et al. (2008). Effective use of PI3K and MEK 
inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. 
Nature medicine 14, 1351-1356. 
Facchinetti, F., Bluthgen, M.V., Tergemina-Clain, G., Faivre, L., Pignon, J.P., Planchard, D., Remon, 
J., Soria, J.C., Lacroix, L., and Besse, B. (2017a). LKB1/STK11 mutations in non-
small cell lung cancer patients: Descriptive analysis and prognostic value. Lung 
cancer (Amsterdam, Netherlands) 112, 62-68. 
Facchinetti, F., Proto, C., Minari, R., Garassino, M., and Tiseo, M. (2017b). Mechanisms of 
Resistance to Target Therapies in Non-small Cell Lung Cancer. Handbook of 
experimental pharmacology. 
Facciabene, A., Motz, G.T., and Coukos, G. (2012). T-regulatory cells: key players in tumor immune 
escape and angiogenesis. Cancer research 72, 2162-2171. 
Faget, J., Groeneveld, S., Boivin, G., Sankar, M., Zangger, N., Garcia, M., Guex, N., Zlobec, I., 
Steiner, L., Piersigilli, A., et al. (2017). Neutrophils and Snail Orchestrate the 




Falls, D.L. (2003). Neuregulins: functions, forms, and signaling strategies. Experimental cell 
research 284, 14-30. 
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., 
Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016). Atezolizumab versus 
docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): 
a multicentre, open-label, phase 2 randomised controlled trial. Lancet (London, 
England) 387, 1837-1846. 
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, 
D., and Bray, F. (2015). Cancer incidence and mortality worldwide: sources, methods 
and major patterns in GLOBOCAN 2012. International journal of cancer 136, E359-
386. 
Fernandez-Cuesta, L., Plenker, D., Osada, H., Sun, R., Menon, R., Leenders, F., Ortiz-Cuaran, S., 
Peifer, M., Bos, M., Dassler, J., et al. (2014). CD74-NRG1 fusions in lung 
adenocarcinoma. Cancer discovery 4, 415-422. 
Ferone, G., Song, J.Y., Sutherland, K.D., Bhaskaran, R., Monkhorst, K., Lambooij, J.P., Proost, N., 
Gargiulo, G., and Berns, A. (2016). SOX2 Is the Determining Oncogenic Switch in 
Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin. Cancer 
cell 30, 519-532. 
Finlay, C.A., Hinds, P.W., and Levine, A.J. (1989). The p53 proto-oncogene can act as a suppressor 
of transformation. Cell 57, 1083-1093. 
Fisher, G.H., Wellen, S.L., Klimstra, D., Lenczowski, J.M., Tichelaar, J.W., Lizak, M.J., Whitsett, 
J.A., Koretsky, A., and Varmus, H.E. (2001). Induction and apoptotic regression of 
lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence 
of tumor suppressor genes. Genes & development 15, 3249-3262. 
Fleming, T.J., Fleming, M.L., and Malek, T.R. (1993). Selective expression of Ly-6G on myeloid 
lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation 
antigen (Gr-1) detects members of the Ly-6 family. Journal of immunology 
(Baltimore, Md : 1950) 151, 2399-2408. 
Forbes, S.A., Bindal, N., Bamford, S., Cole, C., Kok, C.Y., Beare, D., Jia, M., Shepherd, R., Leung, 
K., Menzies, A., et al. (2011). COSMIC: mining complete cancer genomes in the 
Catalogue of Somatic Mutations in Cancer. Nucleic acids research 39, D945-950. 
Friboulet, L., Li, N., Katayama, R., Lee, C.C., Gainor, J.F., Crystal, A.S., Michellys, P.Y., Awad, 
M.M., Yanagitani, N., Kim, S., et al. (2014). The ALK inhibitor ceritinib overcomes 
crizotinib resistance in non-small cell lung cancer. Cancer discovery 4, 662-673. 
Fridman, W.H., Dieu-Nosjean, M.C., Pages, F., Cremer, I., Damotte, D., Sautes-Fridman, C., and 
Galon, J. (2013). The immune microenvironment of human tumors: general 
significance and clinical impact. Cancer microenvironment : official journal of the 
International Cancer Microenvironment Society 6, 117-122. 
Fuller, S.J., Sivarajah, K., and Sugden, P.H. (2008). ErbB receptors, their ligands, and the 
consequences of their activation and inhibition in the myocardium. Journal of 
molecular and cellular cardiology 44, 831-854. 
Furrukh, M. (2013). Tobacco Smoking and Lung Cancer: Perception-changing facts. Sultan Qaboos 
University medical journal 13, 345-358. 
Gabrielson, E. (2006). Worldwide trends in lung cancer pathology. Respirology (Carlton, Vic) 11, 
533-538. 
Gabrilovich, D.I. (2017). Myeloid-Derived Suppressor Cells. Cancer immunology research 5, 3-8. 
Gabrilovich, D.I., and Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the 
immune system. Nature reviews Immunology 9, 162-174. 
Ganesan, A.P., Johansson, M., Ruffell, B., Yagui-Beltran, A., Lau, J., Jablons, D.M., and Coussens, 
L.M. (2013). Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell 
107 
 
responses to lung adenocarcinoma. Journal of immunology (Baltimore, Md : 1950) 
191, 2009-2017. 
Gao, H., Korn, J.M., Ferretti, S., Monahan, J.E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, 
G., Zhang, Y., et al. (2015). High-throughput screening using patient-derived tumor 
xenografts to predict clinical trial drug response. Nature medicine 21, 1318-1325. 
Gao, X., Dai, M., Li, Q., Wang, Z., Lu, Y., and Song, Z. (2017). HMGA2 regulates lung cancer 
proliferation and metastasis. Thoracic cancer 8, 501-510. 
Gao, Y., Zhang, W., Han, X., Li, F., Wang, X., Wang, R., Fang, Z., Tong, X., Yao, S., Li, F., et al. 
(2014). YAP inhibits squamous transdifferentiation of Lkb1-deficient lung 
adenocarcinoma through ZEB2-dependent DNp63 repression. Nature 
communications 5, 4629. 
Garnett, S., Dutchak, K.L., McDonough, R.V., and Dankort, D. (2017). p53 loss does not permit 
escape from Braf(V600E)-induced senescence in a mouse model of lung cancer. 
Oncogene 36, 6325-6335. 
Garrett, T.P., McKern, N.M., Lou, M., Elleman, T.C., Adams, T.E., Lovrecz, G.O., Kofler, M., 
Jorissen, R.N., Nice, E.C., Burgess, A.W., et al. (2003). The crystal structure of a 
truncated ErbB2 ectodomain reveals an active conformation, poised to interact with 
other ErbB receptors. Molecular cell 11, 495-505. 
Garrido, F., Ruiz-Cabello, F., Cabrera, T., Perez-Villar, J.J., Lopez-Botet, M., Duggan-Keen, M., 
and Stern, P.L. (1997). Implications for immunosurveillance of altered HLA class I 
phenotypes in human tumours. Immunology today 18, 89-95. 
Gautschi, O., Huegli, B., Ziegler, A., Gugger, M., Heighway, J., Ratschiller, D., Mack, P.C., 
Gumerlock, P.H., Kung, H.J., Stahel, R.A., et al. (2007). Origin and prognostic value 
of circulating KRAS mutations in lung cancer patients. Cancer letters 254, 265-273. 
Geick, A., Redecker, P., Ehrhardt, A., Klocke, R., Paul, D., and Halter, R. (2001). Uteroglobin 
promoter-targeted c-MYC expression in transgenic mice cause hyperplasia of Clara 
cells and malignant transformation of T-lymphoblasts and tubular epithelial cells. 
Transgenic research 10, 501-511. 
George, J., Lim, J.S., Jang, S.J., Cun, Y., Ozretic, L., Kong, G., Leenders, F., Lu, X., Fernandez-
Cuesta, L., Bosco, G., et al. (2015). Comprehensive genomic profiles of small cell 
lung cancer. Nature 524, 47-53. 
Gerdes, M.J., Sevinsky, C.J., Sood, A., Adak, S., Bello, M.O., Bordwell, A., Can, A., Corwin, A., 
Dinn, S., Filkins, R.J., et al. (2013). Highly multiplexed single-cell analysis of 
formalin-fixed, paraffin-embedded cancer tissue. Proceedings of the National 
Academy of Sciences of the United States of America 110, 11982-11987. 
Gerlach, M.M., Merz, F., Wichmann, G., Kubick, C., Wittekind, C., Lordick, F., Dietz, A., and 
Bechmann, I. (2014). Slice cultures from head and neck squamous cell carcinoma: a 
novel test system for drug susceptibility and mechanisms of resistance. British journal 
of cancer 110, 479-488. 
Gerlinger, M., Rowan, A.J., Horswell, S., Math, M., Larkin, J., Endesfelder, D., Gronroos, E., 
Martinez, P., Matthews, N., Stewart, A., et al. (2012). Intratumor heterogeneity and 
branched evolution revealed by multiregion sequencing. The New England journal of 
medicine 366, 883-892. 
Gettinger, S.N., Horn, L., Gandhi, L., Spigel, D.R., Antonia, S.J., Rizvi, N.A., Powderly, J.D., Heist, 
R.S., Carvajal, R.D., Jackman, D.M., et al. (2015). Overall Survival and Long-Term 
Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-
4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. 
Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology 33, 2004-2012. 
108 
 
Giangreco, A., Reynolds, S.D., and Stripp, B.R. (2002). Terminal bronchioles harbor a unique airway 
stem cell population that localizes to the bronchoalveolar duct junction. The American 
journal of pathology 161, 173-182. 
Giardiello, F.M., Welsh, S.B., Hamilton, S.R., Offerhaus, G.J., Gittelsohn, A.M., Booker, S.V., 
Krush, A.J., Yardley, J.H., and Luk, G.D. (1987). Increased risk of cancer in the Peutz-
Jeghers syndrome. The New England journal of medicine 316, 1511-1514. 
Gierut, J.J., Jacks, T.E., and Haigis, K.M. (2014). In vivo delivery of lenti-Cre or adeno-Cre into 
mice using intranasal instillation. Cold Spring Harbor protocols 2014, 307-309. 
Glasser, S.W., Korfhagen, T.R., Wert, S.E., Bruno, M.D., McWilliams, K.M., Vorbroker, D.K., and 
Whitsett, J.A. (1991). Genetic element from human surfactant protein SP-C gene 
confers bronchiolar-alveolar cell specificity in transgenic mice. The American journal 
of physiology 261, L349-356. 
Goldstraw, P., Chansky, K., Crowley, J., Rami-Porta, R., Asamura, H., Eberhardt, W.E., Nicholson, 
A.G., Groome, P., Mitchell, A., and Bolejack, V. (2016). The IASLC Lung Cancer 
Staging Project: Proposals for Revision of the TNM Stage Groupings in the 
Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. Journal of 
thoracic oncology : official publication of the International Association for the Study 
of Lung Cancer 11, 39-51. 
Gordon, J.W., Scangos, G.A., Plotkin, D.J., Barbosa, J.A., and Ruddle, F.H. (1980). Genetic 
transformation of mouse embryos by microinjection of purified DNA. Proceedings of 
the National Academy of Sciences of the United States of America 77, 7380-7384. 
Gordon, T., and Bosland, M. (2009). Strain-dependent differences in susceptibility to lung cancer in 
inbred mice exposed to mainstream cigarette smoke. Cancer letters 275, 213-220. 
Gray, N. (2006). The consequences of the unregulated cigarette. Tobacco control 15, 405-408. 
Greshock, J., Bachman, K.E., Degenhardt, Y.Y., Jing, J., Wen, Y.H., Eastman, S., McNeil, E., Moy, 
C., Wegrzyn, R., Auger, K., et al. (2010). Molecular target class is predictive of in 
vitro response profile. Cancer research 70, 3677-3686. 
Gridelli, C., Rossi, A., Carbone, D.P., Guarize, J., Karachaliou, N., Mok, T., Petrella, F., Spaggiari, 
L., and Rosell, R. (2015). Non-small-cell lung cancer. Nature reviews Disease primers 
1, 15009. 
Guy, P.M., Platko, J.V., Cantley, L.C., Cerione, R.A., and Carraway, K.L., 3rd (1994). Insect cell-
expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proceedings of 
the National Academy of Sciences of the United States of America 91, 8132-8136. 
Gwinn, D.M., Shackelford, D.B., Egan, D.F., Mihaylova, M.M., Mery, A., Vasquez, D.S., Turk, 
B.E., and Shaw, R.J. (2008). AMPK phosphorylation of raptor mediates a metabolic 
checkpoint. Molecular cell 30, 214-226. 
Gysin, S., Salt, M., Young, A., and McCormick, F. (2011). Therapeutic strategies for targeting ras 
proteins. Genes & cancer 2, 359-372. 
Hagiwara, K., McMenamin, M.G., Miura, K., and Harris, C.C. (1999). Mutational analysis of the 
p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic 
primers. Cancer research 59, 4165-4169. 
Halvorsen, A.R., Silwal-Pandit, L., Meza-Zepeda, L.A., Vodak, D., Vu, P., Sagerup, C., Hovig, E., 
Myklebost, O., Borresen-Dale, A.L., Brustugun, O.T., et al. (2016). TP53 Mutation 
Spectrum in Smokers and Never Smoking Lung Cancer Patients. Frontiers in genetics 
7, 85. 
Han, X., Li, F., Fang, Z., Gao, Y., Li, F., Fang, R., Yao, S., Sun, Y., Li, L., Zhang, W., et al. (2014). 
Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to 
squamous cell carcinoma. Nature communications 5, 3261. 
Hanahan, D., and Coussens, L.M. (2012). Accessories to the crime: functions of cells recruited to the 
tumor microenvironment. Cancer cell 21, 309-322. 
109 
 
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70. 
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-
674. 
Hao, J.J., Lin, D.C., Dinh, H.Q., Mayakonda, A., Jiang, Y.Y., Chang, C., Jiang, Y., Lu, C.C., Shi, 
Z.Z., Xu, X., et al. (2016). Spatial intratumoral heterogeneity and temporal clonal 
evolution in esophageal squamous cell carcinoma. Nature genetics 48, 1500-1507. 
Hardie, D.G. (2007). AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. 
Nature reviews Molecular cell biology 8, 774-785. 
Harvey, J.J. (1964). AN UNIDENTIFIED VIRUS WHICH CAUSES THE RAPID PRODUCTION 
OF TUMOURS IN MICE. Nature 204, 1104-1105. 
Hawley, S.A., Ross, F.A., Chevtzoff, C., Green, K.A., Evans, A., Fogarty, S., Towler, M.C., Brown, 
L.J., Ogunbayo, O.A., Evans, A.M., et al. (2010). Use of cells expressing gamma 
subunit variants to identify diverse mechanisms of AMPK activation. Cell metabolism 
11, 554-565. 
Hearle, N., Schumacher, V., Menko, F.H., Olschwang, S., Boardman, L.A., Gille, J.J., Keller, J.J., 
Westerman, A.M., Scott, R.J., Lim, W., et al. (2006). Frequency and spectrum of 
cancers in the Peutz-Jeghers syndrome. Clinical cancer research : an official journal 
of the American Association for Cancer Research 12, 3209-3215. 
Hecht, S.S. (2012). Lung carcinogenesis by tobacco smoke. International journal of cancer 131, 
2724-2732. 
Hellyer, N.J., Cheng, K., and Koland, J.G. (1998). ErbB3 (HER3) interaction with the p85 regulatory 
subunit of phosphoinositide 3-kinase. The Biochemical journal 333 ( Pt 3), 757-763. 
Hemminki, A. (1999). The molecular basis and clinical aspects of Peutz-Jeghers syndrome. Cellular 
and molecular life sciences : CMLS 55, 735-750. 
Hemminki, A., Markie, D., Tomlinson, I., Avizienyte, E., Roth, S., Loukola, A., Bignell, G., Warren, 
W., Aminoff, M., Hoglund, P., et al. (1998). A serine/threonine kinase gene defective 
in Peutz-Jeghers syndrome. Nature 391, 184-187. 
Hemminki, A., Tomlinson, I., Markie, D., Jarvinen, H., Sistonen, P., Bjorkqvist, A.M., Knuutila, S., 
Salovaara, R., Bodmer, W., Shibata, D., et al. (1997). Localization of a susceptibility 
locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization 
and targeted linkage analysis. Nature genetics 15, 87-90. 
Hendler, F.J., and Ozanne, B.W. (1984). Human squamous cell lung cancers express increased 
epidermal growth factor receptors. The Journal of clinical investigation 74, 647-651. 
Herbst, R.S., Baas, P., Kim, D.W., Felip, E., Perez-Gracia, J.L., Han, J.Y., Molina, J., Kim, J.H., 
Arvis, C.D., Ahn, M.J., et al. (2016). Pembrolizumab versus docetaxel for previously 
treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a 
randomised controlled trial. Lancet (London, England) 387, 1540-1550. 
Herriges, M., and Morrisey, E.E. (2014). Lung development: orchestrating the generation and 
regeneration of a complex organ. Development (Cambridge, England) 141, 502-513. 
Hezel, A.F., and Bardeesy, N. (2008). LKB1; linking cell structure and tumor suppression. Oncogene 
27, 6908-6919. 
Hinds, P., Finlay, C., and Levine, A.J. (1989). Mutation is required to activate the p53 gene for 
cooperation with the ras oncogene and transformation. Journal of virology 63, 739-
746. 
Hirsch, F.R., Varella-Garcia, M., Bunn, P.A., Jr., Di Maria, M.V., Veve, R., Bremmes, R.M., Baron, 
A.E., Zeng, C., and Franklin, W.A. (2003). Epidermal growth factor receptor in non-
small-cell lung carcinomas: correlation between gene copy number and protein 
expression and impact on prognosis. Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology 21, 3798-3807. 
110 
 
Hirsch, F.R., Varella-Garcia, M., Franklin, W.A., Veve, R., Chen, L., Helfrich, B., Zeng, C., Baron, 
A., and Bunn, P.A., Jr. (2002). Evaluation of HER-2/neu gene amplification and 
protein expression in non-small cell lung carcinomas. British journal of cancer 86, 
1449-1456. 
Ho, V.M., Schaffer, B.E., Karnezis, A.N., Park, K.S., and Sage, J. (2009). The retinoblastoma gene 
Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic 
K-Ras. Oncogene 28, 1393-1399. 
Hobbs, G.A., Der, C.J., and Rossman, K.L. (2016). RAS isoforms and mutations in cancer at a glance. 
Journal of cell science 129, 1287-1292. 
Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. (1991). p53 mutations in human 
cancers. Science (New York, NY) 253, 49-53. 
Horio, Y., Chen, A., Rice, P., Roth, J.A., Malkinson, A.M., and Schrump, D.S. (1996). Ki-ras and 
p53 mutations are early and late events, respectively, in urethane-induced pulmonary 
carcinogenesis in A/J mice. Molecular carcinogenesis 17, 217-223. 
Hu, W., Feng, Z., and Levine, A.J. (2012). The Regulation of Multiple p53 Stress Responses is 
Mediated through MDM2. Genes & cancer 3, 199-208. 
Huang, A., Zhang, B., Wang, B., Zhang, F., Fan, K.X., and Guo, Y.J. (2013). Increased 
CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with 
extrathoracic metastasis and poor response to chemotherapy in non-small cell lung 
cancer patients. Cancer immunology, immunotherapy : CII 62, 1439-1451. 
Ihle, N.T., Byers, L.A., Kim, E.S., Saintigny, P., Lee, J.J., Blumenschein, G.R., Tsao, A., Liu, S., 
Larsen, J.E., Wang, J., et al. (2012). Effect of KRAS oncogene substitutions on protein 
behavior: implications for signaling and clinical outcome. Journal of the National 
Cancer Institute 104, 228-239. 
Inoki, K., Zhu, T., and Guan, K.L. (2003). TSC2 mediates cellular energy response to control cell 
growth and survival. Cell 115, 577-590. 
Iwanaga, K., Yang, Y., Raso, M.G., Ma, L., Hanna, A.E., Thilaganathan, N., Moghaddam, S., Evans, 
C.M., Li, H., Cai, W.W., et al. (2008). Pten inactivation accelerates oncogenic K-ras-
initiated tumorigenesis in a mouse model of lung cancer. Cancer research 68, 1119-
1127. 
Jackman, D.M., Yeap, B.Y., Sequist, L.V., Lindeman, N., Holmes, A.J., Joshi, V.A., Bell, D.W., 
Huberman, M.S., Halmos, B., Rabin, M.S., et al. (2006). Exon 19 deletion mutations 
of epidermal growth factor receptor are associated with prolonged survival in non-
small cell lung cancer patients treated with gefitinib or erlotinib. Clinical cancer 
research : an official journal of the American Association for Cancer Research 12, 
3908-3914. 
Jackson, E.L., Olive, K.P., Tuveson, D.A., Bronson, R., Crowley, D., Brown, M., and Jacks, T. 
(2005). The differential effects of mutant p53 alleles on advanced murine lung cancer. 
Cancer research 65, 10280-10288. 
Jackson, E.L., Willis, N., Mercer, K., Bronson, R.T., Crowley, D., Montoya, R., Jacks, T., and 
Tuveson, D.A. (2001). Analysis of lung tumor initiation and progression using 
conditional expression of oncogenic K-ras. Genes & development 15, 3243-3248. 
Janes, M.R., Zhang, J., Li, L.S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S.J., 
Darjania, L., et al. (2018). Targeting KRAS Mutant Cancers with a Covalent G12C-
Specific Inhibitor. Cell 172, 578-589.e517. 
Janne, P.A., Shaw, A.T., Pereira, J.R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F.A., 
Grinsted, L., Zazulina, V., Smith, P., et al. (2013). Selumetinib plus docetaxel for 
KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, 
placebo-controlled, phase 2 study. The Lancet Oncology 14, 38-47. 
111 
 
Jenne, D.E., Reimann, H., Nezu, J., Friedel, W., Loff, S., Jeschke, R., Muller, O., Back, W., and 
Zimmer, M. (1998). Peutz-Jeghers syndrome is caused by mutations in a novel serine 
threonine kinase. Nature genetics 18, 38-43. 
Ji, H., Li, D., Chen, L., Shimamura, T., Kobayashi, S., McNamara, K., Mahmood, U., Mitchell, A., 
Sun, Y., Al-Hashem, R., et al. (2006a). The impact of human EGFR kinase domain 
mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. 
Cancer cell 9, 485-495. 
Ji, H., Ramsey, M.R., Hayes, D.N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M.C., 
Shimamura, T., Perera, S.A., et al. (2007). LKB1 modulates lung cancer 
differentiation and metastasis. Nature 448, 807-810. 
Ji, H., Zhao, X., Yuza, Y., Shimamura, T., Li, D., Protopopov, A., Jung, B.L., McNamara, K., Xia, 
H., Glatt, K.A., et al. (2006b). Epidermal growth factor receptor variant III mutations 
in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proceedings of the 
National Academy of Sciences of the United States of America 103, 7817-7822. 
Jin, G., Kim, M.J., Jeon, H.S., Choi, J.E., Kim, D.S., Lee, E.B., Cha, S.I., Yoon, G.S., Kim, C.H., 
Jung, T.H., et al. (2010). PTEN mutations and relationship to EGFR, ERBB2, KRAS, 
and TP53 mutations in non-small cell lung cancers. Lung cancer (Amsterdam, 
Netherlands) 69, 279-283. 
Jishage, K., Nezu, J., Kawase, Y., Iwata, T., Watanabe, M., Miyoshi, A., Ose, A., Habu, K., Kake, 
T., Kamada, N., et al. (2002). Role of Lkb1, the causative gene of Peutz-Jegher's 
syndrome, in embryogenesis and polyposis. Proceedings of the National Academy of 
Sciences of the United States of America 99, 8903-8908. 
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R.T., Crowley, D., Tuveson, D.A., and Jacks, T. 
(2001). Somatic activation of the K-ras oncogene causes early onset lung cancer in 
mice. Nature 410, 1111-1116. 
Joseph, D., Puttaswamy, R.K., and Krovvidi, H. (2013). Non-respiratory functions of the lung. 
Continuing Education in Anaesthesia Critical Care & Pain 13, 98-102. 
Joshi, A., Zanwar, S., Noronha, V., Patil, V.M., Chougule, A., Kumar, R., Janu, A., Mahajan, A., 
Kapoor, A., and Prabhash, K. (2017). EGFR mutation in squamous cell carcinoma of 
the lung: does it carry the same connotation as in adenocarcinomas? OncoTargets and 
therapy 10, 1859-1863. 
Joshi, N.S., Akama-Garren, E.H., Lu, Y., Lee, D.Y., Chang, G.P., Li, A., DuPage, M., Tammela, T., 
Kerper, N.R., Farago, A.F., et al. (2015). Regulatory T Cells in Tumor-Associated 
Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. Immunity 43, 
579-590. 
Julien, S., Merino-Trigo, A., Lacroix, L., Pocard, M., Goere, D., Mariani, P., Landron, S., Bigot, L., 
Nemati, F., Dartigues, P., et al. (2012). Characterization of a large panel of patient-
derived tumor xenografts representing the clinical heterogeneity of human colorectal 
cancer. Clinical cancer research : an official journal of the American Association for 
Cancer Research 18, 5314-5328. 
Junttila, M.R., and de Sauvage, F.J. (2013). Influence of tumour micro-environment heterogeneity 
on therapeutic response. Nature 501, 346-354. 
Junttila, M.R., Karnezis, A.N., Garcia, D., Madriles, F., Kortlever, R.M., Rostker, F., Brown Swigart, 
L., Pham, D.M., Seo, Y., Evan, G.I., et al. (2010). Selective activation of p53-
mediated tumour suppression in high-grade tumours. Nature 468, 567-571. 
Kar, A., and Gutierrez-Hartmann, A. (2013). Molecular mechanisms of ETS transcription factor-
mediated tumorigenesis. Critical reviews in biochemistry and molecular biology 48, 
522-543. 
Katayama, R., Shaw, A.T., Khan, T.M., Mino-Kenudson, M., Solomon, B.J., Halmos, B., Jessop, 
N.A., Wain, J.C., Yeo, A.T., Benes, C., et al. (2012). Mechanisms of acquired 
112 
 
crizotinib resistance in ALK-rearranged lung Cancers. Science translational medicine 
4, 120ra117. 
Kellar, A., Egan, C., and Morris, D. (2015). Preclinical Murine Models for Lung Cancer: Clinical 
Trial Applications. BioMed research international 2015, 621324. 
Kemphues, K.J., Priess, J.R., Morton, D.G., and Cheng, N.S. (1988). Identification of genes required 
for cytoplasmic localization in early C. elegans embryos. Cell 52, 311-320. 
Kerr, E.M., Gaude, E., Turrell, F.K., Frezza, C., and Martins, C.P. (2016). Mutant Kras copy number 
defines metabolic reprogramming and therapeutic susceptibilities. Nature 531, 110-
113. 
Khosravi, R., Maya, R., Gottlieb, T., Oren, M., Shiloh, Y., and Shkedy, D. (1999). Rapid ATM-
dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA 
damage. Proceedings of the National Academy of Sciences of the United States of 
America 96, 14973-14977. 
Khuder, S.A. (2001). Effect of cigarette smoking on major histological types of lung cancer: a meta-
analysis. Lung cancer (Amsterdam, Netherlands) 31, 139-148. 
Kilic, A., Landreneau, R.J., Luketich, J.D., Pennathur, A., and Schuchert, M.J. (2011). Density of 
tumor-infiltrating lymphocytes correlates with disease recurrence and survival in 
patients with large non-small-cell lung cancer tumors. The Journal of surgical research 
167, 207-210. 
Kim, C.F., Jackson, E.L., Woolfenden, A.E., Lawrence, S., Babar, I., Vogel, S., Crowley, D., 
Bronson, R.T., and Jacks, T. (2005). Identification of bronchioalveolar stem cells in 
normal lung and lung cancer. Cell 121, 823-835. 
Kim, E.K., Kim, K.A., Lee, C.Y., and Shim, H.S. (2017). The frequency and clinical impact of HER2 
alterations in lung adenocarcinoma. PloS one 12, e0171280. 
Kim, J.Y., Welsh, E.A., Fang, B., Bai, Y., Kinose, F., Eschrich, S.A., Koomen, J.M., and Haura, E.B. 
(2016). Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-
Driven AKT Signaling in KRAS-Mutant Lung Cancer. Molecular cancer research : 
MCR 14, 1019-1029. 
Kirsten, W.H., and Mayer, L.A. (1967). Morphologic responses to a murine erythroblastosis virus. 
Journal of the National Cancer Institute 39, 311-335. 
Kishimoto, Y., Murakami, Y., Shiraishi, M., Hayashi, K., and Sekiya, T. (1992). Aberrations of the 
p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer 
research 52, 4799-4804. 
Kitai, H., Ebi, H., Tomida, S., Floros, K.V., Kotani, H., Adachi, Y., Oizumi, S., Nishimura, M., 
Faber, A.C., and Yano, S. (2016). Epithelial-to-Mesenchymal Transition Defines 
Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK 
Inhibition in KRAS-Mutant Lung Cancer. Cancer discovery 6, 754-769. 
Kiviharju-af Hallstrom, T.M., Jaamaa, S., Monkkonen, M., Peltonen, K., Andersson, L.C., Medema, 
R.H., Peehl, D.M., and Laiho, M. (2007). Human prostate epithelium lacks Wee1A-
mediated DNA damage-induced checkpoint enforcement. Proceedings of the National 
Academy of Sciences of the United States of America 104, 7211-7216. 
Klapper, L.N., Glathe, S., Vaisman, N., Hynes, N.E., Andrews, G.C., Sela, M., and Yarden, Y. 
(1999). The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as 
a shared coreceptor for multiple stroma-derived growth factors. Proceedings of the 
National Academy of Sciences of the United States of America 96, 4995-5000. 
Knudson, A.G. (2001). Two genetic hits (more or less) to cancer. Nature reviews Cancer 1, 157-162. 
Koera, K., Nakamura, K., Nakao, K., Miyoshi, J., Toyoshima, K., Hatta, T., Otani, H., Aiba, A., and 
Katsuki, M. (1997). K-ras is essential for the development of the mouse embryo. 
Oncogene 15, 1151-1159. 
113 
 
Koerfer, J., Kallendrusch, S., Merz, F., Wittekind, C., Kubick, C., Kassahun, W.T., Schumacher, G., 
Moebius, C., Gassler, N., Schopow, N., et al. (2016). Organotypic slice cultures of 
human gastric and esophagogastric junction cancer. Cancer medicine 5, 1444-1453. 
Koinis, F., Vetsika, E.K., Aggouraki, D., Skalidaki, E., Koutoulaki, A., Gkioulmpasani, M., 
Georgoulias, V., and Kotsakis, A. (2016). Effect of First-Line Treatment on Myeloid-
Derived Suppressor Cells' Subpopulations in the Peripheral Blood of Patients with 
Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of 
the International Association for the Study of Lung Cancer 11, 1263-1272. 
Koivunen, J.P., Kim, J., Lee, J., Rogers, A.M., Park, J.O., Zhao, X., Naoki, K., Okamoto, I., 
Nakagawa, K., Yeap, B.Y., et al. (2008). Mutations in the LKB1 tumour suppressor 
are frequently detected in tumours from Caucasian but not Asian lung cancer patients. 
British journal of cancer 99, 245-252. 
Koyama, S., Akbay, E.A., Li, Y.Y., Aref, A.R., Skoulidis, F., Herter-Sprie, G.S., Buczkowski, K.A., 
Liu, Y., Awad, M.M., Denning, W.L., et al. (2016). STK11/LKB1 Deficiency 
Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to 
Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer research 76, 
999-1008. 
Kress, M., May, E., Cassingena, R., and May, P. (1979). Simian virus 40-transformed cells express 
new species of proteins precipitable by anti-simian virus 40 tumor serum. Journal of 
virology 31, 472-483. 
Krumdieck, C.L. (2013). Development of a live tissue microtome: reflections of an amateur 
machinist. Xenobiotica; the fate of foreign compounds in biological systems 43, 2-7. 
Kruspig, B., Monteverde, T., Neidler, S., Hock, A., Kerr, E., Nixon, C., Clark, W., Hedley, A., Laing, 
S., Coffelt, S.B., et al. (2018). The ERBB network facilitates KRAS-driven lung 
tumorigenesis. Science translational medicine 10. 
Kuner, R., Muley, T., Meister, M., Ruschhaupt, M., Buness, A., Xu, E.C., Schnabel, P., Warth, A., 
Poustka, A., Sultmann, H., et al. (2009). Global gene expression analysis reveals 
specific patterns of cell junctions in non-small cell lung cancer subtypes. Lung cancer 
(Amsterdam, Netherlands) 63, 32-38. 
Kurppa, K.J., Denessiouk, K., Johnson, M.S., and Elenius, K. (2016). Activating ERBB4 mutations 
in non-small cell lung cancer. Oncogene 35, 1283-1291. 
Lane, D.P., and Crawford, L.V. (1979). T antigen is bound to a host protein in SV40-transformed 
cells. Nature 278, 261-263. 
Lassen, U., Osterlind, K., Hansen, M., Dombernowsky, P., Bergman, B., and Hansen, H.H. (1995). 
Long-term survival in small-cell lung cancer: posttreatment characteristics in patients 
surviving 5 to 18+ years--an analysis of 1,714 consecutive patients. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology 13, 1215-
1220. 
Lee, C.L., Moding, E.J., Huang, X., Li, Y., Woodlief, L.Z., Rodrigues, R.C., Ma, Y., and Kirsch, 
D.G. (2012). Generation of primary tumors with Flp recombinase in FRT-flanked p53 
mice. Disease models & mechanisms 5, 397-402. 
Lee, J., Kim, S., Kim, P., Liu, X., Lee, T., Kim, K.M., Do, I.G., Park, J.O., Park, S.H., Jang, J., et al. 
(2013). A novel proteomics-based clinical diagnostics technology identifies 
heterogeneity in activated signaling pathways in gastric cancers. PloS one 8, e54644. 
Lee, K.F., Simon, H., Chen, H., Bates, B., Hung, M.C., and Hauser, C. (1995). Requirement for 
neuregulin receptor erbB2 in neural and cardiac development. Nature 378, 394-398. 
Lee, W.C., Diao, L., Wang, J., Zhang, J., Roarty, E.B., Varghese, S., Chow, C.W., Fujimoto, J., 
Behrens, C., Cascone, T., et al. (2018). Multiregion gene expression profiling reveals 
heterogeneity in molecular subtypes and immunotherapy response signatures in lung 
114 
 
cancer. Modern pathology : an official journal of the United States and Canadian 
Academy of Pathology, Inc. 
Leeman, K.T., Fillmore, C.M., and Kim, C.F. (2014). Lung stem and progenitor cells in tissue 
homeostasis and disease. Current topics in developmental biology 107, 207-233. 
Lefrancais, E., Ortiz-Munoz, G., Caudrillier, A., Mallavia, B., Liu, F., Sayah, D.M., Thornton, E.E., 
Headley, M.B., David, T., Coughlin, S.R., et al. (2017). The lung is a site of platelet 
biogenesis and a reservoir for haematopoietic progenitors. Nature 544, 105-109. 
Levrero, M., De Laurenzi, V., Costanzo, A., Gong, J., Wang, J.Y., and Melino, G. (2000). The 
p53/p63/p73 family of transcription factors: overlapping and distinct functions. 
Journal of cell science 113 ( Pt 10), 1661-1670. 
Li, C., Sun, Y., Fang, R., Han, X., Luo, X., Wang, R., Pan, Y., Hu, H., Zhang, Y., Pao, W., et al. 
(2012). Lung adenocarcinomas with HER2-activating mutations are associated with 
distinct clinical features and HER2/EGFR copy number gains. Journal of thoracic 
oncology : official publication of the International Association for the Study of Lung 
Cancer 7, 85-89. 
Li, F., Han, X., Li, F., Wang, R., Wang, H., Gao, Y., Wang, X., Fang, Z., Zhang, W., Yao, S., et al. 
(2015a). LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell 
Lung Cancer Plasticity and Therapeutic Response. Cancer cell 27, 698-711. 
Li, F., He, J., Wei, J., Cho, W.C., and Liu, X. (2015b). Diversity of epithelial stem cell types in adult 
lung. Stem cells international 2015, 728307. 
Li, L., Wei, Y., Van Winkle, L., Zhang, Q.Y., Zhou, X., Hu, J., Xie, F., Kluetzman, K., and Ding, X. 
(2011). Generation and characterization of a Cyp2f2-null mouse and studies on the 
role of CYP2F2 in naphthalene-induced toxicity in the lung and nasal olfactory 
mucosa. The Journal of pharmacology and experimental therapeutics 339, 62-71. 
Li, S., Liu, S., Deng, J., Akbay, E.A., Hai, J., Ambrogio, C., Zhang, L., Zhou, F., Jenkins, R.W., 
Adeegbe, D.O., et al. (2018). Assessing Therapeutic Efficacy of MEK Inhibition in a 
KRAS G12C-Driven Mouse Model of Lung Cancer. Clinical cancer research : an 
official journal of the American Association for Cancer Research. 
Li, Y., Li, F., Jiang, F., Lv, X., Zhang, R., Lu, A., and Zhang, G. (2016). A Mini-Review for Cancer 
Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway &amp; 
Translational Blockade of Immune Checkpoints. International journal of molecular 
sciences 17. 
Litvak, A.M., Paik, P.K., Woo, K.M., Sima, C.S., Hellmann, M.D., Arcila, M.E., Ladanyi, M., Rudin, 
C.M., Kris, M.G., and Riely, G.J. (2014). Clinical characteristics and course of 63 
patients with BRAF mutant lung cancers. Journal of thoracic oncology : official 
publication of the International Association for the Study of Lung Cancer 9, 1669-
1674. 
Liu, C.Y., Wang, Y.M., Wang, C.L., Feng, P.H., Ko, H.W., Liu, Y.H., Wu, Y.C., Chu, Y., Chung, 
F.T., Kuo, C.H., et al. (2010). Population alterations of L-arginase- and inducible 
nitric oxide synthase-expressed CD11b+/CD14(-)/CD15+/CD33+ myeloid-derived 
suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small 
cell lung cancer. Journal of cancer research and clinical oncology 136, 35-45. 
Liu, H., Zhang, T., Ye, J., Li, H., Huang, J., Li, X., Wu, B., Huang, X., and Hou, J. (2012a). Tumor-
infiltrating lymphocytes predict response to chemotherapy in patients with advance 
non-small cell lung cancer. Cancer immunology, immunotherapy : CII 61, 1849-1856. 
Liu, J., Cho, S.N., Akkanti, B., Jin, N., Mao, J., Long, W., Chen, T., Zhang, Y., Tang, X., Wistub, II, 
et al. (2015). ErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor 
Growth and Metastasis. Cell reports. 
Liu, X., Krawczyk, E., Suprynowicz, F.A., Palechor-Ceron, N., Yuan, H., Dakic, A., Simic, V., 
Zheng, Y.L., Sripadhan, P., Chen, C., et al. (2017). Conditional reprogramming and 
115 
 
long-term expansion of normal and tumor cells from human biospecimens. Nature 
protocols 12, 439-451. 
Liu, X., Ory, V., Chapman, S., Yuan, H., Albanese, C., Kallakury, B., Timofeeva, O.A., Nealon, C., 
Dakic, A., Simic, V., et al. (2012b). ROCK inhibitor and feeder cells induce the 
conditional reprogramming of epithelial cells. Am J Pathol 180, 599-607. 
Liu, Y., Marks, K., Cowley, G.S., Carretero, J., Liu, Q., Nieland, T.J., Xu, C., Cohoon, T.J., Gao, P., 
Zhang, Y., et al. (2013). Metabolic and functional genomic studies identify 
deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer discovery 
3, 870-879. 
Liu, Y., Zhang, J., Li, L., Yin, G., Zhang, J., Zheng, S., Cheung, H., Wu, N., Lu, N., Mao, X., et al. 
(2016). Genomic heterogeneity of multiple synchronous lung cancer. Nature 
communications 7, 13200. 
Loeb, K.R., and Loeb, L.A. (2000). Significance of multiple mutations in cancer. Carcinogenesis 21, 
379-385. 
Loffredo Sampaolo, C. (1956). [Chick embryo heart in organotypic culture]. Bollettino della Societa 
italiana di biologia sperimentale 32, 1580-1582. 
Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, 
P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., et al. (2004). Activating mutations 
in the epidermal growth factor receptor underlying responsiveness of non-small-cell 
lung cancer to gefitinib. The New England journal of medicine 350, 2129-2139. 
Maeurer, M.J., Gollin, S.M., Martin, D., Swaney, W., Bryant, J., Castelli, C., Robbins, P., Parmiani, 
G., Storkus, W.J., and Lotze, M.T. (1996). Tumor escape from immune recognition: 
lethal recurrent melanoma in a patient associated with downregulation of the peptide 
transporter protein TAP-1 and loss of expression of the immunodominant MART-
1/Melan-A antigen. The Journal of clinical investigation 98, 1633-1641. 
Mainardi, S., Mijimolle, N., Francoz, S., Vicente-Duenas, C., Sanchez-Garcia, I., and Barbacid, M. 
(2014). Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma. 
Proceedings of the National Academy of Sciences of the United States of America 
111, 255-260. 
Majumder, B., Baraneedharan, U., Thiyagarajan, S., Radhakrishnan, P., Narasimhan, H., 
Dhandapani, M., Brijwani, N., Pinto, D.D., Prasath, A., Shanthappa, B.U., et al. 
(2015). Predicting clinical response to anticancer drugs using an ex vivo platform that 
captures tumour heterogeneity. Nature communications 6, 6169. 
Malkoski, S.P., Cleaver, T.G., Thompson, J.J., Sutton, W.P., Haeger, S.M., Rodriguez, K.J., Lu, S.L., 
Merrick, D., and Wang, X.J. (2014). Role of PTEN in basal cell derived lung 
carcinogenesis. Molecular carcinogenesis 53, 841-846. 
Malkoski, S.P., Haeger, S.M., Cleaver, T.G., Rodriguez, K.J., Li, H., Lu, S.L., Feser, W.J., Baron, 
A.E., Merrick, D., Lighthall, J.G., et al. (2012). Loss of transforming growth factor 
beta type II receptor increases aggressive tumor behavior and reduces survival in lung 
adenocarcinoma and squamous cell carcinoma. Clinical cancer research : an official 
journal of the American Association for Cancer Research 18, 2173-2183. 
Manchado, E., Weissmueller, S., Morris, J.P.t., Chen, C.C., Wullenkord, R., Lujambio, A., de 
Stanchina, E., Poirier, J.T., Gainor, J.F., Corcoran, R.B., et al. (2016). A combinatorial 
strategy for treating KRAS-mutant lung cancer. Nature 534, 647-651. 
Manning, G., Whyte, D.B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002). The protein kinase 
complement of the human genome. Science (New York, NY) 298, 1912-1934. 
Mao, L., Lee, J.S., Kurie, J.M., Fan, Y.H., Lippman, S.M., Lee, J.J., Ro, J.Y., Broxson, A., Yu, R., 
Morice, R.C., et al. (1997). Clonal genetic alterations in the lungs of current and 
former smokers. Journal of the National Cancer Institute 89, 857-862. 
116 
 
Marshall, E.A., Ng, K.W., Kung, S.H., Conway, E.M., Martinez, V.D., Halvorsen, E.C., Rowbotham, 
D.A., Vucic, E.A., Plumb, A.W., Becker-Santos, D.D., et al. (2016). Emerging roles 
of T helper 17 and regulatory T cells in lung cancer progression and metastasis. 
Molecular cancer 15, 67. 
Martin, S.G., and St Johnston, D. (2003). A role for Drosophila LKB1 in anterior-posterior axis 
formation and epithelial polarity. Nature 421, 379-384. 
Marvel, D., and Gabrilovich, D.I. (2015). Myeloid-derived suppressor cells in the tumor 
microenvironment: expect the unexpected. The Journal of clinical investigation 125, 
3356-3364. 
Massarelli, E., Varella-Garcia, M., Tang, X., Xavier, A.C., Ozburn, N.C., Liu, D.D., Bekele, B.N., 
Herbst, R.S., and Wistuba, II (2007). KRAS mutation is an important predictor of 
resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors 
in non-small-cell lung cancer. Clinical cancer research : an official journal of the 
American Association for Cancer Research 13, 2890-2896. 
Matsumoto, S., Iwakawa, R., Takahashi, K., Kohno, T., Nakanishi, Y., Matsuno, Y., Suzuki, K., 
Nakamoto, M., Shimizu, E., Minna, J.D., et al. (2007). Prevalence and specificity of 
LKB1 genetic alterations in lung cancers. Oncogene 26, 5911-5918. 
McCubrey, J.A., Steelman, L.S., Chappell, W.H., Abrams, S.L., Montalto, G., Cervello, M., 
Nicoletti, F., Fagone, P., Malaponte, G., Mazzarino, M.C., et al. (2012). Mutations 
and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which 
alter therapy response. Oncotarget 3, 954-987. 
McLure, K.G., and Lee, P.W. (1998). How p53 binds DNA as a tetramer. The EMBO journal 17, 
3342-3350. 
Meijer, T.G., Naipal, K.A., Jager, A., and van Gent, D.C. (2017). Ex vivo tumor culture systems for 
functional drug testing and therapy response prediction. Future science OA 3, Fso190. 
Melino, G., De Laurenzi, V., and Vousden, K.H. (2002). p73: Friend or foe in tumorigenesis. Nature 
reviews Cancer 2, 605-615. 
Merz, F., Gaunitz, F., Dehghani, F., Renner, C., Meixensberger, J., Gutenberg, A., Giese, A., 
Schopow, K., Hellwig, C., Schafer, M., et al. (2013). Organotypic slice cultures of 
human glioblastoma reveal different susceptibilities to treatments. Neuro-oncology 
15, 670-681. 
Meuwissen, R., and Berns, A. (2005). Mouse models for human lung cancer. Genes & development 
19, 643-664. 
Meuwissen, R., Linn, S.C., Linnoila, R.I., Zevenhoven, J., Mooi, W.J., and Berns, A. (2003). 
Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in 
a conditional mouse model. Cancer cell 4, 181-189. 
Meuwissen, R., Linn, S.C., van der Valk, M., Mooi, W.J., and Berns, A. (2001). Mouse model for 
lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras 
oncogene. Oncogene 20, 6551-6558. 
Meylan, E., Dooley, A.L., Feldser, D.M., Shen, L., Turk, E., Ouyang, C., and Jacks, T. (2009). 
Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. 
Nature 462, 104-107. 
Midha, A., Dearden, S., and McCormack, R. (2015). EGFR mutation incidence in non-small-cell 
lung cancer of adenocarcinoma histology: a systematic review and global map by 
ethnicity (mutMapII). American journal of cancer research 5, 2892-2911. 
Miettinen, P.J., Berger, J.E., Meneses, J., Phung, Y., Pedersen, R.A., Werb, Z., and Derynck, R. 
(1995). Epithelial immaturity and multiorgan failure in mice lacking epidermal 
growth factor receptor. Nature 376, 337-341. 
Miller, V.A., Kris, M.G., Shah, N., Patel, J., Azzoli, C., Gomez, J., Krug, L.M., Pao, W., Rizvi, N., 
Pizzo, B., et al. (2004). Bronchioloalveolar pathologic subtype and smoking history 
117 
 
predict sensitivity to gefitinib in advanced non-small-cell lung cancer. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology 22, 
1103-1109. 
Mills, A.A., Zheng, B., Wang, X.J., Vogel, H., Roop, D.R., and Bradley, A. (1999). p63 is a p53 
homologue required for limb and epidermal morphogenesis. Nature 398, 708-713. 
Mitsudomi, T., Viallet, J., Mulshine, J.L., Linnoila, R.I., Minna, J.D., and Gazdar, A.F. (1991). 
Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines 
from small-cell lung cancer cell lines. Oncogene 6, 1353-1362. 
Moll, H.P., Pranz, K., Musteanu, M., Grabner, B., Hruschka, N., Mohrherr, J., Aigner, P., Stiedl, P., 
Brcic, L., Laszlo, V., et al. (2018). Afatinib restrains K-RAS-driven lung 
tumorigenesis. Science translational medicine 10. 
Momcilovic, M., McMickle, R., Abt, E., Seki, A., Simko, S.A., Magyar, C., Stout, D.B., Fishbein, 
M.C., Walser, T.C., Dubinett, S.M., et al. (2015). Heightening Energetic Stress 
Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers. Cancer research 
75, 4910-4922. 
Moran, T., Palmero, R., Provencio, M., Insa, A., Majem, M., Reguart, N., Bosch-Barrera, J., Isla, D., 
Costa, E.C., Lee, C., et al. (2017). A phase Ib trial of continuous once-daily oral 
afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-
positive non-small cell lung cancer and/or disease progression following prior 
erlotinib or gefitinib. Lung cancer (Amsterdam, Netherlands) 108, 154-160. 
Morgan, K.M., Riedlinger, G.M., Rosenfeld, J., Ganesan, S., and Pine, S.R. (2017). Patient-Derived 
Xenograft Models of Non-Small Cell Lung Cancer and Their Potential Utility in 
Personalized Medicine. Frontiers in oncology 7, 2. 
Moya-Horno, I., Viteri, S., Karachaliou, N., and Rosell, R. (2018). Combination of immunotherapy 
with targeted therapies in advanced non-small cell lung cancer (NSCLC). Therapeutic 
advances in medical oncology 10, 1758834017745012. 
Mukhopadhyay, A., Berrett, K.C., Kc, U., Clair, P.M., Pop, S.M., Carr, S.R., Witt, B.L., and Oliver, 
T.G. (2014). Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung 
cancer. Cell reports 8, 40-49. 
Multhoff, G., Molls, M., and Radons, J. (2011). Chronic inflammation in cancer development. 
Frontiers in immunology 2, 98. 
Mumenthaler, S.M., Foo, J., Choi, N.C., Heise, N., Leder, K., Agus, D.B., Pao, W., Michor, F., and 
Mallick, P. (2015). The Impact of Microenvironmental Heterogeneity on the 
Evolution of Drug Resistance in Cancer Cells. Cancer informatics 14, 19-31. 
Munder, M., Schneider, H., Luckner, C., Giese, T., Langhans, C.D., Fuentes, J.M., Kropf, P., 
Mueller, I., Kolb, A., Modolell, M., et al. (2006). Suppression of T-cell functions by 
human granulocyte arginase. Blood 108, 1627-1634. 
Naipal, K.A., Verkaik, N.S., Ameziane, N., van Deurzen, C.H., Ter Brugge, P., Meijers, M., 
Sieuwerts, A.M., Martens, J.W., O'Connor, M.J., Vrieling, H., et al. (2014). 
Functional ex vivo assay to select homologous recombination-deficient breast tumors 
for PARP inhibitor treatment. Clinical cancer research : an official journal of the 
American Association for Cancer Research 20, 4816-4826. 
Naipal, K.A., Verkaik, N.S., Sanchez, H., van Deurzen, C.H., den Bakker, M.A., Hoeijmakers, J.H., 
Kanaar, R., Vreeswijk, M.P., Jager, A., and van Gent, D.C. (2016). Tumor slice 
culture system to assess drug response of primary breast cancer. BMC Cancer 16, 78. 
Nakagawa, K., Yasumitu, T., Fukuhara, K., Shiono, H., and Kikui, M. (2003). Poor prognosis after 
lung resection for patients with adenosquamous carcinoma of the lung. The Annals of 
thoracic surgery 75, 1740-1744. 
118 
 
Nomura, M., Shigematsu, H., Li, L., Suzuki, M., Takahashi, T., Estess, P., Siegelman, M., Feng, Z., 
Kato, H., Marchetti, A., et al. (2007). Polymorphisms, mutations, and amplification 
of the EGFR gene in non-small cell lung cancers. PLoS medicine 4, e125. 
Nowell, P.C. (1976). The clonal evolution of tumor cell populations. Science (New York, NY) 194, 
23-28. 
Novikova, D.S., Garabadzhiu, A.V., Melino, G., Barlev, N.A., and Tribulovich, V.G. (2015). AMP-
activated protein kinase: structure, function, and role in pathological processes. 
Biochemistry Biokhimiia 80, 127-144. 
Ochocki, J.D., and Simon, M.C. (2013). Nutrient-sensing pathways and metabolic regulation in stem 
cells. The Journal of cell biology 203, 23-33. 
Okudela, K., Suzuki, M., Kageyama, S., Bunai, T., Nagura, K., Igarashi, H., Takamochi, K., Suzuki, 
K., Yamada, T., Niwa, H., et al. (2007). PIK3CA mutation and amplification in human 
lung cancer. Pathology international 57, 664-671. 
Olivier, M., Eeles, R., Hollstein, M., Khan, M.A., Harris, C.C., and Hainaut, P. (2002). The IARC 
TP53 database: new online mutation analysis and recommendations to users. Human 
mutation 19, 607-614. 
Ostrand-Rosenberg, S., and Sinha, P. (2009). Myeloid-derived suppressor cells: linking 
inflammation and cancer. Journal of immunology (Baltimore, Md : 1950) 182, 4499-
4506. 
Ou, S.H., Kwak, E.L., Siwak-Tapp, C., Dy, J., Bergethon, K., Clark, J.W., Camidge, D.R., Solomon, 
B.J., Maki, R.G., Bang, Y.J., et al. (2011). Activity of crizotinib (PF02341066), a dual 
mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) 
inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. 
Journal of thoracic oncology : official publication of the International Association for 
the Study of Lung Cancer 6, 942-946. 
Owen, M.R., Doran, E., and Halestrap, A.P. (2000). Evidence that metformin exerts its anti-diabetic 
effects through inhibition of complex 1 of the mitochondrial respiratory chain. The 
Biochemical journal 348 Pt 3, 607-614. 
Palmer, A.C., and Sorger, P.K. (2017). Combination Cancer Therapy Can Confer Benefit via Patient-
to-Patient Variability without Drug Additivity or Synergy. Cell 171, 1678-
1691.e1613. 
Pang, X., and Liu, M. (2016). A combination therapy for KRAS-mutant lung cancer by targeting 
synthetic lethal partners of mutant KRAS. Chinese journal of cancer 35, 92. 
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, 
V., Fulton, L., et al. (2004). EGF receptor gene mutations are common in lung cancers 
from "never smokers" and are associated with sensitivity of tumors to gefitinib and 
erlotinib. Proceedings of the National Academy of Sciences of the United States of 
America 101, 13306-13311. 
Pao, W., Wang, T.Y., Riely, G.J., Miller, V.A., Pan, Q., Ladanyi, M., Zakowski, M.F., Heelan, R.T., 
Kris, M.G., and Varmus, H.E. (2005). KRAS mutations and primary resistance of lung 
adenocarcinomas to gefitinib or erlotinib. PLoS medicine 2, e17. 
Papageorgiou, A., Stravoravdi, P., Sahpazidou, D., Natsis, K., Chrysogelou, E., and Toliou, T. 
(2000). Effect of navelbine on inhibition of tumor growth, cellular differentiation and 
estrogen receptor status on Lewis lung carcinoma. Chemotherapy 46, 188-194. 
Parada, L.F., Tabin, C.J., Shih, C., and Weinberg, R.A. (1982). Human EJ bladder carcinoma 
oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297, 474-478. 
Peifer, M., Fernandez-Cuesta, L., Sos, M.L., George, J., Seidel, D., Kasper, L.H., Plenker, D., 
Leenders, F., Sun, R., Zander, T., et al. (2012). Integrative genome analyses identify 




Pemovska, T., Kontro, M., Yadav, B., Edgren, H., Eldfors, S., Szwajda, A., Almusa, H., Bespalov, 
M.M., Ellonen, P., Elonen, E., et al. (2013). Individualized systems medicine strategy 
to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer 
discovery 3, 1416-1429. 
Perera, S.A., Li, D., Shimamura, T., Raso, M.G., Ji, H., Chen, L., Borgman, C.L., Zaghlul, S., 
Brandstetter, K.A., Kubo, S., et al. (2009). HER2YVMA drives rapid development of 
adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin 
combination therapy. Proceedings of the National Academy of Sciences of the United 
States of America 106, 474-479. 
Pfeifer, G.P., Denissenko, M.F., Olivier, M., Tretyakova, N., Hecht, S.S., and Hainaut, P. (2002). 
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated 
cancers. Oncogene 21, 7435-7451. 
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., 
Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016). Immunogenic 
Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity 44, 
343-354. 
Pillay, J., Tak, T., Kamp, V.M., and Koenderman, L. (2013). Immune suppression by neutrophils 
and granulocytic myeloid-derived suppressor cells: similarities and differences. 
Cellular and molecular life sciences : CMLS 70, 3813-3827. 
Pirie, K., Peto, R., Green, J., Reeves, G.K., and Beral, V. (2016). Lung cancer in never smokers in 
the UK Million Women Study. International journal of cancer 139, 347-354. 
Politi, K., Ayeni, D., and Lynch, T. (2015). The Next Wave of EGFR Tyrosine Kinase Inhibitors 
Enter the Clinic. Cancer cell 27, 751-753. 
Politi, K., Zakowski, M.F., Fan, P.D., Schonfeld, E.A., Pao, W., and Varmus, H.E. (2006). Lung 
adenocarcinomas induced in mice by mutant EGF receptors found in human lung 
cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. 
Genes & development 20, 1496-1510. 
Port, J.L.F., Muthalagu, N., Raja, M., Ceteci, F., Monteverde, T., Kruspig, B., Hedley, A., Kalna, G., 
Lilla, S., Neilson, L., et al. (2018). Colorectal tumors require NUAK1 for protection 
from oxidative stress. Cancer discovery. 
Powrozek, T., Krawczyk, P., Ramlau, R., Sura, S., Wojas-Krawczyk, K., Kucharczyk, T., Walczyna, 
B., Szumilo, J., Szyszka-Barth, K., Milecki, P., et al. (2014). EGFR gene mutations 
in patients with adenosquamous lung carcinoma. Asia-Pacific journal of clinical 
oncology 10, 340-345. 
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R.L., 
Bardelli, A., and Bernards, R. (2012). Unresponsiveness of colon cancer to 
BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-
103. 
Prior, I.A., and Hancock, J.F. (2012). Ras trafficking, localization and compartmentalized signalling. 
Seminars in cell & developmental biology 23, 145-153. 
Rask, L., Fregil, M., Hogdall, E., Mitchelmore, C., and Eriksen, J. (2013). Development of a 
metastatic fluorescent Lewis Lung carcinoma mouse model: identification of mRNAs 
and microRNAs involved in tumor invasion. Gene 517, 72-81. 
Rawlins, E.L., Okubo, T., Xue, Y., Brass, D.M., Auten, R.L., Hasegawa, H., Wang, F., and Hogan, 
B.L. (2009). The role of Scgb1a1+ Clara cells in the long-term maintenance and repair 
of lung airway, but not alveolar, epithelium. Cell stem cell 4, 525-534. 
Repasky, G.A., Chenette, E.J., and Der, C.J. (2004). Renewing the conspiracy theory debate: does 
Raf function alone to mediate Ras oncogenesis? Trends in cell biology 14, 639-647. 
Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. (2001). Stem cells, cancer, and cancer 
stem cells. Nature 414, 105-111. 
120 
 
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S.M., 
Hida, T., Kowalski, D.M., Dols, M.C., et al. (2017). Atezolizumab versus docetaxel 
in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-
label, multicentre randomised controlled trial. Lancet (London, England) 389, 255-
265. 
Rocco, G., Morabito, A., Leone, A., Muto, P., Fiore, F., and Budillon, A. (2016). Management of 
non-small cell lung cancer in the era of personalized medicine. The international 
journal of biochemistry & cell biology 78, 173-179. 
Rock, J.R., Barkauskas, C.E., Cronce, M.J., Xue, Y., Harris, J.R., Liang, J., Noble, P.W., and Hogan, 
B.L. (2011). Multiple stromal populations contribute to pulmonary fibrosis without 
evidence for epithelial to mesenchymal transition. Proceedings of the National 
Academy of Sciences of the United States of America 108, E1475-1483. 
Rock, J.R., Onaitis, M.W., Rawlins, E.L., Lu, Y., Clark, C.P., Xue, Y., Randell, S.H., and Hogan, 
B.L. (2009). Basal cells as stem cells of the mouse trachea and human airway 
epithelium. Proceedings of the National Academy of Sciences of the United States of 
America 106, 12771-12775. 
Rock, J.R., Randell, S.H., and Hogan, B.L. (2010). Airway basal stem cells: a perspective on their 
roles in epithelial homeostasis and remodeling. Disease models & mechanisms 3, 545-
556. 
Rodriguez, P.C., and Ochoa, A.C. (2008). Arginine regulation by myeloid derived suppressor cells 
and tolerance in cancer: mechanisms and therapeutic perspectives. Immunological 
reviews 222, 180-191. 
Rodriguez, P.C., Zea, A.H., Culotta, K.S., Zabaleta, J., Ochoa, J.B., and Ochoa, A.C. (2002). 
Regulation of T cell receptor CD3zeta chain expression by L-arginine. The Journal of 
biological chemistry 277, 21123-21129. 
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-
Gomez, R., Pallares, C., Sanchez, J.M., et al. (2012). Erlotinib versus standard 
chemotherapy as first-line treatment for European patients with advanced EGFR 
mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, 
randomised phase 3 trial. The Lancet Oncology 13, 239-246. 
Rosell, R., Karachaliou, N., Morales-Espinosa, D., Costa, C., Molina, M.A., Sansano, I., Gasco, A., 
Viteri, S., Massuti, B., Wei, J., et al. (2013). Adaptive resistance to targeted therapies 
in cancer. Translational lung cancer research 2, 152-159. 
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, 
G., Isla, D., Provencio, M., et al. (2009). Screening for epidermal growth factor 
receptor mutations in lung cancer. The New England journal of medicine 361, 958-
967. 
Rudin, C.M., Durinck, S., Stawiski, E.W., Poirier, J.T., Modrusan, Z., Shames, D.S., Bergbower, 
E.A., Guan, Y., Shin, J., Guillory, J., et al. (2012). Comprehensive genomic analysis 
identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nature 
genetics 44, 1111-1116. 
Ruiz-Ceja, K.A., and Chirino, Y.I. (2017). Current FDA-approved treatments for non-small cell lung 
cancer and potential biomarkers for its detection. Biomedicine & pharmacotherapy = 
Biomedecine & pharmacotherapie 90, 24-37. 
Ryckman, C., Vandal, K., Rouleau, P., Talbot, M., and Tessier, P.A. (2003). Proinflammatory 
activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil 
chemotaxis and adhesion. Journal of immunology (Baltimore, Md : 1950) 170, 3233-
3242. 
Sadowski, P.D. (1995). The Flp recombinase of the 2-microns plasmid of Saccharomyces cerevisiae. 
Progress in nucleic acid research and molecular biology 51, 53-91. 
121 
 
Saeed, K., Rahkama, V., Eldfors, S., Bychkov, D., Mpindi, J.P., Yadav, B., Paavolainen, L., 
Aittokallio, T., Heckman, C., Wennerberg, K., et al. (2017). Comprehensive Drug 
Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-
resistant Prostate Cancer. European urology 71, 319-327. 
Sakai, Y., Sasahira, T., Ohmori, H., Yoshida, K., and Kuniyasu, H. (2006). Conjugated linoleic acid 
reduced metastasized LL2 tumors in mouse peritoneum. Virchows Archiv : an 
international journal of pathology 449, 341-347. 
Sanchez-Cespedes, M. (2007). A role for LKB1 gene in human cancer beyond the Peutz-Jeghers 
syndrome. Oncogene 26, 7825-7832. 
Sanchez-Cespedes, M., Parrella, P., Esteller, M., Nomoto, S., Trink, B., Engles, J.M., Westra, W.H., 
Herman, J.G., and Sidransky, D. (2002). Inactivation of LKB1/STK11 is a common 
event in adenocarcinomas of the lung. Cancer research 62, 3659-3662. 
Santos, E., Tronick, S.R., Aaronson, S.A., Pulciani, S., and Barbacid, M. (1982). T24 human bladder 
carcinoma oncogene is an activated form of the normal human homologue of BALB- 
and Harvey-MSV transforming genes. Nature 298, 343-347. 
Sasaki, H., Yokota, K., Hikosaka, Y., Moriyama, S., Yano, M., and Fujii, Y. (2012). Increased Sox2 
copy number in lung squamous cell carcinomas. Experimental and therapeutic 
medicine 3, 44-48. 
Sasaki, T., Koivunen, J., Ogino, A., Yanagita, M., Nikiforow, S., Zheng, W., Lathan, C., Marcoux, 
J.P., Du, J., Okuda, K., et al. (2011). A novel ALK secondary mutation and EGFR 
signaling cause resistance to ALK kinase inhibitors. Cancer research 71, 6051-6060. 
Sasaki, T., Rodig, S.J., Chirieac, L.R., and Janne, P.A. (2010). The biology and treatment of EML4-
ALK non-small cell lung cancer. European journal of cancer (Oxford, England : 1990) 
46, 1773-1780. 
Schaber, M.D., O'Hara, M.B., Garsky, V.M., Mosser, S.C., Bergstrom, J.D., Moores, S.L., Marshall, 
M.S., Friedman, P.A., Dixon, R.A., and Gibbs, J.B. (1990). Polyisoprenylation of Ras 
in vitro by a farnesyl-protein transferase. The Journal of biological chemistry 265, 
14701-14704. 
Schmid, K., Oehl, N., Wrba, F., Pirker, R., Pirker, C., and Filipits, M. (2009). EGFR/KRAS/BRAF 
mutations in primary lung adenocarcinomas and corresponding locoregional lymph 
node metastases. Clinical cancer research : an official journal of the American 
Association for Cancer Research 15, 4554-4560. 
Schramek, D., Kotsinas, A., Meixner, A., Wada, T., Elling, U., Pospisilik, J.A., Neely, G.G., Zwick, 
R.H., Sigl, V., Forni, G., et al. (2011). The stress kinase MKK7 couples oncogenic 
stress to p53 stability and tumor suppression. Nature genetics 43, 212-219. 
Serizawa, M., Takahashi, T., Yamamoto, N., and Koh, Y. (2013). Genomic aberrations associated 
with erlotinib resistance in non-small cell lung cancer cells. Anticancer research 33, 
5223-5233. 
Shackelford, D.B., Abt, E., Gerken, L., Vasquez, D.S., Seki, A., Leblanc, M., Wei, L., Fishbein, 
M.C., Czernin, J., Mischel, P.S., et al. (2013). LKB1 inactivation dictates therapeutic 
response of non-small cell lung cancer to the metabolism drug phenformin. Cancer 
cell 23, 143-158. 
Shaw, A.T., Kim, D.W., Nakagawa, K., Seto, T., Crino, L., Ahn, M.J., De Pas, T., Besse, B., 
Solomon, B.J., Blackhall, F., et al. (2013). Crizotinib versus chemotherapy in 
advanced ALK-positive lung cancer. The New England journal of medicine 368, 
2385-2394. 
Shepherd, F.A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E.H., Hirsh, V., Thongprasert, S., Campos, 
D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005). Erlotinib in previously 




Shi, X., Wu, H., Lu, J., Duan, H., Liu, X., and Liang, Z. (2016). Screening for major driver oncogene 
alterations in adenosquamous lung carcinoma using PCR coupled with next-
generation and Sanger sequencing methods. Scientific reports 6, 22297. 
Shojaee, S., and Nana-Sinkam, P. (2017). Recent advances in the management of non-small cell lung 
cancer. F1000Research 6, 2110. 
Siegel, R.L., Miller, K.D., and Jemal, A. (2018). Cancer statistics, 2018. CA: a cancer journal for 
clinicians 68, 7-30. 
Singh, A., Misra, V., Thimmulappa, R.K., Lee, H., Ames, S., Hoque, M.O., Herman, J.G., Baylin, 
S.B., Sidransky, D., Gabrielson, E., et al. (2006). Dysfunctional KEAP1-NRF2 
interaction in non-small-cell lung cancer. PLoS medicine 3, e420. 
Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A.C., Devasthali, V., Thompson, J.D., 
Cheng, J.H., Bou Reslan, H., Ho, C.C., et al. (2010). Assessing therapeutic responses 
in Kras mutant cancers using genetically engineered mouse models. Nature 
biotechnology 28, 585-593. 
Singh, S.R. (2012). Stem cell niche in tissue homeostasis, aging and cancer. Current medicinal 
chemistry 19, 5965-5974. 
Sinha, P., Okoro, C., Foell, D., Freeze, H.H., Ostrand-Rosenberg, S., and Srikrishna, G. (2008). 
Proinflammatory S100 proteins regulate the accumulation of myeloid-derived 
suppressor cells. Journal of immunology (Baltimore, Md : 1950) 181, 4666-4675. 
Skoulidis, F., Byers, L.A., Diao, L., Papadimitrakopoulou, V.A., Tong, P., Izzo, J., Behrens, C., 
Kadara, H., Parra, E.R., Canales, J.R., et al. (2015). Co-occurring genomic alterations 
define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, 
immune profiles, and therapeutic vulnerabilities. Cancer discovery 5, 860-877. 
Smith, E.L., Zamarin, D., and Lesokhin, A.M. (2014). Harnessing the immune system for cancer 
therapy. Current opinion in oncology 26, 600-607. 
Snyder, E.L., Watanabe, H., Magendantz, M., Hoersch, S., Chen, T.A., Wang, D.G., Crowley, D., 
Whittaker, C.A., Meyerson, M., Kimura, S., et al. (2013). Nkx2-1 represses a latent 
gastric differentiation program in lung adenocarcinoma. Molecular cell 50, 185-199. 
Soda, M., Choi, Y.L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, 
H., Kurashina, K., Hatanaka, H., et al. (2007). Identification of the transforming 
EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566. 
Soda, M., Takada, S., Takeuchi, K., Choi, Y.L., Enomoto, M., Ueno, T., Haruta, H., Hamada, T., 
Yamashita, Y., Ishikawa, Y., et al. (2008). A mouse model for EML4-ALK-positive 
lung cancer. Proceedings of the National Academy of Sciences of the United States 
of America 105, 19893-19897. 
Song, X., Krelin, Y., Dvorkin, T., Bjorkdahl, O., Segal, S., Dinarello, C.A., Voronov, E., and Apte, 
R.N. (2005). CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells 
in mice bearing tumors of IL-1beta-secreting cells. Journal of immunology 
(Baltimore, Md : 1950) 175, 8200-8208. 
Song, Z., Lin, B., Shao, L., and Zhang, Y. (2013). Therapeutic efficacy of gefitinib and erlotinib in 
patients with advanced lung adenosquamous carcinoma. Journal of the Chinese 
Medical Association : JCMA 76, 481-485. 
Sordella, R., Bell, D.W., Haber, D.A., and Settleman, J. (2004). Gefitinib-sensitizing EGFR 
mutations in lung cancer activate anti-apoptotic pathways. Science (New York, NY) 
305, 1163-1167. 
Soria, J.C., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K.H., Goker, E., Georgoulias, V., Li, W., 
Isla, D., et al. (2015). Afatinib versus erlotinib as second-line treatment of patients 
with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label 
randomised controlled phase 3 trial. The Lancet Oncology 16, 897-907. 
123 
 
Sos, M.L., Michel, K., Zander, T., Weiss, J., Frommolt, P., Peifer, M., Li, D., Ullrich, R., Koker, M., 
Fischer, F., et al. (2009). Predicting drug susceptibility of non-small cell lung cancers 
based on genetic lesions. The Journal of clinical investigation 119, 1727-1740. 
Sousa, S.F., Fernandes, P.A., and Ramos, M.J. (2008). Farnesyltransferase inhibitors: a detailed 
chemical view on an elusive biological problem. Current medicinal chemistry 15, 
1478-1492. 
Spagnolo, D.M., Gyanchandani, R., Al-Kofahi, Y., Stern, A.M., Lezon, T.R., Gough, A., Meyer, 
D.E., Ginty, F., Sarachan, B., Fine, J., et al. (2016). Pointwise mutual information 
quantifies intratumor heterogeneity in tissue sections labeled with multiple fluorescent 
biomarkers. Journal of pathology informatics 7, 47. 
St Clair, S., and Manfredi, J.J. (2006). The dual specificity phosphatase Cdc25C is a direct target for 
transcriptional repression by the tumor suppressor p53. Cell cycle (Georgetown, Tex) 
5, 709-713. 
Steiner, P., Joynes, C., Bassi, R., Wang, S., Tonra, J.R., Hadari, Y.R., and Hicklin, D.J. (2007). 
Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung 
cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. 
Clinical cancer research : an official journal of the American Association for Cancer 
Research 13, 1540-1551. 
Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., 
Smith, R., Parker, A., et al. (2004). Lung cancer: intragenic ERBB2 kinase mutations 
in tumours. Nature 431, 525-526. 
Sternberg, N., and Hamilton, D. (1981). Bacteriophage P1 site-specific recombination. I. 
Recombination between loxP sites. Journal of molecular biology 150, 467-486. 
Subramanian, J., and Govindan, R. (2007). Lung cancer in never smokers: a review. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology 25, 
561-570. 
Subramanian, J., and Govindan, R. (2013). Molecular profile of lung cancer in never smokers. EJC 
supplements : EJC : official journal of EORTC, European Organization for Research 
and Treatment of Cancer  [et al] 11, 248-253. 
Sugaya, M., Takenoyama, M., Osaki, T., Yasuda, M., Nagashima, A., Sugio, K., and Yasumoto, K. 
(2002). Establishment of 15 cancer cell lines from patients with lung cancer and the 
potential tools for immunotherapy. Chest 122, 282-288. 
Sullivan, I., and Planchard, D. (2016). ALK inhibitors in non-small cell lung cancer: the latest 
evidence and developments. Therapeutic advances in medical oncology 8, 32-47. 
Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., 
Grernrum, W., Tzani, A., et al. (2014). Intrinsic resistance to MEK inhibition in 
KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. 
Cell reports 7, 86-93. 
Sun, S., Schiller, J.H., and Gazdar, A.F. (2007). Lung cancer in never smokers--a different disease. 
Nature reviews Cancer 7, 778-790. 
Sutherland, K.D., Proost, N., Brouns, I., Adriaensen, D., Song, J.Y., and Berns, A. (2011). Cell of 
origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types 
of adult mouse lung. Cancer cell 19, 754-764. 
Sutherland, K.D., Song, J.Y., Kwon, M.C., Proost, N., Zevenhoven, J., and Berns, A. (2014). 
Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma. 
Proceedings of the National Academy of Sciences of the United States of America 
111, 4952-4957. 
Suzuki, A., Kusakai, G., Kishimoto, A., Lu, J., Ogura, T., and Esumi, H. (2003). ARK5 suppresses 
the cell death induced by nutrient starvation and death receptors via inhibition of 
124 
 
caspase 8 activation, but not by chemotherapeutic agents or UV irradiation. Oncogene 
22, 6177-6182. 
Suzuki, Y., Orita, M., Shiraishi, M., Hayashi, K., and Sekiya, T. (1990). Detection of ras gene 
mutations in human lung cancers by single-strand conformation polymorphism 
analysis of polymerase chain reaction products. Oncogene 5, 1037-1043. 
Takagi, Y., Osada, H., Kuroishi, T., Mitsudomi, T., Kondo, M., Niimi, T., Saji, S., Gazdar, A.F., 
Takahashi, T., Minna, J.D., et al. (1998). p53 mutations in non-small-cell lung cancers 
occurring in individuals without a past history of active smoking. British journal of 
cancer 77, 1568-1572. 
Takahashi, T., Sonobe, M., Kobayashi, M., Yoshizawa, A., Menju, T., Nakayama, E., Mino, N., 
Iwakiri, S., Sato, K., Miyahara, R., et al. (2010). Clinicopathologic features of non-
small-cell lung cancer with EML4-ALK fusion gene. Annals of surgical oncology 17, 
889-897. 
Takahashi, T., Takahashi, T., Suzuki, H., Hida, T., Sekido, Y., Ariyoshi, Y., and Ueda, R. (1991). 
The p53 gene is very frequently mutated in small-cell lung cancer with a distinct 
nucleotide substitution pattern. Oncogene 6, 1775-1778. 
Taneja, T.K., and Sharma, S.K. (2004). Markers of small cell lung cancer. World journal of surgical 
oncology 2, 10. 
Terry, J., Leung, S., Laskin, J., Leslie, K.O., Gown, A.M., and Ionescu, D.N. (2010). Optimal 
immunohistochemical markers for distinguishing lung adenocarcinomas from 
squamous cell carcinomas in small tumor samples. The American journal of surgical 
pathology 34, 1805-1811. 
Thomas, K.R., and Capecchi, M.R. (1987). Site-directed mutagenesis by gene targeting in mouse 
embryo-derived stem cells. Cell 51, 503-512. 
Threadgill, D.W., Dlugosz, A.A., Hansen, L.A., Tennenbaum, T., Lichti, U., Yee, D., LaMantia, C., 
Mourton, T., Herrup, K., Harris, R.C., et al. (1995). Targeted disruption of mouse 
EGF receptor: effect of genetic background on mutant phenotype. Science (New 
York, NY) 269, 230-234. 
Thun, M.J., Hannan, L.M., Adams-Campbell, L.L., Boffetta, P., Buring, J.E., Feskanich, D., 
Flanders, W.D., Jee, S.H., Katanoda, K., Kolonel, L.N., et al. (2008). Lung cancer 
occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. 
PLoS medicine 5, e185. 
Tiainen, M., Ylikorkala, A., and Makela, T.P. (1999). Growth suppression by Lkb1 is mediated by a 
G(1) cell cycle arrest. Proceedings of the National Academy of Sciences of the United 
States of America 96, 9248-9251. 
Tidcombe, H., Jackson-Fisher, A., Mathers, K., Stern, D.F., Gassmann, M., and Golding, J.P. (2003). 
Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from 
embryonic lethality. Proceedings of the National Academy of Sciences of the United 
States of America 100, 8281-8286. 
Tochigi, N., Dacic, S., Nikiforova, M., Cieply, K.M., and Yousem, S.A. (2011). Adenosquamous 
carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and 
amplification status in a western patient population. American journal of clinical 
pathology 135, 783-789. 
Travis, W.D., Brambilla, E., Noguchi, M., Nicholson, A.G., Geisinger, K., Yatabe, Y., Ishikawa, Y., 
Wistuba, I., Flieder, D.B., Franklin, W., et al. (2013). Diagnosis of lung cancer in 
small biopsies and cytology: implications of the 2011 International Association for 
the Study of Lung Cancer/American Thoracic Society/European Respiratory Society 
classification. Archives of pathology & laboratory medicine 137, 668-684. 
Travis, W.D., Brambilla, E., Noguchi, M., Nicholson, A.G., Geisinger, K., Yatabe, Y., Powell, C.A., 
Beer, D., Riely, G., Garg, K., et al. (2011). International Association for the Study of 
125 
 
Lung Cancer/American Thoracic Society/European Respiratory Society: international 
multidisciplinary classification of lung adenocarcinoma: executive summary. 
Proceedings of the American Thoracic Society 8, 381-385. 
Tsai, F.D., Lopes, M.S., Zhou, M., Court, H., Ponce, O., Fiordalisi, J.J., Gierut, J.J., Cox, A.D., 
Haigis, K.M., and Philips, M.R. (2015). K-Ras4A splice variant is widely expressed 
in cancer and uses a hybrid membrane-targeting motif. Proceedings of the National 
Academy of Sciences of the United States of America 112, 779-784. 
Tsao, M.S., Sakurada, A., Cutz, J.C., Zhu, C.Q., Kamel-Reid, S., Squire, J., Lorimer, I., Zhang, T., 
Liu, N., Daneshmand, M., et al. (2005). Erlotinib in lung cancer - molecular and 
clinical predictors of outcome. The New England journal of medicine 353, 133-144. 
Tsimberidou, A.M., Rudek, M.A., Hong, D., Ng, C.S., Blair, J., Goldsweig, H., and Kurzrock, R. 
(2010). Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic 
acid (salirasib) in patients with solid tumors. Cancer chemotherapy and pharmacology 
65, 235-241. 
Tu, S., Bhagat, G., Cui, G., Takaishi, S., Kurt-Jones, E.A., Rickman, B., Betz, K.S., Penz-
Oesterreicher, M., Bjorkdahl, O., Fox, J.G., et al. (2008). Overexpression of 
interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-
derived suppressor cells in mice. Cancer cell 14, 408-419. 
Turke, A.B., Song, Y., Costa, C., Cook, R., Arteaga, C.L., Asara, J.M., and Engelman, J.A. (2012). 
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on 
ERBB receptors. Cancer research 72, 3228-3237. 
Turner, N.C., and Reis-Filho, J.S. (2012). Genetic heterogeneity and cancer drug resistance. The 
Lancet Oncology 13, e178-185. 
Ugocsai, K., Mandoky, L., Tiszlavicz, L., and Molnar, J. (2005). Investigation of HER2 
overexpression in non-small cell lung cancer. Anticancer research 25, 3061-3066. 
Vaahtomeri, K., and Makela, T.P. (2011). Molecular mechanisms of tumor suppression by LKB1. 
FEBS letters 585, 944-951. 
Vahakangas, K.H., Bennett, W.P., Castren, K., Welsh, J.A., Khan, M.A., Blomeke, B., Alavanja, 
M.C., and Harris, C.C. (2001). p53 and K-ras mutations in lung cancers from former 
and never-smoking women. Cancer research 61, 4350-4356. 
Vaira, V., Fedele, G., Pyne, S., Fasoli, E., Zadra, G., Bailey, D., Snyder, E., Faversani, A., Coggi, 
G., Flavin, R., et al. (2010). Preclinical model of organotypic culture for 
pharmacodynamic profiling of human tumors. Proceedings of the National Academy 
of Sciences of the United States of America 107, 8352-8356. 
Wang, L., Zhu, B., Zhang, M., and Wang, X. (2017). Roles of immune microenvironment 
heterogeneity in therapy-associated biomarkers in lung cancer. Seminars in cell & 
developmental biology 64, 90-97. 
Wang, T., Nelson, R.A., Bogardus, A., and Grannis, F.W., Jr. (2010). Five-year lung cancer survival: 
which advanced stage nonsmall cell lung cancer patients attain long-term survival? 
Cancer 116, 1518-1525. 
Varghese, A.M., Zakowski, M.F., Yu, H.A., Won, H.H., Riely, G.J., Krug, L.M., Kris, M.G., 
Rekhtman, N., Ladanyi, M., Wang, L., et al. (2014). Small-cell lung cancers in 
patients who never smoked cigarettes. Journal of thoracic oncology : official 
publication of the International Association for the Study of Lung Cancer 9, 892-896. 
Vassella, E., Langsch, S., Dettmer, M.S., Schlup, C., Neuenschwander, M., Frattini, M., Gugger, M., 
and Schafer, S.C. (2015). Molecular profiling of lung adenosquamous carcinoma: 
hybrid or genuine type? Oncotarget 6, 23905-23916. 
Wculek, S.K., and Malanchi, I. (2015). Neutrophils support lung colonization of metastasis-initiating 
breast cancer cells. Nature 528, 413-417. 
126 
 
Weiss, J., Sos, M.L., Seidel, D., Peifer, M., Zander, T., Heuckmann, J.M., Ullrich, R.T., Menon, R., 
Maier, S., Soltermann, A., et al. (2010). Frequent and focal FGFR1 amplification 
associates with therapeutically tractable FGFR1 dependency in squamous cell lung 
cancer. Science translational medicine 2, 62ra93. 
Wennerberg, K., Rossman, K.L., and Der, C.J. (2005). The Ras superfamily at a glance. Journal of 
cell science 118, 843-846. 
Westcott, P.M., and To, M.D. (2013). The genetics and biology of KRAS in lung cancer. Chinese 
journal of cancer 32, 63-70. 
Wingo, S.N., Gallardo, T.D., Akbay, E.A., Liang, M.C., Contreras, C.M., Boren, T., Shimamura, T., 
Miller, D.S., Sharpless, N.E., Bardeesy, N., et al. (2009). Somatic LKB1 mutations 
promote cervical cancer progression. PloS one 4, e5137. 
Virmani, A.K., Fong, K.M., Kodagoda, D., McIntire, D., Hung, J., Tonk, V., Minna, J.D., and 
Gazdar, A.F. (1998). Allelotyping demonstrates common and distinct patterns of 
chromosomal loss in human lung cancer types. Genes, chromosomes & cancer 21, 
308-319. 
Wong, D.W., Leung, E.L., So, K.K., Tam, I.Y., Sihoe, A.D., Cheng, L.C., Ho, K.K., Au, J.S., Chung, 
L.P., and Pik Wong, M. (2009). The EML4-ALK fusion gene is involved in various 
histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. 
Cancer 115, 1723-1733. 
Wong, M.C.S., Lao, X.Q., Ho, K.F., Goggins, W.B., and Tse, S.L.A. (2017). Incidence and mortality 
of lung cancer: global trends and association with socioeconomic status. Scientific 
reports 7, 14300. 
Woodard, G.A., Jones, K.D., and Jablons, D.M. (2016). Lung Cancer Staging and Prognosis. Cancer 
treatment and research 170, 47-75. 
Wu, K., Chang, Q., Lu, Y., Qiu, P., Chen, B., Thakur, C., Sun, J., Li, L., Kowluru, A., and Chen, F. 
(2013). Gefitinib resistance resulted from STAT3-mediated Akt activation in lung 
cancer cells. Oncotarget 4, 2430-2438. 
Xiao, Z., Jiang, Q., Willette-Brown, J., Xi, S., Zhu, F., Burkett, S., Back, T., Song, N.Y., Datla, M., 
Sun, Z., et al. (2013). The pivotal role of IKKalpha in the development of spontaneous 
lung squamous cell carcinomas. Cancer cell 23, 527-540. 
Xu, C., Fillmore, C.M., Koyama, S., Wu, H., Zhao, Y., Chen, Z., Herter-Sprie, G.S., Akbay, E.A., 
Tchaicha, J.H., Altabef, A., et al. (2014). Loss of Lkb1 and Pten leads to lung 
squamous cell carcinoma with elevated PD-L1 expression. Cancer cell 25, 590-604. 
Xu, X., Rock, J.R., Lu, Y., Futtner, C., Schwab, B., Guinney, J., Hogan, B.L., and Onaitis, M.W. 
(2012). Evidence for type II cells as cells of origin of K-Ras-induced distal lung 
adenocarcinoma. Proceedings of the National Academy of Sciences of the United 
States of America 109, 4910-4915. 
Xue, Y., Hou, S., Ji, H., and Han, X. (2017). Evolution from genetics to phenotype: reinterpretation 
of NSCLC plasticity, heterogeneity, and drug resistance. Protein & cell 8, 178-190. 
Yadav, B., Pemovska, T., Szwajda, A., Kulesskiy, E., Kontro, M., Karjalainen, R., Majumder, M.M., 
Malani, D., Murumagi, A., Knowles, J., et al. (2014). Quantitative scoring of 
differential drug sensitivity for individually optimized anticancer therapies. Scientific 
reports 4, 5193. 
Yamamoto, H., Shigematsu, H., Nomura, M., Lockwood, W.W., Sato, M., Okumura, N., Soh, J., 
Suzuki, M., Wistuba, II, Fong, K.M., et al. (2008). PIK3CA mutations and copy 
number gains in human lung cancers. Cancer research 68, 6913-6921. 
Yang, A., Walker, N., Bronson, R., Kaghad, M., Oosterwegel, M., Bonnin, J., Vagner, C., Bonnet, 
H., Dikkes, P., Sharpe, A., et al. (2000). p73-deficient mice have neurological, 




Yang, G., Rosen, D.G., Zhang, Z., Bast, R.C., Jr., Mills, G.B., Colacino, J.A., Mercado-Uribe, I., and 
Liu, J. (2006). The chemokine growth-regulated oncogene 1 (Gro-1) links RAS 
signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. 
Proceedings of the National Academy of Sciences of the United States of America 
103, 16472-16477. 
Yang, M.-J., Hsu, C.-K., Chang, H.-J., Yen, L.-C., Tsao, D.-A., Chiu, H.-H., Huang, Y.-T., Chen, 
Y.-F., Wang, J.-Y., and Lin, S.-R. (2009). The KRAS Mutation is Highly Correlated 
With EGFR Alterations in Patients With Non-small Cell Lung Cancer, Vol 1. 
Yang, P., Cerhan, J.R., Vierkant, R.A., Olson, J.E., Vachon, C.M., Limburg, P.J., Parker, A.S., 
Anderson, K.E., and Sellers, T.A. (2002). Adenocarcinoma of the lung is strongly 
associated with cigarette smoking: further evidence from a prospective study of 
women. American journal of epidemiology 156, 1114-1122. 
Yarden, Y., and Sliwkowski, M.X. (2001). Untangling the ErbB signalling network. Nature reviews 
Molecular cell biology 2, 127-137. 
Ye, X.Z., Yu, S.C., and Bian, X.W. (2010). Contribution of myeloid-derived suppressor cells to 
tumor-induced immune suppression, angiogenesis, invasion and metastasis. Journal 
of genetics and genomics = Yi chuan xue bao 37, 423-430. 
Ylikorkala, A., Rossi, D.J., Korsisaari, N., Luukko, K., Alitalo, K., Henkemeyer, M., and Makela, 
T.P. (2001). Vascular abnormalities and deregulation of VEGF in Lkb1-deficient 
mice. Science (New York, NY) 293, 1323-1326. 
Youn, J.I., Nagaraj, S., Collazo, M., and Gabrilovich, D.I. (2008). Subsets of myeloid-derived 
suppressor cells in tumor-bearing mice. Journal of immunology (Baltimore, Md : 
1950) 181, 5791-5802. 
Yuan, H., Myers, S., Wang, J., Zhou, D., Woo, J.A., Kallakury, B., Ju, A., Bazylewicz, M., Carter, 
Y.M., Albanese, C., et al. (2012). Use of reprogrammed cells to identify therapy for 
respiratory papillomatosis. The New England journal of medicine 367, 1220-1227. 
Yuan, Y. (2016). Spatial Heterogeneity in the Tumor Microenvironment. Cold Spring Harbor 
perspectives in medicine 6. 
Yun, C.H., Mengwasser, K.E., Toms, A.V., Woo, M.S., Greulich, H., Wong, K.K., Meyerson, M., 
and Eck, M.J. (2008). The T790M mutation in EGFR kinase causes drug resistance 
by increasing the affinity for ATP. Proceedings of the National Academy of Sciences 
of the United States of America 105, 2070-2075. 
Zhang, X., Gureasko, J., Shen, K., Cole, P.A., and Kuriyan, J. (2006). An allosteric mechanism for 
activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-
1149. 
Zhang, Z., Lee, J.C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., 
Levine, A.D., Rho, J.K., et al. (2012). Activation of the AXL kinase causes resistance 
to EGFR-targeted therapy in lung cancer. Nature genetics 44, 852-860. 
Zheng, D., Yin, L., and Chen, J. (2014). Evidence for Scgb1a1(+) cells in the generation of p63(+) 
cells in the damaged lung parenchyma. American journal of respiratory cell and 
molecular biology 50, 595-604. 
Zilfou, J.T., and Lowe, S.W. (2009). Tumor suppressive functions of p53. Cold Spring Harbor 
perspectives in biology 1, a001883. 
Zimmermann, M., Lampe, J., Lange, S., Smirnow, I., Konigsrainer, A., Hann-von-Weyhern, C., 
Fend, F., Gregor, M., Bitzer, M., and Lauer, U.M. (2009). Improved reproducibility 
in preparing precision-cut liver tissue slices. Cytotechnology 61, 145-152. 
Zuo, W., Zhang, T., Wu, D.Z., Guan, S.P., Liew, A.A., Yamamoto, Y., Wang, X., Lim, S.J., Vincent, 
M., Lessard, M., et al. (2015). p63(+)Krt5(+) distal airway stem cells are essential for 
lung regeneration. Nature 517, 616-620. 
 
